Cell-type-specific patterns of gene expression

ABSTRACT

Among the methods, compositions, combinations and kits provided herein are those for determining gene expression levels in one or more cell types in heterogeneous cell samples, for identifying genes differentially expressed in different cell types, and for detecting a cell type in a sample from a subject. Also provided herein are methods, compositions, combinations and kits for determining gene expression levels in cells corresponding to phenotypes, and for identifying a phenotype of a subject by detecting differentially expressed genes.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority under 35 U.S.C. §119 from Provisional Application Ser. No. 60/535,382, filed Jan. 9, 2004, and Provisional Application Ser. No. 60/536,163, filed Jan. 12, 2004. The disclosures of these applications are incorporated herein by reference.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

The U.S. Government has certain rights in this disclosure pursuant to Grant No. CA84998 awarded by the National Institutes of Health.

ELECTRONIC FILE APPENDIX

Submitted herewith in computer readable form are table appendices and a sequence listing. The table appendices are contained in a compact disc, and are listed under the filenames “Table 2.txt” “Table 8.txt” “Table 15.txt” and “Table 16.txt”, which were created Jan. 10, 2005, and are 863 kb, 426 kb, 510 kb, and 1,583 kb, respectively, in size. The sequence listing is contained on the same compact disc, and is listed under the filename 15670-073SEQ001.txt, and is 237,457 kb in size. All subject matter of the table appendix and sequence listing files on compact disk is incorporated herein by reference.

TECHNICAL FIELD

This invention relates to methods for determining gene expression in cells.

BACKGROUND

Numerous diseases and disorders are the result of specific gene expression in a tissue. For example, prostate cancer is the most common malignancy in men and is the cause of considerable morbidity and mortality (Howe et al., J. Natl. Cancer Inst. 93, 824-842, 2001). There is therefore a major incentive to try to identify genes that could be reliable early diagnostic and prognostic markers and therapeutic targets for such diseases and disorders.

SUMMARY

The methods, compositions, combinations and kits provided herein employ a regression-based approach for identification of cell-type-specific patterns of gene expression in samples containing more than one type of cell. In one example, the methods, compositions, combinations and kits provided herein employ a regression-based approach for identification of cell-type-specific patterns of gene expression in cancer. These methods, compositions, combinations and kits provided herein can be used in the identification of genes that are differentially expressed in malignant versus non-malignant cells and further identify tumor-dependent changes in gene expression of non-malignant cells associated with malignant cells relative to non-malignant cells not associated with malignant cells. The methods, compositions, combinations and kits provided herein also can be used in correlating a phenotype with gene expression in one or more cell types.

Provided herein are methods, compositions, combinations and kits for determining gene expression levels in one or more cell types in heterogeneous cell samples. For example such a method can include determining the relative content of each cell type in two or more related heterogeneous cell samples, wherein at least two of the samples do not contain the same relative content of each cell type; measuring overall levels of one or more gene expression analytes in each sample; determining the regression relationship between the relative content of each cell type and the measured overall levels; and calculating the level of each of the one or more analytes in each cell type according to the regression relationship, wherein gene expression levels correspond to the calculated levels of analytes. For example such a method can include determining the relative content of each cell type in two or more related heterogeneous cell samples, wherein at least two of the samples do not contain the same relative content of each cell type; measuring overall levels of two or more gene expression analytes in each sample; determining the regression relationship between the relative content of each cell type and the measured overall levels; and calculating the level of each of the two or more analytes in each cell type according to the regression relationship, wherein gene expression levels correspond to the calculated levels of analytes. Such methods can further include identifying genes differentially expressed in at least one cell type relative to at least one other cell type. In such methods, the analyte can be selected from a nucleic acid molecule and a protein.

In another embodiment, methods, compositions, combinations and kits are provided for identifying genes differentially expressed in malignant cells relative to non-malignant cells. Such a method can include determining the relative content of each cell type in two or more cell samples of the same tissue or organ, wherein the two or more cell samples include at least a first sample containing malignant cells and a second sample that does not contain the same relative content of each cell type as the first sample; measuring overall expression levels of one or more genes in each sample; determining the regression relationship between the relative content of each cell type and the measured overall levels; calculating the level of each of the one or more genes in each cell type according to the regression relationship; and identifying genes differentially expressed in malignant cells relative to non-malignant cells. Such a method also can include determining the relative content of each cell type in two or more cell samples of the same tissue or organ, wherein the two or more cell samples include at least a first sample containing malignant cells and a second sample that does not contain the same relative content of each cell type as the first sample; measuring overall expression levels of two or more genes in each sample; determining the regression relationship between the relative content of each cell type and the measured overall levels; calculating the level of each of the two or more genes in each cell type according to the regression relationship; and identifying genes differentially expressed in malignant cells relative to non-malignant cells.

Also provided herein are methods, compositions, combinations and kits for characterizing one or more cell types in a subject. For example, such a method can include measuring expression levels of one or more genes in a heterogeneous cell sample from a subject; comparing the measured levels to a plurality of reference expression levels of the one or more genes, wherein the plurality of reference levels are indicative of two or more cell types; and if the measured levels match reference levels indicative of a specific cell type in the sample, identifying a subject as having the specific cell type. In another example, such a method can include measuring expression levels of two or more genes in a heterogeneous cell sample from a subject; comparing the measured levels to a plurality of reference expression levels of the two or more genes, wherein the plurality of reference levels are indicative of two or more cell types; and if the measured levels match reference levels indicative of a specific cell type in the sample, identifying a subject as having the specific cell type. In another embodiment, provided herein are methods, compositions, combinations and kits for characterizing one or more cell types in a subject, by measuring expression levels of one or more genes in a cell sample from a subject; comparing the measured levels to reference expression levels of the one or more genes, wherein the reference expression levels are determined according to the methods provided herein; and if the measured levels match reference levels indicative of a specific cell type in the sample, identifying a subject as having the specific cell type. In another embodiment, provided herein are methods, compositions, combinations and kits for characterizing one or more cell types in a subject, by measuring expression levels of two or more genes in a cell sample from a subject; comparing the measured levels to reference expression levels of the two or more genes, wherein the reference expression levels are determined according to the methods provided herein; and if the measured levels match reference levels indicative of a specific cell type in the sample, identifying a subject as having the specific cell type. In such methods, the specific cell type can be selected from the group consisting of malignant cell and non-malignant cell adjacent to a malignant cell in a subject. Also provided herein are methods for identifying a subject as having malignant cells, by measuring expression levels of one or more genes in a heterogeneous cell sample from a subject; comparing the measured levels to a plurality of reference expression levels of the one or more genes, wherein the plurality of reference levels are indicative of two or more cell types; and if the measured levels match reference levels indicative of in malignant cells in the sample or of non-malignant cells in the sample that had been adjacent to malignant cells in the subject, identifying a subject as having malignant cells. Also provided herein are methods for identifying a subject as having malignant cells, by measuring expression levels of two or more genes in a heterogeneous cell sample from a subject; comparing the measured levels to a plurality of reference expression levels of the two or more genes, wherein the plurality of reference levels are indicative of two or more cell types; and if the measured levels match reference levels indicative of in malignant cells in the sample or of non-malignant cells in the sample that had been adjacent to malignant cells in the subject, identifying a subject as having malignant cells. In another embodiment, provided herein are methods of identifying a subject as having malignant cells, by measuring expression levels of one or more genes in-a cell sample from a subject; comparing the measured levels to reference expression levels of the one or more genes, wherein the reference expression levels are determined according to the methods provided herein; and if the measured levels match reference levels indicative of in malignant cells in the sample or of non-malignant cells in the sample that had been adjacent to malignant cells in the subject, identifying a subject as having malignant cells. In another embodiment, provided herein are methods of identifying a subject as having malignant cells, by measuring expression levels of two or more genes in a cell sample from a subject; comparing the measured levels to reference expression levels of the two or more genes, wherein the reference expression levels are determined according to the methods provided herein; and if the measured levels match reference levels indicative of in malignant cells in the sample or of non-malignant cells in the sample that had been adjacent to malignant cells in the subject, identifying a subject as having malignant cells. In another embodiment,provided herein are methods of identifying a subject as having malignant cells, by assaying a cell sample from a subject for non-malignant cells in the sample that had been adjacent to malignant cells in the subject; and if the malignant-cell-adjacent non-malignant cells are present in the sample, identifying a subject as having malignant cells. In such methods the malignant-cell-adjacent non-malignant cells can be stromal cells.

Also provided herein are methods, compositions, combinations and kits for determining gene expression levels in one or more cell types corresponding to two or more phenotypes. For example, such a method can include determining the relative content of each cell type in two or more related heterogeneous cell samples, wherein at least two of the samples do not contain the same relative content of each cell type, and wherein at least two of the samples correspond to different phenotypes; measuring overall levels of one or more gene expression analytes in each sample; determining the regression relationship between the relative content of each cell type for each phenotype and the measured overall levels; and calculating the level of each of the one or more analytes in each cell type for each phenotype according to the regression relationship, wherein gene expression levels in each cell type for each phenotype correspond to the calculated levels of analytes. In another example, such a method can include determining the relative content of each cell type in two or more related heterogeneous cell samples, wherein at least two of the samples do not contain the same relative content of each cell type, and wherein at least two of the samples correspond to different phenotypes; measuring overall levels of two or more gene expression analytes in each sample; determining the regression relationship between the relative content of each cell type for each phenotype and the measured overall levels; and calculating the level of each of the two or more analytes in each cell type for each phenotype according to the regression relationship, wherein gene expression levels in each cell type for each phenotype correspond to the calculated levels of analytes. Also provided herein are methods, compositions, combinations and kits for identifying a phenotype of a subject. For example, such a method can include measuring expression levels of one or more genes in a cell sample from a subject; comparing the measured levels to reference expression levels of the one or more genes, wherein the reference expression levels are determined according to methods provided herein; and if the measured levels match reference levels indicative of a specific phenotype, identifying a subject as having the specific phenotype. In another example, such a method can include measuring expression levels of two or more genes in a cell sample from a subject; comparing the measured levels to reference expression levels of the two or more genes, wherein the reference expression levels are determined according to methods provided herein; and if the measured levels match reference levels indicative of a specific phenotype, identifying a subject as having the specific phenotype. Also provided are methods wherein the phenotype can be indicative of prognosis of a disease or disorder.

Also provided herein are methods, compositions, combinations and kits for determining gene expression levels in one or more cell types indicative of a disease or disorder. For example, the method can include determining the relative content of each cell type in two or more related heterogeneous cell samples, wherein at least two of the samples do not contain the same relative content of each cell type, and wherein at least one sample is from a subject with a disease or disorder and at least one sample is from a subject without a disease or disorder; measuring overall levels of one or more gene expression analytes in each sample; determining the regression relationship between the relative content of each cell type for both disease and non-disease and the measured overall levels; and calculating the level of each of the one or more analytes in each cell type for both disease and non-disease according to the regression relationship, wherein gene expression levels in each cell type for both disease and non-disease correspond to the calculated levels of analytes. In another example, the method can include determining the relative content of each cell type in two or more related heterogeneous cell samples, wherein at least two of the samples do not contain the same relative content of each cell type, and wherein at least one sample is from a subject with a disease or disorder and at least one sample is from a subject without a disease or disorder; measuring overall levels of two or more gene expression analytes in each sample; determining the regression relationship between the relative content of each cell type for both disease and non-disease and the measured overall levels; and calculating the level of each of the two or more analytes in each cell type for both disease and non-disease according to the regression relationship, wherein gene expression levels in each cell type for both disease and non-disease correspond to the calculated levels of analytes. Also provided are methods of identifying a disease or disorder in a subject by measuring expression levels of one or more genes in a cell sample from a subject; comparing the measured levels to reference expression levels of the one or more genes, wherein the reference expression levels are determined according to methods provided herein; and if the measured levels match reference levels indicative of a specific disease or disorder, identifying a subject as having the specific disease or disorder. Also provided are methods of identifying a disease or disorder in a subject by measuring expression levels of two or more genes in a cell sample from a subject; comparing the measured levels to reference expression levels of the two or more genes, wherein the reference expression levels are determined according to methods provided herein; and if the measured levels match reference levels indicative of a specific disease or disorder, identifying a subject as having the specific disease or disorder. In methods that include determining disease prognosis, the prognosis can be tumor relapse, aggressiveness of tumor, indolence of tumor, survival, or likelihood of successful treatment of tumor. In some embodiments of the methods provided herein, the sample is clinically classified as negative of a tumor, and presence in the sample of non-malignant cells adjacent to malignant cells can be indicative of tumor, tumor relapse, aggressiveness of tumor, indolence of tumor, survival, or likelihood of successful treatment of tumor.

Also provided herein are methods, compositions, combinations and kits for identifying environment-dependent changes in gene expression of a cell type. For example, such a method can include determining the relative content of each cell type in two or more related heterogeneous cell samples, wherein at least two of the samples do not contain the same relative content of each cell type, and wherein cells of the same type that are in different cell environments are separately classified; measuring overall levels of one or more gene expression analytes in each sample; determining the regression relationship between the relative content of each cell classification and the measured overall levels; calculating the level of each of the one or more analytes in each cell classification according to the regression relationship; and identifying genes differentially expressed in separately classified cells of the same type, thereby identifying environment-dependent changes in gene expression of a cell type. In another example, such a method can include determining the relative content of each cell type in two or more related heterogeneous cell samples, wherein at least two of the samples do not contain the same relative content of each cell type, and wherein cells of the same type that are in different cell environments are separately classified; measuring overall levels of two or more gene expression analytes in each sample; determining the regression relationship between the relative content of each cell classification and the measured overall levels; calculating the level of each of the two or more analytes in each cell classification according to the regression relationship; and identifying genes differentially expressed in separately classified cells of the same type, thereby identifying environment-dependent changes in gene expression of a cell type. Another method of identifying tumor-dependent changes in gene expression of a cell type includes determining the relative content of each cell type in two or more related heterogeneous cell samples, wherein at least two of the samples do not contain the same relative content of each cell type, and wherein cells associated with tumor are classified separately from cells of the same type that are not associated with tumor; measuring overall levels of one or more gene expression analytes in each sample; determining the regression relationship between the relative content of each cell classification and the measured overall levels; calculating the level of each of the one or more analytes in each cell classification according to the regression relationship; and identifying genes differentially expressed in cells associated with tumor relative to cells of the same type that are not associated with tumor. Another method of identifying tumor-dependent changes in gene expression of a cell type includes determining the relative content of each cell type in two or more related heterogeneous cell samples, wherein at least two of the samples do not contain the same relative content of each cell type, and wherein cells associated with tumor are classified separately from cells of the same type that are not associated with tumor; measuring overall levels of two or more gene expression analytes in each sample; determining the regression relationship between the relative content of each cell classification and the measured overall levels; calculating the level of each of the two or more analytes in each cell classification according to the regression relationship; and identifying genes differentially expressed in cells associated with tumor relative to cells of the same type that are not associated with tumor.

Also provided herein are methods, compositions, combinations and kits for identifying a phenotype of a subject. For example, a method can include measuring expression levels of one or more genes in a heterogeneous cell sample from a subject; comparing the measured levels to reference expression levels of the one or more genes, wherein the plurality of reference levels are indicative of two or more phenotypes; and if the measured levels match reference levels indicative of a specific phenotype, identifying a subject as having the specific phenotype. In another example, a method can include measuring expression levels of two or more genes in a heterogeneous cell sample from a subject; comparing the measured levels to reference expression levels of the two or more genes, wherein the plurality of reference levels are indicative of two or more phenotypes; and if the measured levels match reference levels indicative of a specific phenotype, identifying a subject as having the specific phenotype.

In the methods provided herein, all steps can be performed without physically separating the cells in the sample. Further in the methods provided herein, the step of determining the regression relationship can include determining the regression of overall levels of each analyte on the cell proportions.

Also provided herein are methods, compositions, combinations and kits for classifying a cell sample as indicative of prostate cancer or not indicative of prostate cancer. For example, a method can include detecting the expression levels of genes relative to a reference, the genes comprising at least 2 different indicating genes, wherein each indicating gene comprises either: (a) a nucleotide sequence at least 90% identical to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof or (b) a nucleotide sequence that hybridizes under high stringency to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof. In another embodiment, provided herein are methods, compositions, combinations and kits for classifying a cell sample as indicative of prostate cancer or not indicative of prostate cancer. In another embodiment, provided is a use of a combination for the preparation of a composition for classifying a sample as indicative of prostate cancer or not indicative of prostate cancer, wherein the combination detects the expression levels of genes relative to a reference, the genes comprising at least 2 different indicating genes, wherein each indicating gene comprises either: (a) a nucleotide sequence at least 90% identical to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof or (b) a nucleotide sequence that hybridizes under high stringency to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof. In some embodiments, the nucleotide sequences selected from SEQ ID NO:1-38,826 are selected from SEQ ID NO:35,580-38,826.

The methods, compositions, combinations, uses and kits provided herein can be used to detect the expression levels of genes relative to a reference, the genes comprising at least 5, 10, 15, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500, 750, 1,000, 1,250, 1,500, 1,750, 2,000, 2,250, 2,500, or 2750 indicating genes.

Also provided herein are microarrays wherein at least 50%, 70%, 80%, 90%, 95%, 97%, 98% or 99% of the loci of the array specifically detect the expression level of the 2 or more indicating genes of the methods, compositions, combinations, uses and kits provided herein.

Also provided herein are methods, compositions, combinations, uses and kits for treating prostate cancer. For example, a method can include modulating the activity of a gene product selected from the group consisting of:(a) a product of a gene comprising a nucleotide sequence at least 90% identical to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof or (b) a gene product complementary to a nucleotide sequence that hybridizes under high stringency to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof. In some embodiments, the nucleotide sequences selected from SEQ ID NO:1-38,826 are selected from SEQ ID NO:35,580-38,826. In the methods, compositions, combinations, uses and kits provided herein, the compound can be selected from the group consisting of an antibody, an antisense compound, a ribozyme, a DNAzyme, an RNA interference compound, a small molecule, a heterologous nucleic acid molecule encoding the gene, the gene product, and any combination thereof. For example, the modulating compound can specifically bind to mRNA encoding the gene or the protein gene product and thereby inhibit expression of the gene. In other methods, compositions, combinations, uses and kits provided herein, the modulating step can further include administering to a subject with prostate cancer a compound that increases the activity of the gene product selected from the selected from the group consisting of heterologous nucleic acid molecule encoding the gene, the gene product, and a combination thereof. For example the heterologous nucleic acid molecule can be an expression vector.

Also provided herein are methods, compositions, combinations, uses and kits for screening compounds. For example, a method can include contacting with a test compound a cell expressing a gene selected from the group consisting of: (a) a gene comprising a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof; and (b) a gene comprising a nucleotide sequence that hybridizes under high stringency to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof, and measuring expression levels of the gene, wherein a change in expression levels relative to a reference identifies the compound as a compound that modulates a expression of the gene. Another screening method includes contacting with a test compound a gene product selected from the group consisting of: a product of a gene comprising a nucleotide sequence at least 90% identical to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof or (b) a gene product complementary to a nucleotide sequence that hybridizes under high stringency to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof, and either: (i) identifying a test compound that specifically binds to the gene product, or (ii) identifying a test compound that inhibits binding of a compound known to bind the gene product. In some embodiments, the nucleotide sequences selected from SEQ ID NO:1-38,826 are selected from SEQ ID NO:35,580-38,826.

In some of the methods, compositions, combinations, uses and kits provided herein at least one of the gene products corresponds to a Probe or Identifer/LocusLink with a modified t statistic in tumor >2.5 or <−2.5. In others, at least one of the gene products corresponds to a Probe or Identifer/LocusLink with a modified t statistic in benign prostatic hypertrophy (BPH) >2.5 or <−2.5. In others, at least one of the gene products corresponds to a Probe or Identifer/LocusLink with a modified t statistic in stroma >2.5 or <−2.5. In some of the methods, compositions, combinations, uses and kits provided herein the gene product can be selected from the group consisting of: (a) a product of a gene comprising a nucleotide sequence at least 90% identical to the nucleotide sequence of a Probe identified in Table 9 as having a modified t statistic in tumor >2.5 or <−2.5; (b) a product of a gene comprising a nucleotide sequence at least 90% identical to the nucleotide sequence of a gene encoded by an Identifier and LocusLink identified in Table 9 as having a modified t statistic in tumor >2.5 or <−2.5; (c) a product of a gene comprising a nucleotide sequence at least 90% identical to the nucleotide sequence of a Probe identified in Table 10 as having a modified t statistic in stroma >2.5 or <−2.5; and (d) a product of a gene comprising a nucleotide sequence at least 90% identical to the nucleotide sequence of a gene encoded by an Identifier and LocusLink identified in Table 10 as having a modified t statistic in stroma >2.5 or <−2.5. In some of the methods, compositions, combinations, uses and kits provided herein, the modified t statistic can be >3 or <−3, >3.5 or <−3.5, >4 or <−4, >4.5 or <−4.5, or >5 or <−5.

Also provided herein are compounds that modulate the activity of a gene product selected from the group consisting of: (a) a product of a gene comprising a nucleotide sequence at least 90% identical to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof or (b) a gene product complementary to a nucleotide sequence that hybridizes under high stringency to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof. In some embodiments, the nucleotide sequences selected from SEQ ID NO:1-38,826 are selected from SEQ ID NO:35,580-38,826. In certain embodiments, such a compound can be selected from the group consisting of an antibody, an antisense compound, a ribozyme, a DNAzyme, an RNA interference compound, a small molecule, a heterologous nucleic acid molecule encoding the gene, the gene product, and any combination thereof. Some compounds provided herein are present in pharmaceutically acceptable form.

Also provided herein are compounds that indicates the presence of a gene product selected from the group consisting of: (a) a product of a gene comprising a nucleotide sequence at least 90% identical to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof or (b) a gene product complementary to a nucleotide sequence that hybridizes under high stringency to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof. In some embodiments, the nucleotide sequences selected from SEQ ID NO:1-38,826 are selected from SEQ ID NO:35,580-38,826. In certain embodiments, such a compound can be selected from the group consisting of a nucleic acid molecule that specifically binds at least 10 nucleotides in the gene or a complement thereof or a fragment thereof, an antibody that specifically binds the gene or a complement thereof, and an antibody that specifically binds the gene product or a fragment thereof.

Also provided herein are combinations of one or more of the compounds provided herein, or combinations of at least at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20 compounds provided herein.

Also provided herein are diagnostic markers-for prostate cancer as set forth in SEQ ID NO:1-38,826. Also provided herein are kits comprising nucleic acids, polypeptides and/or antibodies useful in detecting the markers set forth in SEQ ID NO:1-38,826 for detecting prostate cancer. Also provided herein are methods of treating or preventing prostate cancer comprising suppressing gene expression or inhibiting or neutralizing the gene product of the genes that are listed as tumor markers and that are differentially expressed in the Tables provided herein and SEQ ID NO:1-38,826. In some such methods antibodies, antisense, ribozyme, a DNAzyme, RNA interference, and/or small molecule therapy to neutralize the gene or gene products, can be used. Also provided herein are prognostic markers for early relapse in prostate cancer as set forth in SEQ ID NO:1-38,826, complements thereof, fragments thereof, and polypeptides encoded thereby. Also provided herein are kits comprising nucleic acids, polypeptides and/or antibodies useful in detecting the markers set forth in SEQ ID NO:1-38,826, complements thereof, fragments thereof, and polypeptides encoded thereby for detecting early relapse of prostate cancer. In some embodiments, the nucleotide sequences selected from SEQ ID NO:1-38,826 are selected from SEQ ID NO:35,580-38,826. Also provided herein are methods of treating or preventing prostate cancer comprising suppressing gene expression or inhibiting or neutralizing the gene product of genes that are up-regulated in the tumor epithelial cells of early relapsed prostate cancer samples, wherein such genes have a T>3 in Table 8, Table 9, Table 10, Table 12 or Table 13. In some such methods antibodies, antisense, ribozyme, a DNAzyme, RNA interference, and/or small molecule therapy to neutralize the gene or gene products, can be used. Also provided herein are computer implemented methods.

The details of the methods, compositions, combinations and kits provided herein, are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

DESCRIPTION OF DRAWINGS

FIG. 1 depicts graphs showing agreement analysis of pathologists' percent estimates by calculation of Pearson correlation coefficients. The figure shows agreement among four pathologists, for the analysis of prostate cancer sections. A total of 363 rankings were analyzed. For any graph, the y- and x-axes give the percent of a given tissue section estimated to be tumor epithelial cells by rater whose initials occur in the diagonal panels found by moving horizontally and vertically respectively. The histograms below the diagonal show few instances in which y_(ij1kj)-y_(ij2kj) exceeds 20%, and usually it is <5%. Further, the k statistics and the Pearson correlations coefficients are all high. Many of the ratings showed <5% tumor cells (histograms on diagonal), making this a good test for presence versus absence of tumor cells.

FIG. 2 shows a ternary graph of sample characteristics. Eighty-eight prostatectomy samples from 41 individuals comprising 50 nontumor and 38 tumor-containing specimens were scored for proportional content of tumor, BPH, stroma, and dilated cystic glands. Vertices represent pure tissue types. Epithelia of dilated cystic glands, nerves, and vessels are small components. Note the wide range of proportions of tumor and stromal cells. Estimated tumor percentages ranged from 0.3% through 100%. The proportions were used in the linear models (x_(kj) in Equation 1) for cell-associated gene expression.

FIG. 3A-C shows statistical modeling. (A) Regression on cell type. The expected cell type expression levels are the coefficients β in models of gene expression as a linear function of fractional cell type (Equation 1) and were calculated by using the lsfit function in R. Modified t statistics were calculated as t=β/(0.0029+β_(se)), where se is the standard error of the coefficient. Volcano plot representations of the data reveal genes associated with the tumor cell type with high confidence in the upper right portion of the graph. (B) Multiple regression on percentage stroma, BPH, and tumor allows direct identification of tumor-BPH differences beyond the effect of stroma. Posterior probabilities akin to those in Efron et al. (J. Am. Stat. Assoc. 96, 1151-1160, 2001) used an estimating equations approach (gee library for R) (R Development Core Team (2004). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org.). BPH-specific gene expression is in the upper left (note CK15), and tumor-specific gene expression is in the upper right (tubulin-β) of the graph. (C) Tumor-stroma interaction model. Inclusion of cross-product terms in the linear model identifies genes in which the contribution of a cell may be more or less than in another tissue environment; i.e., the contributions of individual cell types to the overall profile depend on the proportions of other types present. Data show tumor-stroma cross-product modified t statistics versus probabilities (y axis), which were calculated as in B by comparing actual with permuted modified t statistics. The upper left portion of graph represents a large number of stroma-associated genes with a high likelihood deviation from a strictly linear model. The right portion of the graph reveals a number of tumor-associated genes that deviate from linearity. Among these is TCRγ, which is among the most discriminant tumor/no tumor genes even at low proportions of tumor; i.e., the expression of TCRγ is greater than that predicted by proportion of tumor cells alone. The stromal gene with the greatest deviation was TGF-β2, a candidate paracrine signaling molecule in prostate cancer.

FIG. 4. Validation the GeneChip analysis with LCM/qPCR. Six prostate specimens were used for isolation of each cell type by laser capture microdissection (LCM). Primer sets for 31 selected genes including house keeping genes, including several genes validated by IHC (e.g. Tubulin-β, PSA, Desmin, and Cytokeratin-15), were used for assay of target gene expression by quantitative RT-PCR (qPCR). The qPCR data were subjected to quantile normalization. To assess the independence between modified t-statistics from Table 2 and the specific expression levels obtained by qPCR, Spearman Rank-Order correlation coefficients were evaluated for 20 genes with modified t-statistic >2.4 for at least one cell type (i.e. genes included on Table 2). The levels of significance (the p-values) of these correlation coefficients were estimated by test for association/correlation between paired samples from R (ref. 11). This analysis yielded coefficients of 0.679 (p=0.0066 ), 0.602 (p=0.0029), and 0.511 (p=0.0138 ) for the tumor, BPH, and stroma cell types, respectively. Thus, the qRT-PCR specific expression levels correlated with low probability to the cell-type modified t-statistic, determined for the same genes, as generated from the analysis of the GeneChip data. The graphs plot modified t-statistic along the ordinate against qPCR endpoint value (abscissa).

DETAILED DESCRIPTION DEFINITIONS

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the invention(s) belong. All patents, patent applications, published applications and publications, Genbank sequences, websites and other published materials referred to throughout the entire disclosure herein, unless noted otherwise, are incorporated by reference in their entirety. In the event that there is a plurality of definitions for terms herein, those in this section prevail. Where reference is made to a URL or other such identifier or address, it understood that such identifiers can change and particular information on the internet can come and go, but equivalent information can be found by searching the internet. Reference thereto evidences the availability and public dissemination of such information.

Differential expression, as used herein, refers to both quantitative as well as qualitative differences in the extend of the genes' expression depending on differential development and/or tumor growth. Differentially expressed genes can represent marker genes, and/or target genes. The expression pattern of a differentially expressed gene disclosed herein can be utilized as part of a prognostic or diagnostic evaluation of a subject. The expression pattern of a differentially expressed gene can be used to identify the presence of a particular cell type in a sample. A differentially expressed gene disclosed herein can be used in methods for identifying reagents and compounds and uses of these reagents and compounds for the treatment of a subject as well as methods of treatment.

Biological activity or bioactivity or activity or biological function, which are used interchangeably, herein mean an effector or antigenic function that is directly or indirectly performed by a polypeptide (whether in its native or denatured conformation), or by any fragment thereof in vivo or in vitro. Biological activities include but are not limited to binding to polypeptides, binding to other proteins or molecules, enzymatic activity, signal transduction, activity as a DNA binding protein, as a transcription regulator, ability to bind damaged DNA, etc. A bioactivity can be modulated by directly affecting the subject polypeptide. Alternatively, a bioactivity can be altered by modulating the level of the polypeptide, such as by modulating expression of the corresponding gene.

The term gene expression analyte refers a biological molecule, e.g., a nucleic acid, peptide, hormone, etc., whose presence or concentration can be detected and correlated with gene expression.

As used herein, gene expression levels refers to the amount of biological macromolecule produced from a gene. For example, expression levels of a particular gene can refer to the amount of protein produced from that particular gene, or can refer to the amount of mRNA produced from that particular gene. Gene expression levels can refer to an absolute (e.g., molar or gram-quantity) levels or relative (e.g., the amount relative to a standard, reference, calibration, or to another gene expression level). Typically, gene expression levels used herein are relative expression levels. As used herein in regard to determining the relationship between cell content and expression levels, gene expression levels can be considered in terms of any manner of describing gene expression known in the art. For example, regression methods that consider gene expression levels can consider the measurement of the level of a gene expression analyte, or the level calculated or estimated according to the measurement of the level of a gene expression analyte.

Marker gene, as used herein, refers to a differentially expressed gene which expression pattern can serve as part of a phenotype-indicating method, such as a predictive method, prognostic or diagnostic method, or other cell-type distinguishing evaluation, or which, alternatively, can be used in methods for identifying compounds useful for the treatment or prevention of diseases or disorders, or for identifying compounds that modulate the activity of one or more gene products.

As used herein, a phenotype indicated by methods provided herein can be a diagnostic indication, a prognostic indication, or an indication of the presence of a particular cell type in a subject. Diagnostic indications include indication of a disease or a disorder in the subject, such as presence of tumor or neoplastic disease, inflammatory disease, autoimmune disease, and any other diseases known in the art that can be identified according to the presence or absence of particular cells or by the gene expression of cells. In another embodiment, prognostic indications refers to the likely or expected outcome of a disease or disorder, including, but not limited to, the likelihood of survival of the subject, likelihood of relapse, aggressiveness of the disease or disorder, indolence of the disease or disorder, and likelihood of success of a particular treatment regimen.

As used herein, a gene expression analyte refers to a biological molecule that indicates the expression of a particular gene. For example, a gene expression analyte can be a mRNA of a particular gene, or a fragment thereof (including, e.g., by-products of mRNA splicing and nucleolytic cleavage fragments), a protein of a particular gene or a fragment thereof (including, e.g., post-translationally modified proteins or by-products therefrom, and proteolytic fragments), and other biological molecules such as a carbohydrate, lipid or small molecule, whose presence or absence corresponds to the expression of a particular gene.

As used herein, gene expression levels that correspond to levels of gene expression analytes refers to the relationship between an analyte that indicates the expression of a gene, and the actual level of expression of the gene. Typically the level of a gene expression analyte is measured in experimental methods used to determine gene expression levels. As understood by one skilled in the art, the measured gene expression levels can represent gene expression at a variety of levels of detail (e.g., the absolute amount of a gene expressed, the relative amount of gene expressed, or an indication of increased or decreased levels of expression). The level of detail at which the levels of gene expression analytes can indicate levels of gene expression can be based on a variety of factors that include the number of controls used, the number of calibration experiments or reference levels determined, and other factors known in the art. In some methods provided herein, increase in the levels of a gene expression analyte can indicate increase in the levels of the gene expressed, and a decrease in the levels of a gene expression analyte can indicate decrease in the levels of the gene expressed.

As used herein, a regression relationship between relative content of a cell type and measured overall levels of a gene expression analyte refers to a quantitative relationship between cell type and level of gene expression analyte that is determined according to the methods provided herein based on the amount of cell type present in two or more samples and experimentally measured levels of gene expression analyte. In one embodiment, the regression relationship is determined by determining the regression of overall levels of each gene expression analyte on determined cell proportions. In one embodiment, the regression relationship is determined by linear regression, where the overall expression level or the expression analyte levle is treated as directly proportional to (e.g., linear in) cell percent either for each cell type in turn or all at once and the slopes of these linear relationships can be expressed as beta values.

As used herein, a heterogeneous sample refers to a sample that contains more than one cell type. For example, a heterogeneous sample can contain stromal cells and tumor cells. Typically, as used herein, the different cell types present in a sample are present in greater than about 0.1%, 0.2%, 0.3%, 0.5%, 0.7%, 1%, 2%, 3%, 4% or 5% or greater than 0.1%, 0.2%, 0.3%, 0.5%, 0.7%, 1%, 2%, 3%, 4% or 5%. As is understood in the art, cell samples, such as tissue samples from a subject, can contain minute amounts of a variety of cell types (e.g., nerve, blood, vascular cells). However, cell types that are not present in the sample in amounts greater than about 0.1%, 0.2%, 0.3%, 0.5%, 0.7%, 1%, 2%, 3%, 4% or 5% or greater than 0.1%, 0.2%, 0.3%, 0.5%, 0.7%, 1%, 2%, 3%, 4% or 5%, are not typically considered components of the heterogeneous cell sample, as used herein.

As used herein, related cell samples refers to samples that contain one or more cell types in common. Related cell samples can be samples from the same tissue type or from the same organ. Related cell samples can be from the same or different sources (e.g., same or different individuals or cell cultures, or a combination thereof). As provided herein, in the case of three or more different cell samples, it is not required that all samples contain a common cell type, but if a first sample does not contain any cell types that are present in the other samples, the first sample is not related to the other samples.

As used herein, tumor cells refers to cells with cytological and adherence properties consisting of nuclear and cyoplasmic features and patterns of cell-to-cell association that are known to pathologists skilled in the art as sufficient for the diagnosis as cancers of various types. In some embodiments, tumor cells have abnormal growth properties, such as neoplastic growth properties.

As used herein, cells associated with tumor refers to cells that, while not necessarily malignant, are present in tumorous tissues or organs or particular locations of tissues or organs, and are not present, or are present at insignificant levels, in normal tissues or organs, or in particular locations of tissues or organs.

As used herein, benign prostatic hyperplastic (BPH) cells refers to the cells of the epithelial lining of hyperplastic prostate glands.

As used herein, dilated cystic glands cells refers to the cells of the epithelial lining of dilated (atrophic) cystic prostate glands.

As used herein, stromal cells refers to the combined connective tissue cells and smooth muscle cells forming the stroma of an organ. Exemplary stromal cells are cells of the stroma of the prostate gland.

As used herein, a reference refers to a value or set of related values for one or more variables. In one example, a reference gene expression level refers to a gene expression level in a particular cell type. Reference expression levels can be determined according to the methods provided herein, or by determining gene expression levels of a cell type in a homogenous sample. Reference levels can be in absolute or relative amounts, as is known in the art. In certain embodiments, a reference expression level can be indicative of the presence of a particular cell type. For example, in certain embodiments, only one particular cell type may have high levels of expression of a particular gene, and, thus, observation of a cell type with high measured expression levels can match expression levels of that particular cell type, and thereby indicate the presence of that particular cell type in the sample. In another embodiment, a reference expression level can be indicative of the absence of a particular cell type. As provided herein, two or more references can be considered in determining whether or not a particular cell type is present in a sample, and also can be considered in determining the relative amount of a particular cell type that is present in the sample.

As used herein, a modified t statistic is a numerical representation of the ability of a particular gene product or indicator thereof to indicate the presence or absence of a particular cell type in a sample. A modified t statistic incorporating goodness of fit and effect size can be formulated according to known methods (see, e.g., Tusher (Proc. Natl. Acad. Sci. USA 98, 5116-5121, 2001)), where σβ is the standard error of the coefficient, and k is a small constant, as follows: t=β/(k+σβ)

As used herein, relative content of a cell type or cell proportion refers to the amount of a cell mixture that is populated by a particular cell type. Typically, heterogeneous cell mixtures contain two or more cell types, and, therefore, no single cell type makes up 100% of the mixture. Relative content can be expressed in any of a variety of forms known in the art; For example, relative content can be expressed as a percentage of the total amount of cells in a mixture, or can be expressed relative to the amount of a particular cell type. As used herein, percent cell or percent cell composition is the percent of all cells that a particular cell type accounts for in a heterologous cell mixture, such as a microscopic section sampling a tissue.

By array or matrix is meant an arrangement of addressable locations or addresses on a device. The locations can be arranged in two dimensional arrays, three dimensional arrays, or other matrix formats. The number of locations can range from several to at least hundreds of thousands. Most importantly, each location represents a totally independent reaction site. Arrays include but are not limited to nucleic acid arrays, protein arrays and antibody arrays. A nucleic acid array refers to an array containing nucleic acid probes, such as oligonucleotides, polynucleotides or larger portions of genes. The nucleic acid on the array can be single stranded. Arrays wherein the probes are oligonucleotides are referred to as oligonucleotide arrays or oligonucleotide chips. A microarray, herein also refers to a biochip or biological chip, an array of regions having a density of discrete regions of at least about 100/cm2, and can be at least about 1000/cm2. The regions in a microarray have typical dimensions, e.g., diameters, in the range of between about 10-250 μm, and are separated from other regions in the array by about the same distance. A protein array refers to an array containing polypeptide probes or protein probes which can be in native form or denatured. An antibody array refers to an array containing antibodies which include but are not limited to monoclonal antibodies (e.g. from a mouse), chimeric antibodies, humanized antibodies or phage antibodies and single chain antibodies as well as fragments from antibodies.

The term agonist, as used herein, is meant to refer to an agent that mimics or upregulates (e.g., potentiates or supplements) the bioactivity of a protein. An agonist can be a wild-type protein or derivative thereof having at least one bioactivity of the wild-type protein. An agonist can also be a compound that upregulates expression of a gene or which increases at least one bioactivity of a protein. An agonist can also be a compound which increases the interaction of a polypeptide with another molecule, e.g., a target peptide or nucleic acid.

As used herein a polynucleotide or nucleic acid molecule is a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, this term includes double- and single-stranded DNA and RNA. It also includes known types of modifications, for example, labels which are known in the art, methylation, caps, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), those containing pendant moieties, such as, for example proteins (including e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.),those with intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e.g., metals, radioactive metals, etc.), those containing alkylators, those with modified linkages (e.g., alpha anomeric nucleic acids, etc.), those containing nucleotide analogs (e.g., peptide nucleic acids), as well as unmodified forms of the polynucleotide.

As used herein, a polynucleotide derived from a designated sequence refers to a polynucleotide sequence which is comprised of a sequence of approximately at least about 6 nucleotides, at least about 8 nucleotides, at least about 10-12 nucleotides, or at least about 15-20 nucleotides corresponding to a region of the designated nucleotide sequence. Corresponding polynucleotides are homologous to or complementary to a designated sequence. Typically, the sequence of the region from which the polynucleotide is derived is homologous to or complementary to a sequence that is unique to a gene provided herein.

A recombinant protein is a protein made using recombinant techniques, i.e. through the expression of a recombinant nucleic acid as depicted above. A recombinant protein is distinguished from naturally occurring protein by at least one or more characteristics. For example, the protein may be isolated or purified away from some or all of the proteins and compounds with which it is normally associated in its wild type host, and thus may be substantially pure. For example, an isolated protein is unaccompanied by at least some of the material with which it is normally associated in its natural state, constituting at least about 0.5%, or at least about 5% by weight of the total protein in a given sample. A substantially pure protein comprises at least about 50-75% by weight of the total protein, at least about 80%, or at least about 90%. The definition includes the production of a protein from one organism in a different organism or host cell. Alternatively, the protein may be made at a significantly higher concentration than is normally seen, through the use of an inducible promoter or high expression promoter, such that the protein is made at increased concentration levels. Alternatively, the protein may be in a form not normally found in nature, as in the addition of an epitope tag or amino acid substitutions, insertions and deletions, as discussed below.

As used herein, disease or disorder refers to a pathological condition in an organism resulting from, e.g., infection or genetic defect, and characterized by identifiable symptoms.

Whether any two nucleic acid molecules have nucleotide sequences that are at least, for example, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical can be determined using known computer algorithms such as the FAST A program, using for example, the default parameters as in Pearson et al. (1988) Proc. Natl. Acad. Sci. USA 85:2444 (other programs include the GCG program package (Devereux, J., et al., Nucleic Acids Research 12(I):387 (1984)), BLASTP, BLASTN, FASTA (Atschul, S. F., et al., J Molec Biol 215:403 (1990); Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo et al. (1988) SIAM J Applied Math 48:1073). For example, the BLAST function of the National Center for Biotechnology Information database can be used to determine identity. Other commercially or publicly available programs include, DNAStar MegAlign program (Madison, Wis.) and the University of Wisconsin Genetics Computer Group (UWG) Gap program (Madison Wis.)). Percent homology or identity of proteins and/or nucleic acid molecules can be determined, for example, by comparing sequence information using a GAP computer program (e.g., Needleman et al. (1970) J. Mol. Biol. 48:443, as revised by Smith and Waterman ((1981) Adv. Appl. Math. 2:482). Briefly, the GAP program defines similarity as the number of aligned symbols (i.e., nucleotides or amino acids) which are similar, divided by the total number of symbols in the shorter of the two sequences. Default parameters for the GAP program can include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) and the weighted comparison matrix of Gribskov et al. (1986) Nucl. Acids Res. 14:6745, as described by Schwartz and Dayhoff, eds., ATLAS OF PROTEIN SEQUENCE AND STRUCTURE, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps. Therefore, as used herein, the term identity represents a comparison between a test and a reference polypeptide or polynucleotide.

As used herein, the term at least 90% identical to refers to percent identities from 90 to 100 relative to the reference polypeptides. Identity at a level of 90% or more is indicative of the fact that, assuming for exemplification purposes a test and reference polynucleotide length of 100 amino acids are compared. No more than 10% (i.e., 10 out of 100) amino acids in the test polypeptide differs from that of the reference polypeptides. Similar comparisons can be made between a test and reference polynucleotides. Such differences can be represented as point mutations randomly distributed over the entire length of an amino acid sequence or they can be clustered in one or more locations of varying length up to the maximum allowable, e.g. 10/100 amino acid difference (approximately 90% identity). Differences are defined as nucleic acid or amino acid substitutions, or deletions. At the level of homologies or identities above about 85-90%, the result should be independent of the-program and gap parameters set; such high levels of identity can be assessed readily, often without relying on software.

As used herein, primer refers to an oligonucleotide containing two or more deoxyribonucleotides or ribonucleotides, typically more than three, from which synthesis of a primer extension product can be initiated. Experimental conditions conducive to synthesis include the presence of nucleoside triphosphates and an agent for polymerization and extension, such as DNA polymerase, and a suitable buffer, temperature and pH.

As used herein, animals include any animal, such as, but are not limited to, goats, cows, deer, sheep, rodents, pigs and humans. Non-human animals, exclude humans as the contemplated animal. The SPs provided herein are from any source, animal, plant, prokaryotic and fungal.

As used herein, genetic therapy involves the transfer of heterologous nucleic acid, such as DNA, into certain cells, target cells, of a mammal, particularly a human, with a disorder or conditions for which such therapy is sought. The nucleic acid, such as DNA, is introduced into the selected target cells in a manner such that the heterologous nucleic acid, such as DNA, is expressed and a therapeutic product encoded thereby is produced. Alternatively, the heterologous nucleic acid, such as DNA, can in some manner mediate expression of DNA that encodes the therapeutic product, or it can encode a product, such as a peptide or RNA that in some manner mediates, directly or indirectly, expression of a therapeutic product. Genetic therapy can also be used to deliver nucleic acid encoding a gene product that replaces a defective gene or supplements a gene product produced by the mammal or the cell in which it is introduced. The introduced nucleic acid can encode a therapeutic compound, such as a growth factor inhibitor thereof, or a tumor necrosis factor or inhibitor thereof, such as a receptor therefor, that is not normally produced in the mammalian host or that is not produced in therapeutically effective amounts or at a therapeutically useful time. The heterologous nucleic acid, such as DNA, encoding the therapeutic product can be modified prior to introduction into the cells of the afflicted host in order to enhance or otherwise alter the product or expression thereof. Genetic therapy can also involve delivery of an inhibitor or repressor or other modulator of gene expression.

As used herein, heterologous nucleic acid is nucleic acid that encodes RNA or RNA and proteins that are not normally produced in vivo by the cell in which it is expressed or that mediates or encodes mediators that alter expression of endogenous nucleic acid, such as DNA, by affecting transcription, translation, or other regulatable biochemical processes. Heterologous nucleic acid, such as DNA, can also be referred to as foreign nucleic acid, such as DNA. Any nucleic acid, such as DNA, that one of skill in the art would recognize or consider as heterologous or foreign to the cell in which is expressed is herein encompassed by heterologous nucleic acid; heterologous nucleic acid includes exogenously added nucleic acid that is also expressed endogenously. Examples of heterologous nucleic acid include, but are not limited to, nucleic acid that encodes traceable marker proteins, such as a protein that confers drug resistance, nucleic acid that encodes therapeutically effective substances, such as anti-cancer agents, enzymes and hormones, and nucleic acid, such as DNA, that encodes other types of proteins, such as antibodies. Antibodies that are encoded by heterologous nucleic acid can be secreted or expressed on the surface of the cell in which the heterologous nucleic acid has been introduced. Heterologous nucleic acid is generally not endogenous to the cell into which it is introduced, but has been obtained from another cell or prepared synthetically. Generally, although not necessarily, such nucleic acid encodes RNA and proteins that are not normally produced by the cell in which it is now expressed.

As used herein, a therapeutically effective product for gene therapy is a product that is encoded by heterologous nucleic acid, typically DNA, that, upon introduction of the nucleic acid into a host, a product is expressed that ameliorates or eliminates the symptoms, manifestations of an inherited or acquired disease or that cures the disease. Also included are biologically active nucleic acid molecules, such as RNAi and antisense.

As used herein, disease or disorder treatment or compound refers to any therapeutic regimen and/or agent that, when used alone or in combination with other treatments or compounds, can alleviate, reduce, ameliorate, prevent, or place or maintain in-a state of remission of clinical symptoms or diagnostic markers associated with the disease or disorder.

As used herein, nucleic acids include DNA, RNA and analogs thereof, including peptide nucleic acids (PNA) and mixtures thereof. Nucleic acids can be single or double-stranded. When referring to probes or primers, optionally labeled, with a detectable label, such as a fluorescent or radiolabel, single-stranded molecules are contemplated. Such molecules are typically of a length such that their target is statistically unique or of low copy number (typically less than 5, generally less than 3) for probing or priming a library. Generally a probe or primer contains at least 14, 16 or 30 contiguous of sequence complementary to or identical a gene of interest. Probes and primers can be 10, 20, 30, 50, 100 or more nucleic acids long.

As used herein, operative linkage of heterologous nucleic acids to regulatory and effector sequences of nucleotides, such as promoters, enhancers, transcriptional and translational stop sites, and other signal sequences refers to the relationship between such nucleic acid, such as DNA, and such sequences of nucleotides. Thus, operatively linked or operationally associated refers to the functional relationship of nucleic acid, such as DNA, with regulatory and effector sequences of nucleotides, such as promoters, enhancers, transcriptional and translational stop sites, and other signal sequences. For example, operative linkage of DNA to a promoter refers to the physical and functional relationship between the DNA and the promoter such that the transcription of such DNA is initiated from the promoter by an RNA polymerase that specifically recognizes, binds to and transcribes the DNA. In order to optimize expression and/or in vitro transcription, it can be necessary to remove, add or alter 5′ untranslated portions of the clones to eliminate extra, potential inappropriate alternative translation initiation (i.e., start) codons or other sequences that can interfere with or reduce expression, either at the level of transcription or translation. Alternatively, consensus ribosome binding sites (see, e.g., Kozak J. Biol. Chem. 266:19867-19870 (1991)) can be inserted immediately 5′ of the start codon and can enhance expression. The desirability of (or need for) such modification can be empirically determined.

As used herein, a sequence complementary to at least a portion of an RNA, with reference to antisense oligonucleotides, means a sequence having sufficient complementarity to be able to hybridize with the RNA, generally under moderate or high stringency conditions, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA (or dsRNA) can thus be tested, or triplex formation can be assayed. The ability to hybridize depends on the degree of complementarily and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with a gene encoding RNA it can contain and still form a stable duplex (or triplex, as the case can be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

As used herein, antisense polynucleotides refer to synthetic sequences of nucleotide bases complementary to mRNA or the sense strand of double-stranded DNA. Admixture of sense and antisense polynucleotides under appropriate conditions leads to the binding of the two molecules, or hybridization. When these polynucleotides bind to (hybridize with) mRNA, inhibition of protein synthesis (translation) occurs. When these polynucleotides bind to double-stranded DNA, inhibition of RNA synthesis (transcription) occurs. The resulting inhibition of translation and/or transcription leads to an inhibition of the synthesis of the protein encoded by the sense strand. Antisense nucleic acid molecules typically contain a sufficient number of nucleotides to specifically bind to a target nucleic acid, generally at least 5 contiguous nucleotides, often at least 14 or 16 or 30 contiguous nucleotides or modified nucleotides complementary to the coding portion of a nucleic acid molecule that encodes a gene of interest.

As used herein, antibody refers to an immunoglobulin, whether natural or partially or wholly synthetically produced, including any derivative thereof that retains the specific binding ability the antibody. Hence antibody includes any protein having a binding domain that is homologous or substantially homologous to an immunoglobulin binding domain. Antibodies include members of any immunoglobulin groups, including, but not limited to, IgG, IgM, IgA, IgD, IgY and IgE.

As used herein, antibody fragment refers to-any derivative of an antibody that is less than full-length, retaining at least a portion of the full-length antibody's specific binding ability. Examples of antibody fragments include, but are not limited to, Fab, Fab′, F(ab)₂, single-chain Fvs (scFV), FV, dsFV diabody and Fd fragments. The fragment can include multiple chains linked together, such as by disulfide bridges. An antibody fragment generally contains at least about 50 amino acids and typically at least 200 amino acids.

As used herein, an Fv antibody fragment is composed of one variable heavy domain (V_(H)) and one variable light domain linked by noncovalent interactions.

As used herein, a dsFV refers to an Fv with an engineered intermolecular disulfide bond, which stabilizes the V_(H)-V_(L) pair.

As used herein, an F(ab)₂ fragment is an antibody fragment that results from digestion of an immunoglobulin with pepsin at pH 4.0-4.5; it can be recombinantly expressed to produce the equivalent fragment.

As used herein, Fab fragments are antibody fragments that result from digestion of an immunoglobulin with papain; they can be recombinantly expressed to produce the equivalent fragment.

As used herein, scFVs refer to antibody fragments that contain a variable light chain (V_(L)) and variable heavy chain (V_(H)) covalently connected by a polypeptide linker in any order. The linker is of a length such that the two variable domains are bridged without substantial interference. Included linkers are (Gly-Ser)_(n)residues with some Glu or Lys residues dispersed throughout to increase solubility.

As used herein, humanized antibodies refer to antibodies that are modified to include human sequences of amino acids so that administration to a human does not provoke an immune response. Methods for preparation of such antibodies are known. For example, to produce such antibodies, the encoding nucleic acid in the hybridoma or other prokaryotic or eukaryotic cell, such as an E. coli or a CHO cell, that expresses the monoclonal antibody is altered by recombinant nucleic acid techniques to express an antibody in which the amino acid composition of the non-variable region is based on human antibodies. Computer programs have been designed to identify such non-variable regions.

As used herein, diabodies are dimeric scFV; diabodies typically have shorter peptide linkers than scFvs, and they generally dimerize.

As used herein, production by recombinant means by using recombinant DNA methods means the use of the well known methods of molecular biology for expressing proteins encoded by cloned DNA.

As used herein, an effective amount of a compound for treating a particular disease is an amount that is sufficient to ameliorate, or in some manner reduce the symptoms associated with the disease. Such amount can be administered as a single dosage or can be administered according to a regimen, whereby it is effective. The amount can cure the disease but, typically, is administered in order to ameliorate the symptoms of the disease. Repeated administration can be required to achieve the desired amelioration of symptoms.

As used herein, a compound that modulates the activity of a gene product either decreases or increases or otherwise alters the activity of the protein or, in some manner up- or down-regulates or otherwise alters expression of the nucleic acid in a cell.

As used herein, pharmaceutically acceptable salts, esters or other derivatives of the conjugates include any salts, esters or derivatives that can be readily prepared by those of skill in this art using known methods for such derivatization and that produce compounds that can be administered to animals or humans without substantial toxic effects and that either are pharmaceutically active or are prodrugs.

As used herein, a drug or compound identified by the screening methods provided herein refers to any compound that is a candidate for use as a therapeutic or as a lead compound for the design of a therapeutic. Such compounds can be small molecules, including small organic molecules, peptides, peptide mimetics, antisense molecules or dsRNA, such as RNAi, antibodies, fragments of antibodies, recombinant antibodies and other such compounds that can serve as drug candidates or lead compounds.

As used herein, a non-malignant cell adjacent to a malignant cell in a subject, refers to a cell that has a normal morphology (e.g., is not classified as neoplastic or malignant by a pathologist, cell sorter, or other cell classification method), but, while the cell had been present in tact in the subject, the cell had been adjacent to a malignant cell or malignant cells. As provided herein, cells of a particular type (e.g., stroma) adjacent to a malignant cell or malignant cells can display an expression pattern that differs from cells of the same type that are not adjacent to a malignant cell or malignant cells. In accordance with the methods provided herein, cells that are adjacent to malignant cells can be distinguished from cells of the same type that are adjacent to non-malignant cells, according to their differential gene expression. As used herein regarding the location of cells, adjacent refers to a first cell and a second cell being sufficiently proximal such that the first cell influences the gene expression of the second cell. For example, adjacent cells can include cells that are in direct contact with each other, adjacent cell can include cells within 500 microns, 300 microns, 200 microns 100 microns or 50 microns, of each other.

As used herein, tumor refers to a collection of malignant cells. Malignant as applied to a cell refers to a cell that grows in an uncontrolled fashion. In some embodiments, a malignant cell can be anaplastic. In some embodiments, a malignant cell can be capable of metastasizing.

As used herein: stringency of hybridization in determining percentage mismatch is as follows:

1) high stringency: 0.1×SSPE, 0.1% SDS, 65° C.

2) medium stringency: 0.2×SSPE, 0.1% SDS, 50° C.

3) low stringency: 1.0×SSPE, 0.1% SDS, 50° C.

As used herein, vector (or plasmid) refers to discrete elements that are used to introduce heterologous nucleic acid into cells for either expression or replication thereof. The vectors typically remain episomal, but can be designed to effect integration of a gene or portion thereof into a chromosome of the genome. Also contemplated are vectors that are artificial chromosomes, such as yeast artificial chromosomes and mammalian artificial chromosomes. Selection and use of such vehicles are well known to those of skill in the art. An expression vector includes vectors capable of expressing DNA that is operatively linked with regulatory sequences, such as promoter regions, that are capable of effecting expression of such DNA fragments. Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the cloned DNA. Appropriate expression vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or those that integrate into the host cell genome.

As used herein a disease prognosis refers to a forecast of the probable outcome of a disease or of a probable outcome resultant from a disease. Non-limiting examples of disease prognosis include likely relapse of disease, likely aggressiveness of disease, likely indolence of disease, likelihood of survival of the subject, likelihood of success in treating a disease, condition in which a particular treatment regimen is likely to be more effective than another treatment regimen, and combinations thereof.

As used herein, aggressiveness of a tumor or malignant cell refers to the capacity of one or more cells to attain a position in the body away from the tissue or organ of origin, attach to another portion of the body, and multiply. Experimentally, aggressiveness can be described in one or more manners, including, but not limited to, post-diagnosis survival of subject, relapse of tumor, and metastasis of tumor. Thus, in the disclosures provided herein, data indicative of time length of survival, relapse, non-relapse, time length for metastasis, or non-metastasis, are indicative of the aggressiveness of a tumor or a malignant cell. When survival is considered, one skilled in the art will recognize that aggressiveness is inversely related to the length of time of survival of the subject. When time length for metastasis is considered, one skilled in the art will recognize that aggressiveness is directly related to the length of time of survival of a subject. As used herein, indolence refers to non-aggressiveness of a tumor or malignant cell; thus, the more aggressive a tumor or cell, the less indolent, and vice versa. As an example of a cell attaining a position in the body away from the tissue or organ of origin, a malignant prostate cell can attain an extra-prostatic position, and thus have one characteristic of an aggressive malignant cell. Attachment of cells can be, for example, on the lymph node or bone marrow of a subject, or other sites known in the art.

As used herein, a combination refers to any association between two or among more items.

As used herein, a composition refers to any mixture. It can be a solution, a suspension, liquid, powder, a paste, aqueous, non-aqueous or any combination thereof.

As used herein, fluid refers to any composition that can flow. Fluids thus encompass compositions that are in the form of semi-solids, pastes, solutions, aqueous mixtures, gels, lotions, creams and other such compositions.

For clarity of disclosure, and not by way of limitation, the detailed description is divided into the subsections that follow.

Cell-type-associated patterns of gene expression

Primary tissues are composed of many (e.g., 2 or more) types of cells. Identification of genes expressed in a specific cell type present within a tissue in other methods can require physical separation of that cell type and the cell type's subsequent assay. Although it is possible to physically separate cells according to type, by methods such as laser capture microdissection, centrifugation, FACS, and the like, this is time consuming and costly and in certain embodiments impractical to perform. Known expression profiling assays (either RNA or protein) of primary tissues or other specimens containing multiple cell types either (1) do not take into account that multiple cell types are present or (2) physically separate the component cell types before performing the assay. Other analyses have been performed without regard to the presence of multiple cell types, thereby identifying markers indicative of a shift in the relative proportion of various cell types present in a sample, but not representative of a specific cell type. Previous analytic approaches cannot discern interactions between different types of cells.

Provided herein are methods, compositions and kits based on the development of a model, where the level of each gene product assayed can be correlated to a specific cell type. This approach for determination of cell-type-specific gene expression obviates the need for physical separation of cells from tissues or other specimens with heterogeneous cell content. Furthermore, this method permits determination of the interaction between the different types of cells contained in such heterogeneous mixtures, which would otherwise have been difficult or impossible had the cells been first physically separated and then assayed. Using the approaches provided herein, a number of biomarkers can be identified related to various diseases and disorders. Exemplified herein is the identification of biomarkers for prostate cancer and benign prostatic hypertophy. Such biomarkers can be used in diagnosis and prognosis and treatment decisions.

The methods, compositions, combinations and kits provided herein employ a regression-based approach for identification of cell-type-specific patterns of gene expression in samples containing more than one type of cell. In one example, the methods, compositions, combinations and kits provided herein employ a regression-based approach for identification of cell-type-specific patterns of gene expression in cancer. These methods, compositions, combinations and kits provided herein can be used in the identification of genes that are differentially expressed in malignant versus non-malignant cells and further identify tumor-dependent changes in gene expression of non-malignant cells associated with malignant cells relative to non-malignant cells not associated with malignant cells. The methods,.compositions, combinations and kits provided herein also can be used in correlating a phenotype with gene expression in one or more cell types. For example such a method can include determining the relative content of each cell type in two or more related heterogeneous cell samples, wherein at least two of the samples do not contain the same relative content of each cell type, measuring overall levels of one or more gene expression analytes in each sample, determining the regression relationship between the relative content of each cell type and the measured overall levels, and calculating the level of each of the one or more analytes in each cell type according to the regression relationship, where gene expression levels correspond to the calculated levels of analytes. In another example such a method can include determining the relative content of each cell type in two or more related heterogeneous cell samples, wherein at least two of the samples do not contain the same relative content of each cell type, measuring overall levels of two or more gene expression analytes in each sample, determining the regression relationship between the relative content of each cell type and the measured overall levels, and calculating the level of each of the two or more analytes in each cell type according to the regression relationship, where gene expression levels correspond to the calculated levels of analytes. Such methods can further include identifying genes differentially expressed in at least one cell type relative to at least one other cell type. In such methods, the analyte can be a nucleic acid molecule and a protein.

The methods provided herein can be used for determining cell-type-specific gene expression in any heterogeneous cell population. The methods provided herein can find application in samples known to contain a variety of cell types, such as brain tissue samples and muscle tissue samples. The methods provided herein also can find application in samples in which separation of cell type can represent a tedious or time consuming operation, which is no longer required under the methods provided herein. Samples used in the present methods can be any of a variety of samples, including, but not limited to, blood, cells from blood (including, but not limited to, non-blood cells such as epithelial cells in blood), plasma, serum, spinal fluid, lymph fluid, skin, sputum, alimentary and genitourinary samples (including, but not limited to, urine, semen, seminal fluid, prostate aspirate, prostatic fluid, and fluid from the seminal vesicles), saliva, milk, tissue specimens (including, but not limited to, prostate tissue specimens), tumors, organs, and also samples of in vitro cell culture constituents.

In certain embodiments, the methods provided herein can be used to differentiate true markers of tumor cells, hyperplastic cells, and stromal cells of cancer. As exemplified herein, least squares regression using individual cell-type proportions can be used to produce clear predictions of cell-specific expression for a large number of genes. In an example provided herein applied to prostate cancer, many of these predictions are accepted on the basis of prior knowledge of prostate gene expression and biology, which provide confidence in the method. These are illustrated by numerous genes predicted to be preferentially expressed by stromal cells that are characteristic of connective tissue and only poorly expressed or absent in epithelial cells.

In some embodiments, the methods provided herein allow segregation of molecular tumor and nontumor markers into more discrete and informative groups. Thus, genes identified as tumor-associated can be further categorized into tumor versus stroma (epithelial versus mesenchymal) and tumor versus hyperplastic (perhaps reflecting true differences between the malignant cell and its hyperplastic counterpart). The methods provided herein can be used to distinguish tumor and non-tumor markers in a variety of cancers, including, but not limited to cancers classified by site such as cancer of the oral cavity and pharynx (lip, tongue, salivary gland, floor of mouth, gum and other mouth, nasopharynx, tonsil, oropharynx, hypopharynx, other oral/pharynx); cancers of the digestive system (esophagus; stomach; small intestine; colon and rectum; anus, anal canal, and anorectum; liver; intrahepatic bile duct; gallbladder; other biliary; pancreas; retroperitoneum; peritoneum, omentum, and mesentery; other digestive); cancers of the respiratory system (nasal cavity, middle ear, and sinuses; larynx; lung and bronchus; pleura; trachea, mediastinum, and other respiratory); cancers of the mesothelioma; bones and joints; and soft tissue, including heart; skin cancers, including melanomas and other non-epithelial skin cancers; Kaposi's sarcoma and breast cancer; cancer of the female genital system (cervix.uteri; corpus uteri; uterus, nos; ovary; vagina; vulva; and other female genital); cancers of the male genital system (prostate gland; testis; penis; and other male genital); cancers of the urinary system (urinary bladder; kidney and renal pelvis; ureter; and other urinary); cancers of the eye and orbit; cancers of the brain and nervous system (brain; and other nervous system); cancers of the endocrine system (thyroid gland and other endocrine, including thymus); lymphomas (Hodgkin's disease and non-Hodgkin's lymphoma), multiple myeloma, and leukemias (lymphocytic leukemia; myeloid leukemia; monocytic leukemia; and other leukemias); and cancers classified by histological type, such as Neoplasm, malignant; Carcinoma, NOS; Carcinoma, undifferentiated, NOS; Giant and spindle cell carcinoma; Small cell carcinoma, NOS; Papillary carcinoma, NOS; Squamous cell carcinoma, NOS; Lymphoepithelial carcinoma; Basal cell carcinoma, NOS; Pilomatrix carcinoma; Transitional cell carcinoma, NOS; Papillary transitional cell carcinoma; Adenocarcinoma, NOS; Gastrinoma, malignant; Cholangiocarcinoma; Hepatocellular carcinoma, NOS; Combined hepatocellular carcinoma and cholangiocarcinoma; Trabecular adenocarcinoma; Adenoid cystic carcinoma; Adenocarcinoma in adenomatous polyp; Adenocarcinoma, familial polyposis coli; Solid carcinoma, NOS; Carcinoid tumor, malignant; Bronchiolo-alveolar adenocarcinoma; Papillary adenocarcinoma, NOS; Chromophobe carcinoma; Acidophil carcinoma; oxyphilic adenocarcinoma; Basophil carcinoma; Clear cell adenocarcinoma, NOS; Granular cell carcinoma; Follicular adenocarcinoma, NOS; Papillary and follicular adenocarcinoma; Nonencapsulating sclerosing carcinoma; Adrenal cortical carcinoma; Endometroid carcinoma; Skin appendage carcinoma; Apocrine adenocarcinoma; Sebaceous adenocarcinoma; Ceruminous adenocarcinoma; Mucoepidermoid carcinoma; Cystadenocarcinoma, NOS; Papillary cystadenocarcinoma, NOS; Papillary serous cystadenocarcinoma; Mucinous cystadenocarcinoma, NOS; Mucinous adenocarcinoma; Signet ring cell carcinoma; Infiltrating duct carcinoma; Medullary carcinoma, NOS; Lobular carcinoma; Inflammatory carcinoma; Paget's disease, mammary; Acinar cell carcinoma; Adenosquamous carcinoma; Adenocarcinoma w/squamous metaplasia; Thymoma, malignant; Ovarian stromal tumor, malignant; Thecoma, malignant; Granulosa cell tumor, malignant; Androblastoma, malignant; Sertoli cell carcinoma; Leydig cell tumor, malignant; Lipid cell tumor, malignant; Paraganglioma, malignant; Extra-mammary paraganglioma, malignant; Pheochromocytoma; Glomangiosarcoma; Malignant melanoma, NOS; Amelanotic melanoma; Superficial spreading melanoma; Malig melanoma in giant pigmented nevus; Epithelioid cell melanoma; Blue nevus, malignant; Sarcoma, NOS; Fibrosarcoma, NOS; Fibrous histiocytoma, malignant; Myxosarcoma; Liposarcoma, NOS; Leiomyosarcoma, NOS; Rhabdomyosarcoma, NOS; Embryonal rhabdomyosarcoma; Alveolar rhabdomyosarcoma; Stromal sarcoma, NOS; Mixed tumor, malignant, NOS; Mullerian mixed tumor; Nephroblastoma; Hepatoblastoma; Carcinosarcoma, NOS; Mesenchymoma, malignant; Brenner tumor, malignant; Phyllodes tumor, malignant; Synovial sarcoma, NOS; Mesothelioma, malignant; Dysgerminoma; Embryonal carcinoma, NOS; Teratoma, malignant, NOS; Struma ovarii, malignant; Choriocarcinoma; Mesonephroma, malignant; Hemangiosarcoma; Hemangioendothelioma, malignant; Kaposi's sarcoma; Hemangiopericytoma, malignant; Lymphangiosarcoma; Osteosarcoma, NOS; Juxtacortical osteosarcoma; Chondrosarcoma, NOS; Chondroblastoma, malignant; Mesenchymal chondrosarcoma; Giant cell tumor of bone; Ewing's sarcoma; Odontogenic tumor, malignant; Ameloblastic odontosarcoma; Ameloblastoma, malignant; Ameloblastic fibrosarcoma; Pinealoma, malignant; Chordoma; Glioma, malignant; Ependymoma, NOS; Astrocytoma, NOS; Protoplasmic astrocytoma; Fibrillary astrocytoma; Astroblastoma; Glioblastoma, NOS; Oligodendroglioma, NOS; Oligodendroblastoma; Primitive neuroectodermal; Cerebellar sarcoma, NOS; Ganglioneuroblastoma; Neuroblastoma, NOS; Retinoblastoma, NOS; Olfactory neurogenic tumor; Meningioma, malignant; Neurofibrosarcoma; Neurilemmoma, malignant; Granular cell tumor, malignant; Malignant lymphoma, NOS; Hodgkin's disease, NOS; Hodgkin's; paragranuloma, NOS; Malignant lymphoma, small lymphocytic; Malignant lymphoma, large cell, diffuse; Malignant lymphoma, follicular, NOS; Mycosis fungoides; Other specified non-Hodgkin's lymphomas; Malignant histiocytosis; Multiple myeloma; Mast cell sarcoma; Immunoproliferative small intestinal disease; Leukemia, NOS; Lymphoid leukemia, NOS; Plasma cell leukemia; Erythroleukemia; Lymphosarcoma cell leukemia; Myeloid leukemia, NOS; Basophilic leukemia; Eosinophilic leukemia; Monocytic leukemia, NOS; Mast cell leukemia; Megakaryoblastic leukemia; Myeloid sarcoma; and Hairy cell leukemia.

In an example comparing the results of a prostate tissue analysis using the methods provided herein to the results of previous methods, the vast majority of markers associated with normal prostate tissues in previous microarray-based studies relate to cells of the stroma. This result is not surprising given that normal samples can be composed of a relatively greater proportion of stromal cells.

In the example of prostate analysis, the strongest single discriminator between benign prostate hyperplasia (BPH) cells and tumor cells was CK15, a result confirmed by immunohistochemistry. CK15 has previously received little attention in this context, but BPH markers play an important role in the diagnosis of ambiguous clinical cases.

Transcripts whose expression levels have high covariance with cross-products of tissue proportions suggest that expression in one cell type depends on the proportion of another tissue, as would be expected in a paracrine mechanism. The stroma transcript with the highest dependence on tumor percentage was TGF-92. Another such stroma cell gene for which immunohistochemistry was practical was desmin, which showed altered staining in the tumor-associated stroma. In fact, a large number of typical stroma cell genes displayed dependence on the proportion of tumor, adding evidence to the speculation that tumor-associated stroma differs from non-associated stroma. Tumor-stroma paracrine signaling can be reflected in peritumor halos of altered gene expression that can present a much bigger target for detection than the tumor cells alone.

The methods provided herein provide a straightforward approach using simple and multiple linear regression to identify genes whose expression in tissue is specifically correlated with a specific cell type (e.g., in prostate tissue with either tumor cells, BPH epithelial cells or stromal cells). Context-dependent expression that is not readily attributable to single cell types is also recognized. The investigative approach described here is also applicable to a wide variety of tumor marker discovery investigations in a variety of tissues and organs. The exemplary prostate analysis results presented herein demonstrate the ability to identify a large number of gene candidates as specific products of various cells involved in prostate cancer pathogenesis.

A model for cell-specific gene expression is established by both (1) determination of the proportion of each constituent cell type (e.g., epithelium, stroma, tumor, or other discriminating entity) within a given type of tissue or specimen (e.g., prostate, breast, colon, marrow, and the like) and (2) assay of the expression profile (e.g., RNA or protein) of that same tissue or specimen. In some embodiments, cell type specific expression of a gene can be determined by fitting this model to data from a collection of tissue samples.

The methods provided herein can include a step of determining the relative content of each cell type in a heterogeneous sample. Identification of a cell type in a sample can include identifying cell types that are present in a sample in amounts greater than about 1%, 2%, 3%, 4% or 5% or greater than 1%, 2%, 3%, 4% or 5%.

Any of a variety of known methods for cell type identification can be used herein. For example, cell type can be determined by an individual skilled in the ability to identify cell types, such as a pathologist or a histologist. In another example, cell types can be determined by cell sorting and/or flow cytometry methods known in the art.

The methods provided herein can be used to determine that the nucleotide or proteins are differentially expressed in at least one cell type relative to at least one other cell type. Such genes include those that are up-regulated (i.e. expressed at a higher level), as well as those that are down-regulated (i.e. expressed at a lower level). Such genes also include sequences that have been altered (i.e., truncated sequences or sequences with substitutions, deletions or insertions, including point mutations) and show either the same expression profile or an altered profile. In certain embodiments, the genes can be from humans; however, as will be appreciated by those in the art, genes from other organisms can be useful in animal models of disease and drug evaluation; thus, other genes are provided, from vertebrates, including mammals, including rodents (rats, mice, hamsters, guinea pigs, etc.), primates, and farm animals (including sheep, goats, pigs, cows, horses, etc). In some cases, prokaryotic genes can be useful. Gene expression in any of a variety of organisms can be determined by methods provided herein or otherwise known in the art.

Gene products measured according to the methods provided herein can be nucleic acid molecules, including, but not limited to mRNA or an amplicate or complement thereof, polypeptides, or fragments thereof. Methods and compositions for the detection of nucleic acid molecules and proteins are known in the art. For example, oligonucleotide probes and primers can be used in the detection of nucleic acid molecules, and antibodies can be used in the detection of polypeptides.

In the methods provided herein, one or more gene products can be detected. In some embodiments, two or more gene products are detected. In other embodiments, 3 or more, 4 or more, 5 or more, 7 or more, 10 or more 15 or more, 20 or more 25, or more, 35 or more, 50 or more, 75 or more, or l00 or more gene products can be detected in the methods provided herein.

The expression levels of the marker genes in a sample can be determined by any method or composition known in the art. The expression level can be determined by isolating and determining the level (i.e., amount) of nucleic acid transcribed from each marker gene. Alternatively, or additionally, the level of specific proteins translated from mRNA transcribed from a marker gene can be determined.

Determining the level of expression of specific marker genes can be accomplished by determining the amount of mRNA, or polynucleotides derived therefrom, or protein present in a sample. Any method for determining protein or RNA levels can be used. For example, protein or RNA is isolated from a sample and separated by gel electrophoresis. The separated protein or RNA is then transferred to a solid support, such as a filter. Nucleic acid or protein (e.g., antibody) probes representing one or more markers are then hybridized to the filter by hybridization, and the amount of marker-derived protein or RNA is determined. Such determination can be visual, or machine-aided, for example, by use of a densitometer. Another method of determining protein or RNA levels is by use of a dot-blot or a slot-blot. In this method, protein, RNA, or nucleic acid derived therefrom, from a sample is labeled. The protein, RNA or nucleic acid derived therefrom is then hybridized to a filter containing oligonucleotides or antibodies derived from one or more marker genes, wherein the oligonucleotides or antibodies are placed upon the filter at discrete, easily-identifiable locations. Binding, or lack thereof, of the labeled protein or RNA to the filter is determined visually or by densitometer. Proteins or polynucleotides can be labeled using a radiolabel or a fluorescent (i.e., visible) label.

Methods provided herein can be used to detect mRNA or amplicates thereof, and any fragment thereof. In one example, introns of mRNA or amplicate or fragment thereof can be detected. Processing of mRNA can include splicing, in which introns are removed from the transcript. Detection of introns can be used to detect the presence of the entire mRNA, and also can be used to detect processing of the mRNA, for example, when the intron region alone (e.g., intron not attached to any exons) is detected.

In another embodiment, methods provided herein can be used to detect polypeptides and modifications thereof, where a modification of a polypeptide can be a post-translation modification such as lipidylation, glycosylation, activating proteolysis, and others known in the art, or can include degradational modification such as proteolytic fragments and ubiquitinated polypeptides.

These examples are not intended to be limiting; other methods of determining protein or RNA abundance are known in the art.

Alternatively, proteins can be separated by two-dimensional gel electrophoresis systems. Two-dimensional gel electrophoresis is well-known in the art and can involve isoelectric focusing along a first dimension followed by SDS-PAGE electrophoresis along a second dimension. See, e.g., Hames et al, 1990, GEL ELECTROPHORESIS OF PROTEINS: A PRACTICAL APPROACH, IRL Press, New York; Shevchenko et al., Proc. Nat'l Acad. Sci. USA 93:1440-1445 (1996); Sagliocco et al., Yeast 12:1519-1533 (1996); Lander, Science 274:536-539 (1996). The resulting electropherograms can be analyzed by numerous techniques, including mass spectrometric techniques, western blotting and immunoblot analysis using polyclonal and monoclonal antibodies.

Alternatively, marker-derived protein levels can be determined by constructing an antibody microarray in which binding sites comprise immobilized antibodies, such as monoclonal antibodies, specific to a plurality of protein species encoded by the cell genome. Antibodies can be present for a substantial fraction of the marker-derived proteins of interest. Methods for making monoclonal antibodies are well known (see, e.g., Harlow and Lane, 1988, ANTIBODIES: A LABORATORY MANUAL, Cold Spring Harbor, N.Y., which is incorporated in its entirety for all purposes). In one embodiment, monoclonal antibodies are raised against synthetic peptide fragments designed based on genomic sequence of the cell. With such an antibody array, proteins from the cell are contacted to the array, and their binding is assayed with assays known in the art. The expression, and the level of expression, of proteins of diagnostic or prognostic interest can be detected through immunohistochemical staining of tissue slices or sections.

In another embodiment, expression of marker genes in a number of tissue specimens can be characterized using a tissue array (Kononen et al., Nat. Med 4(7):844-7 (1998)). In a tissue array, multiple tissue samples are assessed on the same microarray. The arrays allow in situ detection of RNA and protein levels; consecutive sections allow the analysis of multiple samples simultaneously.

In some embodiments, polynucleotide microarrays are used to measure expression so that the expression status of each of the markers above is assessed simultaneously. In one embodiment, the microarrays provided herein are oligonucleotide or cDNA arrays comprising probes hybridizable to the genes corresponding to the marker genes described herein.

The microarrays provided herein can comprise probes hybridizable to the genes corresponding to markers able to distinguish cells, identify phenotypes, identify a disease or disorder, or provide a prognosis of a disease or disorder. In particular, provided herein are polynucleotide arrays comprising probes to a subset or subsets of at least 2, 5, 10, 15, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500, 750, 1,000, 1,250, 1,500, 1,750, 2,000, 2,250, 2,500, 2750, 3000, 3500, 4000, 4500, 5000, or more, genetic markers, up to the full set of markers listed in SEQ ID NO:1-38,826. In some embodiments, the nucleotide sequences selected from SEQ ID NO:1-38,826 are selected from SEQ ID NO:35,580-38,826. Also provided herein are probes to markers with a modified t statistic greater than or equal to 2.5, 3, 3.5, 4, 4.5 or 5. Also provided herein are probes to markers with a modified t statistic less than or equal to −2.5, −3, −3.5, −4, −4.5 or −5. In specific embodiments, the invention provides combinations such as arrays in which the markers described herein comprise at least 50%, 60%, 70%, 80%, 85%, 90%, 95% or 98% of the probes on the combination or array.

General methods pertaining to the construction of microarrays comprising the marker sets and/or subsets above are known in the art as described herein.

Microarrays can be prepared by selecting probes that comprise a polypeptide or polynucleotide sequence, and then immobilizing such probes to a solid support or surface. For example, the probes can comprise DNA sequences, RNA sequences, or antibodies. The probes can also comprise amino acid, DNA and/or RNA analogues, or combinations thereof. The probes can be prepared by any method known in the art.

The probe or probes used in the methods of the invention can be immobilized to a solid support which can be either porous or non-porous. For example, the probes of the can be attached to a nitrocellulose or nylon membrane or filter. Alternatively, the solid support or surface can be a glass or plastic surface. In another embodiment, hybridization levels are measured to microarrays of probes consisting of a solid phase on the surface of which are immobilized a population of probes. The solid phase can be a nonporous or, optionally, a porous material such as a gel.

In another embodiment, the microarrays are addressable arrays, such as positionally addressable arrays. More specifically, each probe of the array can be located at a known, predetermined position on the solid support such that the identity (i.e., the sequence) of each probe can be determined from its position in the array (i.e., on the support or surface).

A skilled artisan will appreciate that positive control probes, e.g., probes known to be complementary and hybridizable to sequences in target polynucleotide molecules, and negative control probes, e.g., probes known to not be complementary and hybridizable to sequences in target polynucleotide molecules, can be included on the array. In one embodiment, positive controls can be synthesized along the perimeter of the array. In another embodiment, positive controls can be synthesized in diagonal stripes across the array. Other variations are known in the art. Probes can be immobilized on the to solid surface by any of a variety of methods known in the art.

In certain embodiments, this model can be further extended to include sample characteristics, such as cell or organism phenotypes, allowing cell type specific expression to be linked to observable indicia such as clinical indicators and prognosis (e.g., clinical disease progression, response to therapy, and the like). In one embodiment, a model for prostate tissue is provided, resulting in identification of cell-type-specific markers of cancer, epithelial hypertrophy, and disease progression. In another embodiment, a method for studying differential gene expression between subjects with cancers that relapse and those with cancers that do not relapse, is disclosed. Also provided is the framework for studying mixed cell type samples and more flexible models allowing for cross-talk among genes in a sample. Also provided are extensions to defining differences in expression between samples with different characteristics, such as samples from subjects who subsequently relapse versus those who do not.

Statistical Treatment

The methods provided herein include determining the regression relationship between relative cell content and measured expression levels. For example, the regression relationship can be determined by determining the regression of measured expression levels on cell proportions. Statistical methods for determining regression relationships between variables are known in the art. Such general statistical methods can be used in accordance with the teachings provided herein regarding regression of measured expression levels on cell proportions.

The methods provided herein also include calculating the level of analytes in each cell type based on the regression relationship between relative cell content and expression levels. The regression relationship can be determined according to methods provided herein, and, based on the regression relationship, the level of a particular analyte can be calculated for a particular cell type. The methods provided herein can permit the calculation of any of a variety of analyte for particular cell types. For example, the methods provided herein can permit calculation of a single analyte for a single cell type, or can permit calculation of a plurality of analytes for a single cell type, or can permit calculation of a single analyte for a plurality of cell types, or can permit calculation of a plurality of analytes for a plurality of cell types. Thus, the number of analytes whose level can be calculated for a particular cell type can range from a single analyte to the total number of analytes measured (e.g., the total number of analytes measured using a microarray). In another embodiment, the total number of cell types for which analyte levels can be calculated can range from a single cell type, to all cell types present in a sample at sufficient levels. The levels of analyte for a particular cell type can be used to estimate expression levels of the corresponding gene, as provided elsewhere herein.

The methods provided herein also can include identifying genes differentially expressed in a first cell type relative to a second cell type. Expression levels of one or more genes in a particular cell type can be compared to one or more additional cell types. Differences in expression levels can be represented in any of a variety of manners known in the art, including mathematical or statistical representations, as provided herein. For example, differences in expression level can be represented as a modified t statistic, as described elsewhere herein.

The methods provided herein also can serve as the basis for methods of indicating the presence of a particular cell type in a subject. The methods provided herein can be used for identifying the expression levels in particular cell types. Using any of a variety of classifier methods known in the art, such as a naive Bayes classifier, gene expression levels in cells of a sample from a subject can be compared to reference expression levels to determine the presence of absence, and, optionally, the relative amount, of a particular cell type in the sample. For example, the markers provided herein as associated with prostate tumor, stroma or BPH can be selected in a prostate tumor classifier in accordance with the modified t statistic associated with each marker provided in the Tables herein. Methods for using a modified-t statistic in classifier methods are provided herein and also are known in the art. In another embodiment, the methods provided herein can be used in phenotype-indicating methods such as diagnostic or prognostic methods, in which the gene expression levels in a sample from a subject can be compared to references indicative of one or more particular phenotypes.

For purposes of exemplification, and not for purposes of limitation, an exemplary method of determining gene expression levels in one or more cell types in a heterogeneous cell sample is provided as follows. Suppose that there are four cell types: BPH, Tumor, Stroma, and Cystic Atrophy. Supposing that each cell type has a (possibly) different distribution for y, the expression level for a gene j, denoted by: f _(ij)(y), i ε{BPH, Tumor, Stromia, Cystic Atrophy} and that sample k has proportions X _(k)=(x _(k,) _(BPH) , x _(k,) _(Tumor) , x _(k,) _(Cystic Atrophy) ) of each cell type is studied. The distribution of the expression level for gene j is then ${g_{j}\text{(}y\left. X_{k} \right)} = {\sum\limits_{i}{x_{ki}{f_{ij}(y)}}}$ if the expression levels are additive in the cell proportions as they would be if each cell's expression level depends only on the type of cell (and not, say, on what other types of cells can be present in the sample). In a later section this formulation is extended to cases in which the expression of a given cell type depends on what other types of cells are present.

The average expression level in a sample is then the weighted average of the expectations with weights corresponding to the cell proportions: ${E_{g_{j}}\text{(}y\left. X_{k} \right)} = {\sum\limits_{i}{x_{ki}{E_{fij}(y)}}}$ or $y_{jk} = {{\sum\limits_{i}{x_{ki}\beta_{ij}}} + \varepsilon_{jk}}$ where E_(f_(ij))(y) = β_(ij)  and  ε_(jk) = y_(jk) − E_(g_(j))(yX_(k))

This is the known form for a multiple linear regression equation (without specifying an intercept), and when multiple samples are available one can estimate the β_(ij). Once these estimates are in hand, estimates for the differences in gene expression of two cell types are of the form: {circumflex over (β)}_(i) _(1j) −{circumflex over (β)}_(i) _(2j) and standard methods for testing linear hypotheses about the coefficients β_(ij) can be applied to test whether the average expression levels of cell types i₁ and i₂ are different. The term ‘expression levels’ as used in this exemplification of the method is used in a generic sense: ‘expression levels’ could be readings of mRNA levels, cRNA levels, protein levels, fluorescent intensity from a feature on an array, the logarithm of that reading, some highly post-processed reading, and the like. Thus, differences in the coefficients can correspond to differences, log ratios, or some other functions of the underlying transcript abundance.

For computational convenience, one may in certain embodiments use Z=XT and γ32 T⁻¹β setting up T so that one column of T has all zeroes but for a one in position i₁ and a minus one in position i₂ such as $T = \begin{pmatrix} 1 & 1 & {- 1} & 0 \\ 1 & 1 & 1 & 0 \\ 1 & 0 & 0 & 1 \\ 1 & 0 & 0 & 0 \end{pmatrix}$ The columns of Z that result are the unit vector (all ones), X_(k,BPH)+X_(k,Tumor), X_(k,BPH)−X_(k,Tumor), and X_(k,Stroma). With this setup, twice the coefficient of X_(k,BPH)−X_(k,Tumor) estimates the average difference in expression level of a tumor cell versus a BPH cell. With this parametrization, standard software can be used to provide an estimate and a tesmodified t statistic for the average difference of tumor and BPH cells. Further, this can simplify the specification of restricted models in which two or more of the tissue components have the same average expression level.

The data for a study can contain a large number of samples from a smaller number of different men. It is plausible that the samples from one man may tend to share a common level of expression for a given gene, differences among his cells according to their type notwithstanding. This will tend to lead to positive covariance among the measurements of expression level within men. Ordinary least squares (OLS) estimates are less than fully efficient in such circumstances. One alternative to OLS is to use a weighted least squares approach that treats a collection of samples from a single subject as having a common (non-negative) covariance and identical variances.

The estimating equation for this setup can be solved via iterative methods using software such as the gee library from R (Ross Ihaka and Robert Gentleman. R: A language for data analysis and graphics. Journal of Computational and Graphical Statistics, 5:299-314, 1996)). When the estimated covariance is negative—as sometimes happens when there is an extreme outlier in the dataset—it can be fixed at zero. Also the sandwich estimate (Kung-Yee Liang and Scott L. Zeger. Longitudinal data analysis using generalized linear models. Biometrika, 73:13-22, 1986.) of the covariance structure can be used.

The estimating equation approach will provide a tesmodified t statistic for a single transcript. Assessment of differential expression among a group of 12625 transcripts is handled by permutation methods that honor a suitable null model. That null model is obtained by regressing the expression level on all design terms except for the ‘BPH-tumor’ term using the exchangeable, non-negative correlation structure just mentioned. For performing permutation tests, the correlation structure in the residuals can be accounted for. Let k₁ be the set of n₁ indexes of samples for subject 1. First, we find y_(jk)−ŷ_(jk) =e _(jk), k ε k₁, as the residuals from that fitted null model for subject 1. The inverse square root of the correlation matrix of these residuals is used to transform them, i.e. {tilde over (e)}_(j)=φ^(−1/2)e_(j)., where φ is the (block diagonal) correlation matrix obtained by substituting the estimate of r from gee as the off-diagonal elements of blocks corresponding to measurements for each subject and e_(j). and {tilde over (e)}_(j). are the vector of residuals and transformed residuals for all subjects for gene j. Asymptotically, the ê_(jk) have means and covariances equal to zero. Random permutations of these, {tilde over (e)}_(j).^((i)), i=1, . . . , M, are obtained and used to form pseudo-observations: {tilde over (y)} _(j).^((i)) ={tilde over (y)} _(j).+φ^(1/2) {tilde over (e)} _(j).^((i)) This permutation scheme preserves the null model and enforces its correlation structure asymptotically.

In certain embodiments, the contribution of-each type of cell does not depend on what other cell types are present in the sample. However, there can be instances in which contribution of each type of cell does depend on other cell types present in the sample. It may happen that putatively ‘normal’ cells exhibit genomic features that influence both their expression profiles and their potential to become malignant. Such cells would exhibit the same expression pattern when located in normal tissue, but are more likely to be found in samples that also have tumor cells in them. Another possible effect is that signals generated by tumor cells trigger expression changes in nearby cells that would not be seen if those same cells were located in wholly normal tissue. In either case, the contribution of a cell may be more or less than in another tissue environment leading to a setup in which the contributions of individual cell types to the overall profile depend on the proportions of all types present, viz. ${g_{j}\text{(}y\left. X_{k} \right)} = {\sum\limits_{i}{x_{ki}{f_{ij}\left( {y\left. X_{k} \right)} \right.}}}$ as do the expected proportions ${E_{g_{j}}\text{(}y\left. X_{k} \right)} = {\sum\limits_{i}{x_{ki}E_{fij}\text{(}y\left. X_{k} \right)}}$ or $y_{jk} = {{\sum\limits_{i}{x_{ki}\beta_{ij}}} + \left( X_{k} \right) + \varepsilon_{jk}}$

The methods used herein above can still be applied in the context provided some calculable form is given for β_(ij)(X_(k)). One choice is given by β_(ij)(X _(k))=(φ_(j) R(X _(k)))_(i) where Φ_(j) is a 4×m matrix of unknown coefficients and R(X_(k)) is a column vector of m elements. This reduces to the case in which each cell's expression level depends only on the type of cell when Φ_(j) is 4×1 matrix and R(X_(k)) is just ‘1’.

Consider the case: ${{\phi_{j}\left( X_{k} \right)}{R\left( X_{k} \right)}} = {{\begin{pmatrix} v_{Bj} & v_{Bj} & v_{Bj} & v_{Bj} \\ v_{Tj} & v_{Tj} & v_{Tj} & v_{Tj} \\ v_{Sj} & {v_{Sj} + \delta_{j}} & v_{Sj} & v_{Sj} \\ v_{Cj} & v_{Cj} & v_{Cj} & v_{Cj} \end{pmatrix}\begin{pmatrix} x_{k,B} \\ x_{k,T} \\ x_{k,S} \\ x_{k,C} \end{pmatrix}} = \begin{pmatrix} v_{Bj} \\ v_{Tj} \\ {v_{Sj} + {\delta_{j}x_{k,T}}} \\ v_{Cj} \end{pmatrix}}$ ${{\phi_{j}\left( X_{k} \right)}{R\left( X_{k} \right)}} = {{\begin{pmatrix} v_{Bj} & v_{Bj} & v_{Bj} & v_{Bj} \\ v_{Tj} & v_{Tj} & v_{Tj} & v_{Tj} \\ v_{Sj} & {v_{Sj} + \delta_{j}} & v_{Sj} & v_{Sj} \\ v_{Cj} & v_{Cj} & v_{Cj} & v_{Cj} \end{pmatrix}\begin{pmatrix} x_{k,B} \\ x_{k,T} \\ x_{k,S} \\ x_{k,C} \end{pmatrix}} = \begin{pmatrix} v_{Bj} \\ v_{Tj} \\ {v_{Sj} + {\delta_{j}x_{k,T}}} \\ v_{Cj} \end{pmatrix}}$ (and recall that Σ_(j)X_(k,j)=1) Here the subscript for Tumor has been abbreviated T etc., for brevety. This setup provides that BPH (B), tumor, and cystic atrophy (C) cells have expression profiles that do not depend on the other cell types in the sample. However, the expression levels of stromal cells (S) depend on the proportion of tumor cells as reflected by the coefficient δ_(j). Notice that is linear in X_(k,B), X_(k,T), X_(k,S), X_(k,c), and X_(k,S)X_(k,T) with the unknown X _(k)φ_(j) R(X _(k))=x_(k) _(,B) v _(Bj) +x _(k,T) v _(Tj) +x _(k,S) v _(Sj) +x _(k,S) x _(k,T)δ_(j) +x _(k,C) v _(C) _(j) coefficients being multipliers of those terms. So, the unknowns in this case are linear functions of the gene expression levels and can be determined using standard linear models as was done earlier. The only change here is the addition of the product of X_(k,s) and X_(k,T). Such a product, when significant, is termed an “interaction” and refers to the product archiving a significance level owing to a correlation of X_(k,s) with X_(k,T). Thus, it is possible to accommodate variations in gene expression that occur when the level of a transcript in one cell type is influenced by the amount of another cell type in the sample. In one aspect, a setup involving a dependency of tumor on the amount of stroma ${{\phi_{j}\left( X_{k} \right)}{R\left( X_{k} \right)}} = {{\begin{pmatrix} v_{Bj} & v_{Bj} & v_{Bj} & v_{Bj} \\ v_{Tj} & v_{Tj} & {v_{Tj} + \delta_{j}} & v_{Tj} \\ v_{Sj} & v_{Sj} & v_{Sj} & v_{Sj} \\ v_{Cj} & v_{Cj} & v_{Cj} & v_{Cj} \end{pmatrix}\begin{pmatrix} x_{k,B} \\ x_{k,T} \\ x_{k,S} \\ x_{k,C} \end{pmatrix}} = \begin{pmatrix} v_{Bj} \\ {v_{Tj} + {\delta_{j}x_{k,T}}} \\ v_{Sj} \\ v_{Cj} \end{pmatrix}}$ the expression for X_(k)Φ_(j)R(X_(k)) is precisely as it was just above.

Accordingly, one can screen for dependencies by including as regressors products of the proportions of cell types. In certain embodiments, it may not be possible to detect interactions if two different cell types experience equal and opposite changes—one type expressing more with increases in the other and the other expressing less with increases in the first. In one embodiment, dependence of gene expression refers to the dependence of gene expression in one cell type on the level of gene expression in another cell type. In another embodiment, dependence of gene expression refers to the dependence of gene expression in one cell type on the amount of another cell type.

The contribution of each type of cell can depend on what other cell types are present in the sample, but also can depend on other characteristics of the sample, such as clinical characteristics of the subject who contributed it. For example, clinical characteristics such as disease symptoms, disease prognosis such as relapse and/or aggressiveness of disease, likelihood of success in treating a disease, likelihood of survival, condition in which a particular treatment regimen is likely to be more effective than another treatment regimen, can be correlated with cell expression. For example, cell type specific gene expression can differ between a subject with a cancer that does not relapse after treatment and a subject with a cancer that does relapse after treatment. In this case, the contribution of a cell type may be more or less than in another subject leading to an instance in which the contributions of individual cell types to the overall profile depend on the characteristics of the subject or sample. Here, the model used earlier is extended to allow for dependence on a vector of sample specific covariates, Z_(k): ${g_{j}\text{(}y\left. {X_{k},Z_{k}} \right)} = {\sum\limits_{i}{x_{ki}{f_{ij}\left( {y\left. {X_{k},Z_{k}} \right)} \right.}}}$ as do the expected proportions: ${E_{g_{j}}\text{(}y\left. {X_{k},Z_{k}} \right)} = {\sum\limits_{i}{x_{ki}E_{fij}\text{(}y\left. {X_{k},Z_{k}} \right)}}$ or $y_{jk} = {{\sum\limits_{i}{x_{ki}\beta_{ij}}} + \left( {X_{k},Z_{k}} \right) + \varepsilon_{jk}}$ where E_(f_(ij))(yX_(k), Z_(k)) = β_(ij)(X_(k), Z_(k))andε_(jk) = y_(jk) − E_(gj)(yX_(k), Z_(k)).

The methods used herein above can still be applied in this context provided some reasonable form is given for β_(ij)(X_(k),Z_(k)). One useful choice is given by:

β_(ij)(X _(k) , Z _(k))=(φ_(j) R(Z _(k)))_(i)

Where Φ_(j) is a 4×m matrix of unknown coefficients and R(Z_(k)) is a column vector of m elements.

Consider how this would be used to study differences in gene expression among subjects who relapse and those who do not. In this case, Z_(k) is an indicator variable taking the value zero for samples of subjects who do not relapse and one for those who do. Then ${R\left( Z_{k} \right)} = \begin{pmatrix} 1 \\ Z_{k} \end{pmatrix}$ and Φ_(j) is a four by two matrix of coefficients: $\phi_{j} = \begin{pmatrix} v_{Bj} & \delta_{Bj} \\ v_{Tj} & \delta_{Tj} \\ v_{Sj} & \delta_{Sj} \\ v_{Cj} & \delta_{Cj} \end{pmatrix}$ Notice that this leads to X _(k)φ_(j) R(Z _(k))=x _(k,B) v _(Bj) +x _(k,Tj) +x _(k,S) v _(Sj) +x _(k,C) v _(Cj) +x _(k,B) Z _(k)δ_(Bj) +x _(k,T) Z _(k)δ_(Tj) +x _(k,S) Z _(k)δ_(Sj) +x _(k,C) Z _(k)δ_(Cj) The ν coefficients give the average expression of the different cell types in subjects who do not relapse, while the δ coefficients give the difference between the average expression of the-different cell types in subjects who do relapse and those who do not. Thus, a non-zero value of δ_(T) would indicate that in tumor cells, the average expression level differs for subjects who relapse and those who do not. The above equation is linear in its coefficients, so standard statistical methods can be applied to estimation and inference on the coefficients. Extensions that allow β to depend on both cell proportions and on sample covariates can be determined according to the teachings provided herein or other methods known in the art.

Nucleic Acids

Provided herein are nucleic acid molecules that contain one or more nucleotide sequences provided in SEQ ID NO:1-38,826 or a complement thereof. For purposes of brevity and clarity, reference to one or more nucleotide sequences in SEQ ID NO: 1-38,826 also is intended to refer to the nucleotide sequence complementary thereto, as will be understood by one skilled in the art. In some embodiments, a nucleic acid molecule that contains one or more nucleotide sequences provided in SEQ ID NO:1-38,826 is a gene that encodes RNA and/or a polypeptide. Also provided herein are splice variants of the nucleotide sequences listed in SEQ ID NO:35,580-38,826. Such splice variants also can encode a polypeptide. In particular, nucleic acid molecules encoding genes containing the nucleotide sequences listed in SEQ ID NO:35,580-38,826 from animals, including splice variants thereof are provided. The encoded proteins are also provided. Also provided are functional domains thereof. For each of the nucleic acid molecules provided, the nucleic acid can be DNA or RNA or PNA or other nucleic acid analogs or can include non-natural nucleotide bases. Also provided are isolated nucleic acid molecules that include a sequence of nucleotides complementary to a nucleotide sequence provided in SEQ ID NO:1-38,826. In some embodiments, the nucleotide sequences selected from SEQ ID NO:1-38,826 are selected from SEQ ID NO:35,580-38,826.

Provided herein are tables listing probe sets; nucleotide sequences of the probes in the probe sets; genes associated with the probe set, including, for some tables, genbank accession number, locus ID, nucleotide sequence of the genes, splice regions for the genes, start and stop translation sites for the genes; modified t statistics for each probe set, and additional information described with reference to the individual table. One skilled in the art will recognize the relationship between the tables, such that nucleotide sequence information associated with particular probe sets in a first table can thereby be associated with other features such as modified t statistics by virtue of one or more additional tables that associate probe sets with those features such as modified t statistics. For example, Table 15 lists Probe ID, Probe SEQ ID NOs and Gene SEQ ID NOs to identify the nucleotide sequences of the enclosed sequence listing correspond to each Probe set (Probe ID); subsequent tables (e.g., Table 2 or Table 8) that describe information (e.g., modified t statistics) relating to a particular Probe ID, are therefore contemplated herein to also describe information relating to each nucleotide sequence identified with that Probe ID.

Table 2 provides modified t statistics for an Affymetrix U95Av2 microarray, including Bstat (modified t statistic for BPH), Sstat (modified t statistic for stroma), Tstat (modified t statistic for tumor). The Probe IDs for the U95Av2 microarray that map to a Probe ID for the U133a microarray, and the mapping itself, is provided in Table 17, where the mapping represents Probe IDs of microarrays that can hybridize to the same gene. Probe IDs with identical names for the two arrays are identical. Accordingly, by virtue of the mapping of Table 17, Table 2 Probe IDs can be associated with nucleotide sequences via Table 15. Table 8 provides Probe IDs for Affymetrix U133a microarray, and associated t statistics for BPH, tumor, stroma and cystic atrophy. Table 8 also identifies cell type for which the modified t statistic is greater than 2.5. Table 8 also identifies cell type for which the calculated expression for the associated gene is greater than two-fold more than in other cell types; such information can be used in selection of probes for a classifier, as described elsewhere herein. Table 9 provides the top genes identified as up- and down-regulated in prostate tumor cells of relapse patients, calculated by linear regression including all samples with prostate cancer; in Table 9, “1” is the top up-regulated gene, and “−1” is the top down-regulated gene. The gene(s) referred to in Table 9 (which lists Probe ID) can be determined by way of Table 15. Other tables describing genes in terms of Probe ID also can be interpreted according to Table 15. Tables 9-13 also contains a column that indicates with a “D” those genes that have a greater than 1.5 fold ratio of predicted expression between relapse and non-relapse tissue, as well as an absolute difference in expression that exceeds the expression level reported for most genes queried by the array.

Table 10 provides top genes identified as up- and down-regulated in prostate stroma of relapse patients, calculated by linear regression including all samples with prostate cancer, with numbering as in Table 9. Table 11 identifies exemplary genes whose expression can be examined in methods for identifying or characterizing a sample; and also identifies Probe IDs that can be used for such gene expression identification.

Table 12 provides top 144 genes identified as down-regulated in prostate stroma cells of relapse patients, calculated by linear regression including only samples that did not have detectable tumor cells, with ranking as with Table 9. In some embodiments, Table 13 provides top 100 genes identified as up-regulated in prostate stroma of relapse patients when only samples free of tumor were examined from cases of prostate cancer. Thus, Tables 12 and 13 demonstrate that genes in stroma can be used to determine a prognosis such as relapse, aggressiveness, and indolence of prostate tumor.

Table 15 provides splice variants of the genes provided herein. Each row identifies one or more pairs of numbers that identify the first and last residues of an exon in the gene, where the numbers in the pair are separated by a comma, and different pairs are separated by semicolons. Table 15 also provides the start and stop site of translation of the gene into a polypeptide. As will be understood in the art, multiple splicing combinations are provided for some genes. One skilled in the art can apply the splicing taught in Table 15 and nucleotide sequences listed herein to generate the nucleotide sequence of a spliced mRNA transcript. One skilled in the art also can apply the splicing taught in Table 15 and nucleotide sequences listed herein to generate the amino acid sequence of a polypeptide translated from the spliced transcript. Reference herein to one or more genes (including reference to products of genes) by referring to the SEQ ID NO of the gene or the SEQ ID NO of a nucleotide contained in the gene also contemplates reference to spliced gene sequences for the corresponding SEQ ID NO in accordance with Table 15. Similarly, reference herein to one or more protein gene products also contemplates proteins translated from the splice variants identified in Table 15.

Table 14 provides a list of 35 (nonunique) genes that have been associated with differential expression in aggressive prostate cancer. Among the cell-specific genes identified here (see, e.g., Tables 8-10), those not previously known to be indicator of aggressive prostate cancer are contemplated herein. For example, Table 14 lists genes associated with aggressive prostate cancer that are also found among the genes identified here (see, e.g., Table 9-10). Thus, contemplated herein all genes of Tables 1-13 and 15-17 that are not present in Table 14 represent genes identified herein as genes whose differential expression can be indicative of prostate cancer (in accordance with the corresponding table). For example, cell-specific genes statistically significantly differentially expressed in early relapse prostate cancer by tumor cells (Table 9) or stroma cells (Table 10) of early relapse prostate cancer are biomarkers when used individually or in combination to form panels or profiles of genes for use in the examination of gene expression of prostate tissue by the methods described herein in order to determine whether the examined prostate tissue is similar in gene expression to the pattern of, for example, early relapsed or aggressive disease or indolent disease. When used alone as markers, the methods, compositions and kits provided herein exclude those genes identified in Table 14. When used in combination, genes identified in Table 14 also can be used in the methods, combinations, compositions and kits provided herein, with the exception of use of PSA and PMSA in a combination of only those two genes.

Exemplary, non-limiting examples of genes whose products can be detected in the methods provided herein include, IGF-1, microsimino protein, and MTA-1. In one embodiment detection of the expression of one or more of these genes can be performed in combination with detection of expression of one or more additional genes containing a sequence provided in SEQ ID NO:1-38,826.

Uses of Probes and detection of genes identified in the tables are described herein and exemplified below. It is contemplated herein that uses and methods similar to those exemplified below can be applied to the probe and gene nucleotide sequences in accordance with the teachings provided herein. 0153 Also provided are nucleic acid molecules that have at least 60%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with a nucleotide of SEQ ID NO:1-38,826, or that hybridizes along their full-length or along at least about 70%, 80% or 90% of the full-length nucleic acid to a nucleic acids under conditions of moderate, or high, stringency. In some embodiments, the nucleotide sequences selected from SEQ ID NO:1-38,826 are selected from SEQ ID NO:35,580-38,826.

The isolated nucleic acids can contain least 10 nucleotides, 25 nucleotides, 50 nucleotides, 100 nucleotides, 150 nucleotides, or 200 nucleotides or more, contiguous nucleotides of a sequence provided in SEQ ID NO:1-38,826. In another embodiment, the nucleic acids are smaller than 35, 200 or 500 nucleotides in length. In some embodiments, the nucleotide sequences selected from SEQ ID NO:1-38,826 are selected from SEQ ID NO:35,580-38,826.

Also provided are fragments of the above nucleic acids that can be used as probes or primers and that contain at least about 10 nucleotides, at least about 14 nucleotides, at least about 16 nucleotides, or at least about 30 nucleotides. The length of the probe or primer is a function of the size of the genome probed; the larger the genome, the longer the probe or primer required for specific hybridization to a single site. Those of skill in the art can select appropriately sized probes and primers. Probes and primers as described can be single-stranded. Double stranded probes and primers also can be used, if they are denatured when used. Probes and primers derived from the nucleic acid molecules are provided. Such probes and primers contain at least 8, 14, 16, 30, 100 or more contiguous nucleotides. The probes and primers are optionally labeled with a detectable label, such as a radiolabel or a fluorescent tag, or can be mass differentiated for detection by mass spectrometry or other means. Also provided is an isolated nucleic acid molecule that includes the sequence of molecules that is complementary to the nucleotides provided in SEQ ID NO:1-38,826. Double-stranded RNA (dsRNA), such as RNAi is also provided. In some embodiments, the nucleotide sequences selected from SEQ ID NO:1-38,826 are selected from SEQ ID NO:35,580-38,826.

Plasmids and vectors containing the nucleic acid molecules are also provided. Cells containing the vectors, including cells that express the encoded proteins are provided. The cell can be a bacterial cell, a yeast cell, a fungal cell, a plant cell, an insect cell or an animal cell.

For recombinant expression of one or more of the genes containing a nucleotide sequence provided in SEQ ID NO:1-38,826, the nucleic acid containing all or a portion of the nucleotide sequence encoding the genes can be inserted into an appropriate expression vector, i.e., a vector that contains the elements for the transcription and translation of the inserted protein coding sequence. In some embodiments, the nucleotide sequences selected from SEQ ID NO:1-38,826 are selected from SEQ ID NO:35,580-38,826. The transcriptional and translational signals can also be supplied by the native promoter for the genes, and/or their flanking regions.

Also provided are vectors that contain nucleic acid encoding a gene containing a sequence provided in SEQ ID NO:1-38,826 In some embodiments, the nucleotide sequences selected from SEQ ID NO:1-38,826 are selected from SEQ ID NO:35,580-38,826. Cells containing the vectors are also provided. The cells include eukaryotic and prokaryotic cells, and the vectors are any suitable for use therein.

Prokaryotic and eukaryotic cells containing the vectors are provided. Such cells include bacterial cells, yeast cells, fungal cells, plant cells, insect cells and animal cells. The cells can be used to produce an oligonucleotide or polypeptide gene products by (a) growing the above-described cells under conditions whereby the encoded gene is expressed by the cell, and then (b) recovering the expressed compound.

A variety of host-vector systems can be used to express the protein coding sequence. These include but are not limited to mammalian cell systems infected with virus (e.g. vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g. baculovirus); microorganisms such as yeast containing yeast vectors; or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system used, any one of a number of suitable transcription and translation elements can be used.

Any methods known to those of skill in the art for the insertion of nucleic acid fragments into a vector can be used to construct expression vectors containing a chimeric gene containing appropriate transcriptional/translational control signals and protein coding sequences. These methods can include in vitro recombinant DNA and synthetic techniques and in vivo recombinants (genetic recombination). Expression of nucleic acid sequences encoding polypeptide can be regulated by a second nucleic acid sequence so that the genes or fragments thereof are expressed in a host transformed with the recombinant DNA molecule(s). For example, expression of the proteins can be controlled by any promoter/enhancer known in the art.

Proteins

Protein products of the genes provided in SEQ ID NO:35,580-38,826, derivatives and analogs can be produced by various methods known in the art. For example, once a recombinant cell expressing such a polypeptide, or a domain, fragment or derivative thereof, is identified, the individual gene product can be isolated and analyzed. This is achieved by assays based on the physical and/or functional properties of the protein, including, but not limited to, radioactive labeling of the product followed by analysis by gel electrophoresis, immunoassay, cross-linking to marker-labeled product, and assays of protein activity or antibody binding.

The polypeptides can be isolated and purified by standard methods known in the art (either from natural sources or recombinant host cells expressing the complexes or proteins), including but not restricted to column chromatography (e.g., ion exchange, affinity, gel exclusion, reversed-phase high pressure and fast protein liquid), differential centrifugation, differential solubility, or by any other standard technique used for the purification of proteins. Functional properties can be evaluated using any suitable assay known in the art.

Manipulations of polypeptide sequences can be made at the protein level. Also contemplated herein are polypeptide proteins, domains thereof, derivatives or analogs or fragments thereof, which are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand. Any of numerous chemical modifications can be carried out by known techniques, including but not limited to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH4, acetylation, formulation, oxidation, reduction, metabolic synthesis in the presence of tunicamycin and other such agents.

In addition, domains, analogs and derivatives of a polypeptide provided herein can be chemically synthesized. For example, a peptide corresponding to a portion of a polypeptide provided herein, which includes the desired domain or which mediates the desired activity in vitro can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include but are not limited to the D-isomers of the common amino acids, a-amino isobutyric acid, 4-aminobutyric acid, Abu, 2-aminobutyric acid, .epsilon.-Abu, e-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionoic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, .beta.-alanine, fluoro-amino acids, designer amino acids such as .beta.-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

Screening Methods

The oligonucleotide or polypeptide gene products provided herein can be used in a variety of methods to identify compounds that modulate the activity thereof. As provided herein, the nucleotide sequences and genes identified in SEQ ID NO:35,580-38,826 can be identified in different cell types and in the same cell type in which subject have different phenotypes. Methods are provided herein for screening compounds can include contacting cells with a compound and measuring gene expression levels, wherein a change in expression levels relative to a reference identifies the compound as a compound that modulates a gene expression.

Also provided herein are methods for identification and isolation of agents, such as compounds that bind to products of genes identified in SEQ ID NO:35,580-38,826. The assays are designed to identify agents that bind to the RNA or polypeptide gene product. The identified compounds are candidates or leads for identification of compounds for treatments of tumors and other disorders and diseases.

A variety of methods can be used, as known in the art. These methods can be performed in solution or in solid phase reactions.

Methods for identifying an agent, such as a compound, that specifically binds to an oligonucleotide or polypeptide encoded by a gene identified in SEQ ID NO:35,580-38,826 are provided herein. The method can be practiced by (a) contacting the gene product with one or a plurality of test agents under conditions conducive to binding between the gene product and an agent; and (b) identifying one or more agents within the one or plurality that specifically binds to the gene product. Compounds or agents to be identified can originate from biological samples or from libraries, including, but are not limited to, combinatorial libraries. Exemplary libraries can be fusion-protein-displayed peptide libraries in which random peptides or proteins are presented on the surface of phage particles or proteins expressed from plasmids; support-bound synthetic chemical libraries in which individual compounds or mixtures of compounds are presented on insoluble matrices, such as resin beads, or other libraries known in the art.

Modulators of the Activity of Gene products

Provided herein are compounds that modulate the activity of a gene product from SEQ ID NO:35,580-38,826. These compounds act by directly interacting with the polypeptide or by altering transcription or translation thereof. Such molecules include, but are not limited to, antibodies that specifically bind the polypeptide, antisense nucleic acids or double-stranded RNA (dsRNA) such as RNAi, that alter expression of the polypeptide, antibodies, peptide mimetics and other such compounds.

Antibodies, including polyclonal and monoclonal antibodies, that specifically bind to a polypeptide gene product provided herein are provided. The antibody can be a monoclonal antibody, and the antibody can specifically bind to the polypeptide. The polypeptide and domains, fragments, homologs and derivatives thereof can be used as immunogens to generate antibodies that specifically bind such immunogens. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. In a specific embodiment, antibodies to human polypeptides are produced. Methods for monoclonal and polyclonal antibody production are known in the art. Antibody fragments that specifically bind to the polyeptide or epitopes thereof can be generated by techniques known in the art. For example, such fragments include but are not limited to: the F(ab′)2 fragment, which can be produced by pepsin digestion of the antibody molecule; the Fab′ fragments that can be generated by reducing the disulfide bridges of the F(ab′)2 fragment, the Fab fragments that can be generated by treating the antibody molecular with papain and a reducing agent, and Fv fragments.

Peptide analogs are commonly used in the pharmaceutical industry as non-peptide drugs with properties analogous to those of the template peptide. These types of non-peptide compounds are termed peptide mimetics or peptidomimetics (Luthman et al., A Textbook of Drug Design and Development, 14:386-406, 2nd Ed., Harwood Academic Publishers (1996); Joachim Grante (1994) Angew. Chem. Int. Ed. Engl., 33:1699-1720; Fauchere (1986) J. Adv. Drug Res., 15:29; Veber and Freidinger (1985) TINS, p. 392; and Evans et al. (1987) J. Med. Chem. 30:1229). Peptide mimetics that are structurally similar to therapeutically useful peptides can be used to produce an equivalent or enhanced therapeutic or prophylactic effect. Preparation of peptidomimetics and structures thereof are known to those of skill in this art.

Prognosis and Diagnosis

Products of genes in SEQ ID NO:35,580-38,826 can be detected in diagnostic methods, such as diagnosis of tumors and other diseases or disorders. Such methods can be used to detect, prognose, diagnose, or monitor various conditions, diseases, and disorders. Exemplary compounds that can be used in such detection methods include polypeptides such as antibodies or fragments thereof that specifically bind polypeptides encoded by the genes of SEQ ID NO:35,580-38,826, and oligonucleotides such as DNA probes or primers that specifically bind oligonucleotides such as RNA encoded by the genes of SEQ ID NO:35,580-38,826.

A set of one or more, or two or more compounds for detection of markers containing a nucleotide sequence provided in SEQ ID NO:1-38,826, complements thereof, fragments thereof, or polypeptides encoded thereby, can be selected for any of a variety of assay methods provided herein. For example, one or more, or two or more such compounds can be selected as diagnostic or prognostic indicators. Methods for selecting such compounds and using such compounds in assay methods such as diagnostic and prognostic indicator applications are known in the art. For example, the Tables provided herein list a modified t statistic associated with each marker, where the modified t statistic indicate the ability of the associated marker to indicate (by presence or absence of the marker, according to the modified t statistic) the presence or absence of a particular cell type in a prostate sample.

In another embodiment, marker selection can be performed by considering both modified t statistics and expected intensity of the signal for a particular marker. For example, markers can be selected that have a strong signal in a cell type whose presence or absence is to be determined, and also have a sufficiently large modified t statistic for gene expression in that cell type. Also, markers can be selected that have little or no signal in a cell type whose presence or absence is to be determined, and also have a sufficiently large negative modified t statistic for gene expression in that cell type.

Exemplary assays include immunoassays such as competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), sandwich immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays and protein A immunoassays. Other exemplary assays include hybridization assays which can be carried out by a method by contacting a sample containing nucleic acid with a nucleic acid probe, under conditions such that specific hybridization can occur, and detecting or measuring any resulting hybridization.

Kits for diagnostic use are also provided, that contain in one or more containers an anti-polypeptide antibody, and, optionally, a labeled binding partner to the antibody. A kit is also provided that includes in one or more containers a nucleic acid probe capable of hybridizing to the gene-encoding nucleic acid. In a specific embodiment, a kit can include in one or more containers a pair of primers (e.g., each in the size range of 6-30 nucleotides) that are capable of priming amplification. A kit can optionally further include in a container a predetermined amount of a purified control polypeptide or nucleic acid.

The kits can contain packaging material that is one or more physical structures used to house the contents of the kit, such as invention nucleic acid probes or primers, and the like. The packaging material is constructed by well known methods, and can provide a sterile, contaminant-free environment. The packaging material has a label which indicates that the compounds can be used for detecting a particular oligonucleotide or polypeptide. The packaging materials employed herein in relation to diagnostic systems are those customarily utilized in nucleic acid or protein-based diagnostic systems. A package is to a solid matrix or material such as glass, plastic, paper, foil, and the like, capable of holding within fixed limits an isolated nucleic acid, oligonucleotide, or primer of the present invention. Thus, for example, a package can be a glass vial used to contain milligram quantities of a contemplated nucleic acid, oligonucleotide or primer, or it can be a microtiter plate well to which microgram quantities of a contemplated nucleic acid probe have been operatively affixed. The kits also can include instructions for use, which can include a tangible expression describing the reagent concentration or at least one assay method parameter, such as the relative amounts of reagent and sample to be admixed, maintenance time periods for reagent/sample admixtures, temperature, buffer conditions, and the like.

Pharmaceutical Compositions and Modes of Administration

Pharmaceutical compositions containing the identified compounds that modulate expression of a gene in SEQ ID NO:35,580-38,826 or bind to a gene product are provided herein. Also provided are combinations of such a compound and another treatment or compound for treatment of a disease or disorder, such as a chemotherapeutic compound.

Expression modulator or binding compound and other compounds can be packaged as separate compositions for administration together or sequentially or intermittently. Alternatively, they can provided as a single composition for administration or as two compositions for administration as a single composition. The combinations can be packaged as kits.

Compounds and compositions provided herein can be formulated as pharmaceutical compositions, for example, for single dosage administration. The concentrations of the compounds in the formulations are effective for delivery of an amount, upon administration, that is effective for the intended treatment. In certain embodiments, the compositions are formulated for single dosage administration. To formulate a composition, the weight fraction of a compound or mixture thereof is dissolved, suspended, dispersed or otherwise mixed in a selected vehicle at an effective concentration such that the treated condition is relieved or ameliorated. Pharmaceutical carriers or vehicles suitable for administration of the compounds provided herein include any such carriers known to those skilled in the art to be suitable for the particular mode of administration.

In addition, the compounds can be formulated as the sole pharmaceutically active ingredient in the composition or can be combined with other active ingredients. The active compound is included in the pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the subject treated. The therapeutically effective concentration can be determined empirically by testing the compounds in known in vitro and in vivo systems. The concentration of active compound in the drug composition depends on absorption, inactivation and excretion rates of the active compound, the physicochemical characteristics of the compound, the dosage schedule, and amount administered as well as other factors known to those of skill in the art. Pharmaceutically acceptable derivatives include acids, salts, esters, hydrates, solvates and prodrug forms. The derivative can be selected such that its pharmacokinetic properties are superior to the corresponding neutral compound. Compounds are included in an amount effective for ameliorating or treating the disorder for which treatment is contemplated.

Formulations suitable for a variety of administrations such as perenteral, intramuscular, subcutaneous, alimentary, transdermal, inhaling and other known methods of administration, are known in the art. The pharmaceutical compositions can also be administered by controlled release means and/or delivery devices as known in the art. Kits containing the compositions and/or the combinations with instructions for administration thereof are provided. The kit can further include a needle or syringe, which can be packaged in sterile form, for injecting the complex, and/or a packaged alcohol pad. Instructions are optionally included for administration of the active agent by a clinician or by the patient.

The compounds can be packaged as articles of manufacture containing packaging material, a compound or suitable derivative thereof provided herein, which is effective for treatment of a diseases or disorders contemplated herein, within the packaging material, and a label that indicates that the compound or a suitable derivative thereof is for treating the diseases or disorders contemplated herein. The label can optionally include the disorders for which the therapy is warranted.

Methods of Treatment

The compounds provided herein can be used for treating or preventing diseases or disorders in an animal, such as a mammal, including a human. In one embodiment, the method includes administering to a mammal an effective amount of a compound that modulates the expression of a gene provided in SEQ ID NO:35,580-38,826 or a compound that binds to a product of a gene provided in SEQ ID NO:35,580-38,826, whereby the disease or disorder is treated or prevented. Exemplary inhibitors provided herein are those identified by the screening assays. In addition, antibodies and antisense nucleic acids or double-stranded RNA (dsRNA), such as RNAi, are contemplated.

In a specific embodiment, as described hereinabove, gene expression can be inhibited by antisense nucleic acids. The therapeutic or prophylactic use of nucleic acids of at least six nucleotides, up to about 150 nucleotides, that are antisense to a gene or cDNA is provided. The antisense molecule can be complementary to all or a portion of the gene. For example, the oligonucleotide is at least 10 nucleotides, at least 15 nucleotides, at least 100 nucleotides, or at least 125 nucleotides. The oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone. The oligonucleotide can include other appending groups such as peptides, or agents facilitating transport across the cell membrane, hybridization-triggered cleavage agents or intercalating agents.

RNA interference (RNAi) (see, e.g. Chuang et al. (2000) Proc. Natl. Acad. Sci. U.S.A. 97:4985) can be employed to inhibit the expression of a gene provided in SEQ ID NO:35,580-38,826. Interfering RNA (RNAi) fragments, such as double-stranded (ds) RNAi, can be used to generate loss-of-gene function. Methods relating to the use of RNAi to silence genes in organisms including, mammals, C. elegans, Drosophila and plants, and humans are known. Double-stranded RNA (dsRNA)-expressing constructs are introduced into a host, such as an animal or plant using, a replicable vector that remains episomal or integrates into the genome. By selecting appropriate sequences, expression of dsRNA can interfere with accumulation of endogenous mRNA. RNAi also can be used to inhibit expression in vitro. Regions include at least about 21 (or 21) nucleotides that are selective (i.e. unique) for the selected gene are used to prepare the RNAi. Smaller fragments of about 21 nucleotides can be transformed directly (i.e., in vitro or in vivo) into cells; larger RNAi dsRNA molecules can be introduced using vectors that encode them. dsRNA molecules are at least about 21 bp long or longer, such as 50, 100, 150, 200 and longer. Methods, reagents and protocols for introducing nucleic acid molecules in to cells in vitro and in vivo are known to those of skill in the art.

In an exemplary embodiment, nucleic acids that include a sequence of nucleotides encoding a polypeptide of a gene provided in SEQ ID NO:35,580-38,826, are administered to promote polypeptide function, by way of gene therapy. Gene therapy refers to therapy performed by the administration of a nucleic acid to a subject. In this embodiment, the nucleic acid produces its encoded protein that mediates a therapeutic effect by promoting polypeptide function. Any of the methods for gene therapy available in the art can be used (see, Goldspiel et al., Clinical Pharmacy 12:488-505 (1993); Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, An. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, An. Rev. Biochem. 62:191-217 (1993); TIBTECH 11 (5):155-215 (1993).

In one embodiment, vaccines based on the genes and polypeptides provided herein can be developed. For example genes can be administered as DNA vaccines, either single genes or combinations of genes. Naked DNA vaccines are generally known in the art. Methods for the use of genes as DNA vaccines are well known to one of ordinary skill in the art, and include placing a gene or portion of a gene under the control of a promoter for expression in a patient with cancer. The gene used for DNA vaccines can encode full-length proteins, but can encode portions of the proteins including peptides derived from the protein. For example, a patient can be immunized with a DNA vaccine comprising a plurality of nucleotide sequences derived from a particular gene. In another embodiment, it is possible to immunize a patient with a plurality of genes or portions thereof. Without being bound by theory, expression of the polypeptide encoded by the DNA vaccine, cytotoxic T-cells, helper T-cells and antibodies are induced that recognize and destroy or eliminate cells expressing the proteins provided herein.

DNA vaccines include a gene encoding an adjuvant molecule with the DNA vaccine. Such adjuvant molecules include cytokines that increase the immunogenic response to the polypeptide encoded by the DNA vaccine. Additional or alternative adjuvants are known to those of ordinary skill in the art and find use in the invention.

Animal Models and Transgenics

Also provided herein, the nucleotide the genes, nucleotide molecules and polypeptides disclosed herein find use in generating animal models of cancers, such as lymphomas and carcinomas. As is appreciated by one of ordinary skill in the art, when one of the genes provided herein is repressed or diminished, gene therapy technology wherein antisense RNA directed to the gene will also diminish or repress expression of the gene. An animal generated as such serves as an animal model that finds use in screening bioactive drug candidates. In another embodiment, gene knockout technology, for example as a result of homologous recombination with an appropriate gene targeting vector, will result in the absence of the protein. When desired, tissue-specific expression or knockout of the protein can be accomplished using known methods.

It is also possible that the protein is overexpressed in cancer. As such, transgenic animals can be generated that overexpress the protein. Depending on the desired expression level, promoters of various strengths can be employed to express the transgene. Also, the number of copies of the integrated transgene can be determined and compared for a determination of the expression level of the transgene. Animals generated by such methods find use as animal models and are additionally useful in screening for bioactive molecules to treat cancer.

Computer Programs and Methods

The various techniques, methods, and aspects of the methods provided herein can be implemented in part or in whole using computer-based systems and methods. In another embodiment, computer-based systems and methods can be used to augment or enhance the functionality described above, increase the speed at which the functions can be performed, and provide additional features and aspects as a part of or in addition to those of the invention described elsewhere in this document. Various computer-based systems, methods and implementations in accordance with the above-described technology are presented below.

A processor-based system can include a main memory, such as random access memory (RAM), and can also include a secondary memory. The secondary memory can include, for example, a hard disk drive and/or a removable storage drive, representing a floppy disk drive, a magnetic tape drive, an optical disk drive, etc. The removable storage drive reads from and/or writes to a removable storage medium. Removable storage medium refers to a floppy disk, magnetic tape, optical disk, and the like, which is read by and written to by a removable storage drive. As will be appreciated, the removable storage medium can comprise computer software and/or data.

In alternative embodiments, the secondary memory may include other similar means for allowing computer programs or other instructions to be loaded into a computer system. Such means can include, for example, a removable storage unit and an interface. Examples of such can include a program cartridge and cartridge interface (such as the found in video game devices), a movable memory chip (such as an EPROM or PROM) and associated socket, and other removable storage units and interfaces, which allow software and data to be transferred from the removable storage unit to the computer system.

The computer system can also include a communications interface. Communications interfaces allow software and data to be transferred between computer system and external devices. Examples of communications interfaces can include a modem, a network interface (such as, for example, an Ethernet card), a communications port, a PCMCIA slot and card, and the like. Software and data transferred via a communications interface are in the form of signals, which can be electronic, electromagnetic, optical or other signals capable of being received by a communications interface. These signals are provided to communications interface via a channel capable of carrying signals and can be implemented using a wireless medium, wire or cable, fiber optics or other communications medium. Some examples of a channel can include a phone line, a cellular phone link, an RF link, a network interface, and other communications channels.

In this document, the terms computer program medium and computer usable medium are used to refer generally to media such as a removable storage device, a disk capable of installation in a disk drive, and signals on a channel. These computer program products are means for providing software or program instructions to a computer system.

Computer programs (also called computer control logic) are stored in main memory and/or secondary memory. Computer programs can also be received via a communications interface. Such computer programs, when executed, permit the computer system to perform the features of the invention as discussed herein. In particular, the computer programs, when executed, permit the processor to perform the features of the invention. Accordingly, such computer programs represent controllers of the computer system.

In an embodiment where the elements are implemented using software, the software may be stored in, or transmitted via, a computer program product and loaded into a computer system using a removable storage drive, hard drive or communications interface. The control logic (software), when executed by the processor, causes the processor to perform the functions of the invention as described herein.

In another embodiment, the elements are implemented in hardware using, for example, hardware components such as PALs, application specific integrated circuits (ASICs) or other hardware components. Implementation of a hardware state machine so as to perform the functions described herein will be apparent to person skilled in the relevant art(s). In yet another embodiment, elements are implanted using a combination of both hardware and software.

In another embodiment, the computer-based methods can be accessed or implemented over the World Wide Web by providing access via a Web Page to the methods of the invention. Accordingly, the Web Page is identified by a Universal Resource Locator (URL). The URL denotes both the server machine and the particular file or page on that machine. In this embodiment, it is envisioned that a consumer or client computer system interacts with a browser to select a particular URL, which in turn causes the browser to send a request for that URL or page to the server identified in the URL. The server can respond to the request by retrieving the requested page and transmitting the data for that page back to the requesting client computer system (the client/server interaction can be performed in accordance with the hypertext transport protocol (HTTP)). The selected page is then displayed to the user on the client's display screen. The client may then cause the server containing a computer program of the invention to launch an application to, for example, perform an analysis according to the methods provided herein.

Prostate-Associated Genes

Provided herein are probe and gene sequences that can be indicative of the presence and/or absence of prostate cancer in a subject. Also provided herein are probe and gene sequences that can be indicative of presence and/or absence of benign prostatic hyperplasia (BPH) in a subject. Also provided herein are probe and gene sequences that can be indicative of a prognosis of prostate cancer, where such a prognosis can include likely relapse of prostate cancer, likely aggressiveness of prostate cancer, likely indolence of prostate cancer, likelihood of survival of the subject, likelihood of success in treating prostate cancer, condition in which a particular treatment regimen is likely to be more effective than another treatment regimen, and combinations thereof. In one embodiment, the probe and gene sequences can be indicative of the likely aggressiveness or indolence of prostate cancer.

As provided in the methods and Tables herein, probes have been identified that hybridize to one or more nucleic acids of a prostate sample at different levels according to the presence or absence of prostate tumor, BPH and stroma in the sample. The probes provided herein are listed in conjunction with modified t statistics that represent the ability of that particular probe to indicate the presence or absence of a particular cell type in a prostate sample. Use of modified t statistics for such a determination is described elsewhere herein, and general use of modified t statistics is known in the art. Accordingly, provided herein are nucleotide sequences of probes that can be indicative of the presence or absence of prostate tumor and/or BPH cells, and also can be indicative of the likelihood of prostate tumor relapse in a subject.

Also provided in the methods and Tables herein are nucleotide and predicted amino acid sequences of genes and gene products associated with the probes provided herein. Accordingly, as provided herein, detection of gene products (e.g., mRNA or protein) or other indicators of gene expression, can be indicative of the presence or absence of prostate tumor and/or BPH cells, and also can be indicative of the likelihood of prostate tumor relapse in a subject. As with the probe sequences, the nucleotide and amino acid sequences of these gene products are listed in conjunction with modified t statistics that represent the ability of that particular gene product or indicator thereof to indicate the presence or absence of a particular cell type in a prostate sample.

Methods for determining the presence of prostate tumor and/or BPH cells, the likelihood of prostate tumor relapse in a subject, the likelihood of survival of prostate cancer, the aggressiveness of prostate tumor, the indolence of prostate tumor, survival, and other prognoses of prostate tumor, can be performed in accordance with the teachings and examples provided herein. Also provided herein, a set of probes or gene products can be selected according to their modified t statistic for use in combination (e.g., for use in a microarray) in methods of determining the presence of prostate tumor and/or BPH cells, and/or the likelihood of prostate tumor relapse in a subject.

Also provided herein, the gene products identified as present at increased levels in prostate cancer or in subjects with likely relapse of cancer, can serve as targets for therapeutic compounds and methods. For example an antibody or siRNA targeted to a gene product present at increased levels in prostate cancer can be administered to a subject to decrease the levels of that gene product and to thereby decrease the malignancy of tumor cells, the aggressiveness of a tumor, indolence of a tumor, survival, or the likelihood of tumor relapse. Methods for providing molecules such as antibodies or siRNA to a subject to decrease the level of gene product in a subject are provided herein or are otherwise known in the art.

In another embodiment, the gene products identified as present at decreased levels in prostate cancer or in subjects with likely relapse of cancer, can serve as subjects for therapeutic compounds and methods. For example a nucleic acid molecule, such as a gene expression vector encoding a particular gene, can be administered to a individual with decreased levels of the particular gene product to increase the levels of that gene product and to thereby decrease the malignancy of tumor cells, the aggressiveness of a tumor, indolence of a tumor, likelihood of survival, or the likelihood of tumor relapse. Methods for providing gene expression vectors to a subject to increase the level of gene product in a subject are provided herein or are otherwise known in the art.

The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

EXAMPLES Example 1

Tissue Samples. Prostate samples were obtained from patients that were preoperatively staged as having organ-confined prostate cancer. Institutional Review Board-approved informed consent for participation in this project was obtained from all patients. Tissue samples were collected in the operating room, and specimens were immediately transported to institutional pathologists who provided fresh portions of grossly identifiable or suspected tumor tissue and separate portions of uninvolved tissues. All tissue was snap frozen upon receipt and maintained in liquid nitrogen until used for frozen section preparation at −22° C. Thirty-eight of the contributed cases contained carcinomas. An additional 50 additional samples, consisting of paired adjacent nontumor tissue and separate nontumor bearing cases, also were used, making a total of 88 specimens for analysis. Tissue for expression analysis was provided as 20-μm-thick serial cryosections sections.

Tissue samples for expression analysis were prepared as 10- to 400-mm³ pieces, an amount that was found to be sufficient to yield 10 μg or more of total RNA. Before RNA preparation, 5-μm frozen sections were prepared at −22° C. The first section and a section every 200 μm thereafter were stained with hematoxylin and eosin for histopathological assessment, and all other intervening sections were prepared at 20-μm thickness for RNA extraction. Typically four to eight thin sections were examined per specimen by four pathologists. Preparative (20-μm) sections were lysed in RNA extraction buffer (RNeasy, Qiagen, Valencia, Calif.) and stored at −80° C. Thin sections were examined by four pathologists in a single session using a multihead microscope. Each pathologist assessed each specimen and completed a standardized form indicating the fraction of total area of the section occupied by the aggregate of all prostate carcinoma cells, benign prostatic hypertrophy (BPH) epithelial cells, dilated gland (dilated cystic atrophy) epithelial cells, and stromal cells. Clear spaces of glandular lumina, edema, defects, etc., were not considered, and minor proportions of neural, vascular, or other components were marked as other (median value, 3.1%). Average percentages of estimates from the four pathologists were calculated for epithelial cells of tumor, BPH, and cystic glands and total stromal cells for each sample.

Data Collection. Preoperative and follow-up demographic and clinical variables, histologic scoring, and DNA array data were collected into an internet accessible, secure Oracle database. Each physical object in the study was issued a unique identifier, and relationships between samples, subsamples, patients, and data were maintained.

Amplification and GeneChip Hybridization. Total cellular RNA was isolated by using RNeasy kits (Qiagen) and quantified by RiboGreen fluorescent assay (Molecular Probes, Eugene, Oreg.), and the quality of preparation was examined by using a BioAnalyzer 2100 (Agilent Technologies, Palo Alto, Calif.). Generation of cRNA was performed according to the known Affymetrix protocol. Briefly, double stranded cDNA was synthesized from total RNA by using a reverse transcriptase with a purified oligo(dT) primer containing a RNA polymerase promoter sequence at it's 5′-end. The second cDNA strand was synthesized using DNA polymerase I, RNase H and DNA ligase. The double-stranded cDNA was placed in RNase-free buffer. Labeled cRNA was generated from cDNA by in vitro transcription and incorporating biotinylated nucleotides. Fifteen micrograms of the resulting biotinylated cRNA was fragmented and hybridized to U95Av2 GeneChip® arrays Affymetrix according to the manufacturer's instructions.

Data Analysis. Array images (.dat files) were digitized by using MAS version 5 (Affymetrix). Gene expression values were generated from the resulting raw numerical data (.cel files) by the dCHIP program of Li and Wong (Li and Wong, Proc. Natl. Acad. Sci. USA 98, 31-36, 2001). Most subsequent analyses were carried out by using the R environment and language including the gee-library for generalized estimated equations (Iheka and Gentleman, J. Comput. Graph. Stat. 5, 299-314, 1996; Zeger and Liang, Biometrics 42, 121-130, 1986). Differential expression between dichotomous variables (tumor/no tumor) was detected by a modification of the permutation method in Efron et al. (J. Am. Stat. Assoc. 96, 1151-1160, 2001). Class predictive genes were identified via the nearest shrunken centroids method by using the PAM package of R software (Tibshirani et al. Proc. Natl. Acad. Sci. USA 99, 6567-6572, 2002).

Immunohistochemistry. Selected gene expression results were validated by the direct examination of the distribution of the protein in paraffin sections of five or more of the cases. Indirect immunohistochemistry was performed. The antibodies were obtained and used as follows: directed against desmin and prostate-specific membrane antigen (PSMA) (DAKO, Carpinteria, Calif.), keratin 15 and tubulin 94 (NeoMarkers, Lab Vision Corporation, Fremont, Calif.), prostaglandin-D2 synthase (Cayman Chemical, Ann Arbor, Mich.), and prostate-specific antigen (PSA) (Biodesign International, Saco, Maine).

Laser Capture Microdissection (LCM). Microdissection of freshly prepared frozen sections was performed by using an Arcturus (Mountain View, Calif.) Mark PixCell II LCM apparatus to isolate prostate cancer epithelium, stroma, and hypertrophic benign epithelial prostate cells. Total RNA was prepared from these samples and used in quantitative RT-PCR (qPCR) to validate cell-specific expression analysis as described in detail together with the gene list, primers, graphical relationships of Affymetrix (modified t statistic) to LCM (LCM/qPCR endpoint). From each flash-frozen tissue, 5-μm-thick frozen sections were prepared. Sections were subsequently dehydrated in graded ethanol solutions (70% once, 5-second rinse, 95% twice, 5-second rinse each, 100% two times, 5-second rinse each) and cleared in xylene (two times, 5 min each). After air-drying for 10 min, the PixCell II LCM System from Acturus Engineering (Mountain View, Calif.) was used for laser capture following the manufacturer's protocol. Total RNA was extracted using resin spin-column system (PicoPure RNA isolation kit, Arcturus Engineering).

The 88 tissue samples from 41 subjects undergoing prostatectomy for clinically early stage localized prostate carcinoma were independently scored by a panel of four pathologists for fractional composition of the four cell types. Agreement analysis on the continuous measures of fractional cell type as estimated by four pathologists were assessed as interobserver Pearson correlation coefficients. The average coefficients for tumor, stroma, BPH, and dilated gland cells were 0.92, 0.77, 0.73, and 0.49, respectively, indicating reproducibility of scoring for the predominant cell types. The lesser reproducibility for the dilated gland category was due to the relative paucity of this cell type in the samples (median proportion=5%). The samples were found to contain a wide range of relative tumor cell numbers ranging, in the case of tumor cells, from a low of 0.3% to a high of 100% tumor cells (FIG. 2).

Despite inclusion of samples with very low tumor content, some 1,197 genes were identified as differentially expressed between tumor and nontumor samples (posterior probability >0.95, see supporting information) according to empirical Bayes estimates. Because tumor samples contained, on average, 53.4% cells of epithelial origin (tumor, BPH, dilated glands), and nontumor samples had an average epithelial composition of 24.7% (P=3.5×10-11), differences in gene expression reflected stromal content were suspected. An illustrative subset of transcripts differentially expressed according to class was identified through nearest shrunken centroids discriminant analysis. Of 37 highly discriminant genes, 23 were predictive of nontumor and were mostly archetypal smooth muscle transcripts such as myosin, tropomyosin, actin, and others. Thus, a corollary notion is that tumor markers identified through standard microarray studies may have little significance with respect to tumor-cell biology, being more reflective of fundamental differences between cells of epithelial versus mesenchymal lineage.

To assign gene expression to particular cell types within tumor specimens, a linear model was constructed in which it was assumed that the contribution to gene expression of any one cell type depends only on the proportion of that cell type and its corresponding characteristic cell-type expression level, β_(ij), but not on the proportions of other cell types present. In Equation 1, the average expression level G_(jk) of gene j in a sample k is the average of cell type expectations, β_(ij), weighted by cell type fractions x_(ki). $\begin{matrix} {G_{jk} = {{\sum\limits_{i}{x_{ki}\beta_{ij}}} + ɛ_{jk}}} & \left( {{Equation}\quad 1} \right) \end{matrix}$

Comparing tumor versus no tumor expression levels amounts to using two cell types whose proportions are taken as either 1 and 0 (all tumor) or 0 and 1 (no tumor) in model (Equation 1) and taking the difference of the coefficients. Another procedure uses the proportions assessed by pathologists in a two-cell-type model. Coefficients, standard errors, and intercepts were calculated according to a two-cell type model (e.g., tumor vs. nontumor via simple linear regression of expression level on proportion of tumor cells) for each gene expression vector in 88 microarrays as a function of fractional content of tumor, then of stroma, and then of BPH. Thus, the expected cell type expression level is given as the regression coefficient, X, in the linear model (Equation 1). Modified t statistics incorporating goodness of fit and effect size were calculated according to Tusher (Proc. Natl. Acad. Sci. USA 98, 5116-5121, 2001), where op is the standard error of the coefficient, and k is a small constant. t=β/(k+σ _(β))   (Equation 2)

For n 88, a modified t statistic of 2.4 sets thresholds corresponding >4-fold expected differences in expression between the respective cell types (P<0.02). By these criteria, many transcripts were found to have strong association with a particular cell type (FIG. 3). A global view of predicted cell-specific gene expression was obtained by hierarchical clustering of the modified t statistics from the linear model. A total of 3,384 transcripts displayed cell-type-associated gene expression patterns according to the criteria. The procedure revealed that tumor- and nontumor-associated transcripts could be interpreted in terms of cell type specificity. Thus, 1,096 genes have strong tumor association, yet the majority (683) of these represent primarily differences in tumor-stroma gene expression (tumor>stroma). Conversely, a large number of transcripts are predicted to be stroma associated (stroma and stroma>tumor). Interestingly, a number of genes are strongly associated with BPH cell content (492). A subset of these (196) also showed a strong negative association with tumor cell content, indicating potential clinically useful markers of BPH. In addition, this analysis predicts 413 genes to be tumor specific, being strongly associated with tumor and displaying negative associations with both BPH and stroma.

The transcript groups were characterized by distinct personalities in terms of gene function. The BPH cell-associated groups (B>S, B>T) included a number of previously identified nonmalignant prostate epithelial markers including 15-lipoxygenase-II, CD38, and p63. This group contained a number of neuroendocrine markers such as cystatin-A, chromogranin-A, cholecystokinin, and cholecystokinin receptor. Notably, the BPH group of genes included IL-1 convertase. IL-1 is a putative neuroendocrine morphogen in prostate. The stroma cell compartment was dominated by archetypal smooth muscle and connective tissue-associated genes: vimentin, myosins, actin, and dystrophin. Other strong stroma associations included participants in transforming growth factor (TGF)-s and fibroblast growth factor signaling pathways.

Transcripts with strong tumor associations that were also anticorrelated with other cell types included hepsin, macmarcks, LIM protein, and α-methyl CoA racemase, as noted. A number of enzymes involved in O— and N-linked glycosylation were strongly tumor-specific, including UDP N-acetylglucosamine pyrophosphorylase-1, which in this study carried the third highest cell-type-associated modified t statistic of 7.2. Also noted were several genes participating in small GTP protein signaling pathways. The set of transcripts that were associated with both tumor and BPH cell content included, not surprisingly, PSA. In fact, six separate GeneChip probe sets for this gene present on the Affymetrix arrays segregated into this group.

Specific differences between BPH and tumor cell expression are of interest diagnostically and may shed light on pathogenesis. A four-cell-type model (via multiple regression of expression level on the tissue proportions using no intercept) allows direct and unbiased estimates of differences in expression between two cell types. Simultaneous regression holding the effect of stroma constant accounts for the fact that in the prostate, cell-type-associated differences in gene expression were dominated by the inverse relationship between fractional content of tumor cells and stromal cells. Because multiple samples are used from some subjects, the estimating equations approach implemented in the gee library for R was used. The procedure identified a number of transcripts predicted to be specific for either BPH or tumor cells (FIG. 3B). Cytokeratin-15 (CK15) expression was predicted with high confidence to be associated with the BPH cell type. Other putative BPH epithelial cell markers included the intermediate filament protein NF-H, histone H2AlB, CD38, and 15-lipoxygenase. Transcripts predicted to be specifically expressed in tumor as opposed to BPH cells included β-tubulin, UDP N-acetyl glucosamine pyrophosphorylase 1, and SGP-28, among others.

Including a term dependent on both the tumor cell proportion and the stroma cell proportion (i.e., the cross-product x_(kT)x_(kS)) in Equation 1 for the four-cell-type multiple regression model, the gene expression in stroma (or tumor) cells which is not independent but, rather, dependent on the proportion of tumor (or stroma) was calculated (FIG. 3C). Many genes displayed expression profiles with high tumor-stroma cross product terms including TGF-β2, which in the linear model is predicted to be in stroma. Also among stroma-associated genes with high cross products was desmin. Immunohistochemical staining (see below) supports this finding. High cross-product tumor-associated genes were also identified and included the T cell receptor γ (TCRγ) transcript (Affymetrix probe set 41468_at). In this instance, the high cross-product is the result of TCRγ transcript being a very highly discriminant tumor marker. That is, even relatively low percentage tumor samples display high expression, an exception to the linear model consistent with stromal modulation of tumor TCR expression.

Immunohistochemical Validation. Selected predicted cell-type-specific gene expression patterns were tested by examining the distribution of gene expression on the protein level by using immunohistochemistry. At least five cases of tumor-bearing tissue with adjacent BPH, stroma, and dilated glands were examined with each antibody. 9-Tubulin is predicted to be a strongly tumor-associated gene. Immunohistochemical staining revealed uniform expression in tumor cells of crowded gland-like structures of the tumor but negative in stroma or epithelial cells of adjacent BPH and dilated glands. Prostaglandin-D2 synthase (PD2S) is predicted to be a moderately tumor-associated gene. Apical surfaces of the epithelial cells of tumor-gland structures were highly immunoreactive, whereas BPH glands displayed little or no immunoreactivity. Prostate-specific membrane antigen (PSMA) is predicted to be strongly tumor associated. Staining revealed strong immunoreactivity that was strictly confined to the apical membranes of tumor gland cells, but only weak reactivity was observed in adjacent BPH cells. Desmin is predicted to be a stromal gene with high likelihood of tumor-stroma cell interaction. Numerous desmin-positive spindle shaped cells forming files and parallel clusters fill the stroma tissue component, whereas all epithelial cells are negative. The stroma within zones of tumor is distinct from adjacent normal stroma in that the desmin-positive spindle cell population is sparse, suggesting a distinct remodeling of cells in the tumor-associated stroma. CK15 is predicted to be strongly associated with BPH. Uniform labeling of most cells of myoepithelial of hyperplastic epithelium was apparent, whereas no expression could be detected in adjacent tumor cells of the same cases. PSA is predicted to be present in BPH and tumor cells. Strong immunoreactivity was noted in both tumor and BPH glands. These observations provide direct confirmation of the cell-type-specific expression of proteins as predicted on the basis of the dissection of transcript expression described here.

LCM-qPCR Validation. Five independent specimens and one specimen used for expression analysis were used for isolation of tumor, BPH, and stromal cells by LCM. Primer sets for 28 genes, including several genes validated by immunohistochemistry, were examined by qPCR, such as PSA, β-tubulin, desmin, and Cytokeratin-15, 504 PCR runs in all. The overall pattern of qPCR results exhibited a clear correlation with the expression level based on cell type. To quantitatively examine the relationship, the Pearson correlation coefficient and associated probability for each cell type was calculated between qPCR end points from the LCM samples, and the corresponding modified t statistics derived from the in silico dissection for the same cell type across the 20 genes with complete data. This analysis yielded correlation coefficients of 0.689 (P=0.004), 0.609 (P=0.0042), and 0.524 (P=0.0144) for the tumor, BPH, and stroma cell types, respectively. Thus, all correlation coefficients are statistically significant. It is apparent, therefore, that for all three cell types there is a significant correlation between these two independent and multistep methods of cell-type-specific analysis for the genes examined.

The analysis was conducted in order to discriminate true markers of tumor cells, BPH cells, and stromal cells of Prostate Cancer. Conventional least squares regression using individual cell-type proportions produces clear predictions of cell specific expression for a large number of genes. Many predictions are readily accepted on the basis of prior knowledge of prostate gene expression and biology, which provides confidence in the method. These are strikingly illustrated by numerous genes predicted to be preferentially expressed by stromal cells that are characteristic of connective tissue and only poorly expressed or absent in epithelial cells.

This analysis allows segregation of molecular tumor and non-tumor markers into more discrete and informative groups. Thus, genes identified as tumor-associated may be further categorized into tumor versus stroma (epithelial versus mesenchymal) and tumor versus BPH (perhaps reflecting true differences between the malignant cell and its hyperplastic counterpart). A recent meta-analysis produced a list of 500 genes up-regulated in prostate cancer. Of these 338 (unique Unigene identifiers) were identified in the analysis provided herein as tightly correlated with the presence of tumor. The method presented here indicates that 157 of these tumor-associated transcripts represent a tumor-stroma dichotomy. Another 26 are associated with BPH cells and tumor cells, and 89 are relatively unique to tumor cells. Notably, only 2 transcripts associated by the herein disclosed method with stroma were classified as tumor-associated in the meta-analysis. Conversely, 296 of 500 genes identified in the meta-analysis as indicative of normal prostate can be divided into 271 stromal genes and only 15 genes associated with BPH cells and not malignant cells. Thus, the vast majority of markers associated with normal prostate tissues in recent microarray-based studies are related to cells of the stroma. This result is not surprising given that, at least here, normal samples are composed of a relatively greater proportion of stromal cells.

The strongest single discriminator between BPH cells and tumor cells in this study was cytokeratin-15 (CK15), a result confirmed by immunohistochemistry. CK15 has previously received little attention in this context, but BPH markers play an important role in the diagnosis of ambiguous clinical cases. The clinical utility of CK15 and other predicted BPH markers will require further study.

It was expected that not all genes would be expressed as a linear function of cell-type. Transcripts with high cross-products in the covariance matrix suggest that expression in one cell type was not independent of the proportion of another tissue as would be expected in a paracrine mechanism. The stroma transcript with the highest dependence on tumor percentage was TGF-b2, a cytokine previously identified as important in prostate cell proliferation. Another such stroma cell gene for which immunohistochemistry was practical was desmin which showed considerably altered staining in the tumor associated stroma. In fact, a large number of typical stroma cell genes displayed dependence on the proportion of tumor adding evidence to the speculation that tumor-associated stroma differs fundamentally from non-associated stroma. Tumor-stroma paracrine signaling may be reflected in peri-tumor halos of altered gene expression that may be present a much bigger target for detection than the tumor cells alone.

Recently, a group of genes was identified that correlated with Gleason score and clinical outcome. These studies were restricted to specimens with very high proportions of tumor cells. Therefore, in contrast to the study provided herein, the previous study could not assess the role of cells neighboring the cancer, which may participate in the gene expression signature of tumor and, possibly, its biology.

The experiments have employed a straightforward bioinformatics approach using simple and multiple linear regression to identify genes whose expression is specifically correlated with either tumor cells, BPH epithelial cells or stromal cells. These results confirm a variety of previous observations and importantly identify a large number of gene candidates as specific products of various cells involved in prostate cancer pathogenesis. Context-dependent expression that is not readily attributable to single cell types is also recognized. The investigative approach described here is applicable to a wide variety of tumor marker discovery investigations in other organs.

Laser Capture Microdissection and Extraction. From each flash-frozen tissue, 5 μ thick frozen sections were prepared. Sections were subsequently dehydrated in graded ethanol solutions (70% once, 5 second rinse, 95% twice, 5 second rinse each, 100% two times, 5 second rinse each) and cleared in xylene (two times, 5 min each). After air-drying for 10 min, we used the PixCell II LCM System from Acturus Engineering (Mountain View, Calif.) for laser capture and followed the manufacturer's protocol. Total RNA was extracted using resin spin-column system (PicoPure RNA isolation Kit, Arcturus Engineering).

Analysis of Gene Expression by Real-Time Quantitative (qPCR). First strand cDNA synthesis was performed using all extracted total RNA from each sample (preheated at 65° C., 5min with oligo-dT(15) and dNTPs) in 0.5 μg oligo-dT(15), 50 mM Tris-HCl (pH 8.3 at room temperature), 75 mM KC1, 3 mM MgCl₂, 10 mM dithiothereitol, 0.5 mM dNTPs, 2 units/ul of RNase Inhibitor (Roche) and 10 units/ul SuperScript II RNase H-Reverse Transcriptase (Invitrogen Corporation). Reverse Transcriptase was added after two minutes of incubation at 42° C., then incubate for 50 minutes at 42° C. The reaction was inactivated at 70° C. for 15 min. 20 μl cDNA reaction was diluted to 400 μl and 6 μl was used for analysis of each gene. Real-time quantitative PCR (ABI Prism 7900 Sequence Detection System, Applied Biosystems, Foster City, Calif.) was carried out for the analysis of gene expression by the use of SybrGreen. Real-time PCR reaction contained 1× HotStartTaq PCR Buffer (with 1.5 mM MgCl2), 1:25,000 dilution of SybrGreen I (Molecular Probes), 0.35 μM 6-ROX (Molecular Probes), 0.2 mM dNTPs, 4 mM MgCl2, 0.025 unit/μl HotStartTaq DNA polymerase (Qiagen) and 0.8 μM each primer. Real-time PCR was done in 95° C. for 15 minutes; 50 cycles of 95° C. for 15 seconds, 60° C. for 15 seconds and 72° C. for 30 seconds; followed by a dissociation stage (95° C. 15 seconds, 60° C. 15 seconds, 95° C. 15 seconds, 2% ramping rate from 60° C. to 95° C.). Relative standard curves representing decreasing dilutions of stock cDNA were used for monitoring efficiency of target amplification of each gene. Thirty-one genes were amplified. The primer pair sequences for each of the specific RNA transcripts assayed are listed in Table 1.

Quantile normalization. The intensity values of each LCM sample were quantile normalized; the kth ranked intensity among the K=24 genes for each LCM sample was replaced by the average of the kth ranked values across all samples. For a few LCM samples readings were not been obtained for some genes. These samples were not included in the averaging, but normalized values for the non-missing genes were obtained by replacing the rank, j, among the J valid values for a sample with (j-1)*(K-1)/(J-1)+1 and using this to interpolate among the K averages.

Table 8. Selected Cell-type specific Expressed Genes. The table provides a modified t-statistic calculated as described herein (Equation 2) for each cell type (tumor (T), BPH, (B), and stroma (S)) defined and selected differences (T-B) for each gene with t>2.4. The modified t-statistics t_(ij) incorporates goodness of fit and effect size for every gene j and every tissue type i, where σ_(β) the standard error of the coefficient, β_(ij), and k is a small constant: t_(ij)=β_(ij)(k+σ_(β)). The β_(ij) are determined according to equation (1) as described. For N=88, a modified t-statistic of 2.4 sets thresholds-corresponding greater than four-fold expected differences in expression between the respective cell types (p<0.02). 3384 transcripts displayed cell-type associated gene expression patterns according to the threshold and are listed here. 1096 genes have strong tumor association, yet the majority (683) of these represent primarily differences in tumor-stroma gene expression (tumor>stroma). Conversely, a large number of transcripts are predicted to be stroma associated (groups stroma and stroma>tumor). 492 are strongly associated with BPH cell content. A subset of these (196) also showed a strong negative association with tumor cell content indicating potential clinically useful markers of BPH. 413 are predicted to be tumor specific, being strongly associated with tumor and displaying negative associations with both BPH and stroma (tumor). Columns B, C, and D labeled BSTAT, SSTAT, and TSTAT respectively are the corresponding modified t-statistic values for simple regression using percent composition for each tissue type alone (cf. equation 1), i.e. BPH epithelial cells content, stroma cell content, or tumor epithelial cell content respectively. The modified t-statistic value are color coded Red for modified t-statistic >2.0; Tan for 2.0>modified t-statistic >1.0, Green for t-static <−2.0, and Blue for −2.0<modified t-statistic<−1.0.

The modified t statistics calculated from two-cell-type linear models embody the direction and magnitude as well as goodness of fit of the coefficients. The modified t statistics were filtered to include genes with >4-fold predicted changes in between pure and 0% specific cell type sample composition and an absolute correlation coefficient of >0.25. By these criteria, 3,387 transcripts displayed cell-type-associated gene expression, and the modified t statistics are visualized here by hierarchical clustering. Red corresponds to a positive correlation, and green corresponds to a negative correlation between cell type (B, BPH; S, stroma; T, tumor) and gene expression. Representative genes from each group are at right. Previously available tumor/no tumor distinction is represented by middle labels. The analysis provides for further classification of no tumor markers into stromal (the vast majority) and BPH-associated genes. Likewise, tumor markers can be subdivided. Markers of the tumor-stroma difference may reflect epithelial mesenchymal differences in gene expression. Genes that differ according to the tumor-BPH distinction may reflect changes between malignant and nonmalignant states of prostate epithelium.

Example 2

Identification of Differences in Expression Between Cell-Types and Between Relapse and Non-Relapse Patients.

Methods have been developed which have promise to distinguish cell-specific and relapse-specific differential gene expression which will be assessed on available clinical cases in a prospective observational trial design.

1. Sample Evaluation. Percent sample composition determination. All samples used in microarray analysis were evaluated by four pathologists, who independently estimated percentage of tumor-, stroma-, BPH- and Cystic-Atrophy-cells in every sample using serial frozen sections as described in Example 1. Tissue between these analytical sections was utilized for RNA preparation and expression analysis. The reliability of tissue composition estimates by this method has been checked by carrying out a variety of agreement analyses among the four pathologists such as calculation of agreement of presence or absence of tissue types (kappa) and Pearson correlation coefficient calculations for percent assignments. An example of such an analysis in the case of estimating tumor cell content is shown in FIG. 1 and a summary for the four cells types estimated is shown in Table 3. The percent estimates averaged over the four contributing pathologists for each sample were used to derive cell-specific gene expression estimates as described below and summarized in Example 1; averaged values were used in the analysis.

2. Gene Expression Data Processing.

Total RNA was prepared from samples of known cellular composition and analyzed on Affymetrix GeneChip platforms as described by the manufacturer. The data of the hybridized microarrays were processed by Affymetrix Microarray Suite 5.0.(Affymetrix (2000). Microarray Suite 5.0—User Guide. Affymetrix, Inc.(www.affymetrix.com)). The background estimation and gene expression evaluation was carried out using BioConductor's Affymetrix package (Rafael A. Irizarry, Laurent Gautier, Benjamin Milo Bolstad, Crispin Miller, with contributions from Magnus Astr, Leslie M. Cope, Robert Gentleman Jeff Gentry Wolfgang Huber James MacDonald Benjamin I. P. Rubinstein Christopher Workman and John Zhang (2004). Affymetrix: Methods for Affymetrix oligonucleotide Arrays. R package version 1.5.8.).

3. Two GeneChip data sets. Samples from 55 patients were hybridized to 118 U95Av2 GeneChips and samples from 91 patients were hybridized to 146 U133A GeneChips. Samples from 34 patients were hybridized to both chip types. 54 samples were hybridized to both chip types. These data sets and the distribution among relapse and nonrelapse samples are summarized in Tables 4 & 5.

4. Determination of Cell-Specific Gene Expression by Regression analysis for Four Cell-types. In accord with the common histology of prostate, we assume (1) that the vast majority of cell types of tumor-bearing prostate tissue is accounted for by four cell types: Tumor epithelial cells, BPH epithelial cells, stromal cells (combined smooth muscle and connective tissue cells, and the flattened epithelial lining of dilated cystic glands). We assume (2) that the amount of mRNA of a given gene in extracted prostate tissue is derived from these four cell types in proportion to the amount of that cell type observed in a given case. That is, we postulate that a linear model accounts for the Affymetrix GeneChip Intensity: y _(ij)=β_(BPH,j) x _(BPH,i)+β_(T,j) x _(T,j)+β_(S,j) x _(S,j)+β_(G,j) x _(G,j)+ε_(i,j),   (3) where y_(ij) is the observed gene expression intensity of a gene j in a sample i, _(xxi) is a percentage of cell-type X in sample i and β_(xj) is a regression coefficient for gene j and cell-type X, defining the contribution of the proportion of the cell-type X to the overall gene expression intensity of the gene j, obtained fitting the model.

The β coefficients are the change in gene expression per unit cell (i.e. the slope of plots of gene intensity vs. percent composition) and therefore are cell specific gene intensity coefficients. For the model of equation 3, no distinction has been made in the gene expression properties of tumor cells from different samples which may have different Gleason scores or varying phenotypes such as aggressive growth (Example 1). These β coefficients are, therefore, average characteristic gene expression properties of a given cell type. Aggressive versus indolent disease is treated below in section 6 below.

The coefficients of the model, equation 3, may be obtained by regression analysis (Draper N and Smith H. Applied Regression Analysis. John Wiley and Sons, New York 1981). Because there are multiple samples for some patients and samples for one patient generally have a different correlation structure then other patients, we fitted the model with Generalized Estimation Equation (GEE) by means of the package gee in R (Diggle, P. J., P. Heagerty, et al. (2002). Analysis of Longitudinal Data. Oxford University Press 2nd edition, Oxford, England). The procedure minimizes the residual by an iterative process.

To determine significant β_(xj) values, i.e. significant correlation of gene expression with the amount of a given cell type, we test the null-hypothesis, that correlation coefficient β_(xj)=0. β_(xj) may be significant for only some genes, the significant genes. The tuned modified t-statistic after Tusher (Tusher, V. G., R. Tibshirani, et al. (2001). Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98(9): 5116-21) was computed. It evaluates the correlation of gene j with the proportion of the cell-type X: $\begin{matrix} {{t_{j,X} = \frac{\beta_{X,j}}{\left( {\sigma_{j} + k} \right)}},} & (4) \end{matrix}$ where σ_(j) is a standard error of the coefficient β_(xj) and k is a small constant penalizing the weakly expressed genes (Tusher and Tibshirani 2001).

Cell-specific expression lists have been derived herein. For N=88 GeneChips, a modified t-statistic of 2.4 sets thresholds corresponding to greater than four-fold expected differences in expression between the respective cell types (p<0.02). 3384 transcripts displayed cell-type associated gene expression patterns according to the threshold and are listed here. 1096 genes have strong tumor association, yet the majority (683) of these represent primarily differences in tumor-stroma gene expression (tumor>stroma). Conversely, a large number of transcripts are predicted to be stroma associated (groups stroma and stroma>tumor). 492 are strongly associated with BPH cell content. A subset of these (196) also showed a strong negative association with tumor cell content indicating potential clinically useful markers of BPH. 413 are predicted to be tumor specific, being strongly associated with tumor and displaying negative associations with both BPH and stroma.

5. Independent Replication of Cell-Specific Gene Expression. The analysis of 53 samples on U95Av2 in Example 1 indicated that cell-specific gene expression could be deduced from a knowledge of cell composition. A test was undertaken to determine whether the cell-specific results of multiple regression analysis of sample of known cellular composition was reproducible and general. The multiple linear regression results were quantitatively compared for the samples analyzed by the U95Av2 GeneChips with independent samples analyzed on U133A GeneChips with independent probe sets. First, a mapping between common samples genes of each platform was created.

Mapping between U95Av2 and U133A: replication of Example 1. The mapping of the probe sets from U95Av2 to probe sets of U133A was based on Affymetrix Best Mapping (Affymetrix, Palo Alto, Calif.). 10,507 probe sets of the U95Av2 GeneChip were mapped to 9530 probe sets on the U133A GeneChip. There are approximately 22,000 probe sets on the U133A GeneChip. Thus, the mapped probe sets represents most of the U95Av2 probe sets and over 40% of the U133A probe sets. The 9530 probe sets correspond to approximately 6235 human genes.

Comparison of 4 cell-type regression analysis results for U95 and U133. Regression analysis for 4 cell-types was performed for both the U95Av2 and Ul33a data sets using the intensities of the mapped probe sets. The respective modified t-statistics for four cell types of both GeneChips were determined. The comparison is for 110 samples measured on the U95Av2 and 93 different samples measured by U133A. The results may be assessed by correlating modified t-statistics for these probe sets for each cell type (Table 5).

For modified t-statistics >2.4, i.e. uniformly cell-specifically expressed genes across all samples, the comparison yielded positive Pearson correlation coefficients between modified t-statistics for a given gene are in the range of 0.72 to 0.94 for the four cell types indicating excellent agreement for the determination of the same genes as cell specific in both analyses. Indeed, when all genes represented by the mapped probe sets were considered, significant positive correlations were still observed (Table 5). Since the results represent independent samples and independent gene expression analyses, these observations argue that the method of cell specific gene expression determination is reproducible and robust. Genes that are tissue specific in the U133A set are presented in Table 8.

6. Regression analysis for four cell-types and the categorical variable ‘relapse case’, rs: identification of differentially expressed genes in early relapse Prostate Carcinoma.

During the course of this study a number of patients exhibited postoperative PSA values greater than the test threshold. For the purposes of an interim calculation, all such patients were taken as having exhibited chemical relapse. Relapse in turn is taken as a surrogate marker of Aggressive prostate cancer. To obtain the molecular signature of ‘being a relapse sample’, an extended linear model was built to determine the cell-specific significant genes correlated with the categorical variable rs (‘being a relapse case’): y _(ij)=β′_(BPH,j) x _(BPH,i)+β′_(T,j) x _(T,i)+β′_(S,j) x _(S,j)+β′_(G,j) x _(G,i) +rs(γ_(BPH,j) x _(BPH,i) +γ _(T,j) x _(T,i) +γ _(S,j) x _(S,i)+γ_(G,j) x _(G,i))+ε_(ij),   (5) where β′_(x,j) values define the contribution of the nonrelapsed cell-type expression for gene j and cell-type X; and the γ_(xj) are the regression coefficients, defining the contribution of the relapsed cell-type X to the overall gene expression intensity of gene j. There are two-way interactions of type rs*x_(xj) in the model.

Further, the False Discovery Rate (FDR) was estimated by means of a permutation schema (Good, Phillip: Permutation Tests, A Practical Guide to Resampling Methods for Testing Hypotheses, 1993, Springer Verlag, New York). FDR is a proportion of false positives in a set of significant genes, discovered by some rule. The null-hypothesis was, β_(xj)=0—‘being a relapse case’ has no influence on the overall gene expression. The permutation schema honored the null model and enforced its correlation structure as provided herein. This process was repeated 20-times. The distribution of the modified t-statistic considering the 20 repetitions for every cell-type gave the null-distribution of the modified t-statistics, which was compared to the actual data. The resulting FDR values are in parentheses in Table 6. ˜1100 probe sets of the ˜22,000 probe sets on the Affymetrix U133A GeneChip are significantly differentially expressed between nonrelapsed and early relapse Prostate Cancer. Of these, approximately 13% are false positives. Table 9 contains a list of the most significantly different genes discovered tumor that are changed in patient that have a higher risk of relapse. Table 10 contains genes that are different in stroma in relapse versus non-relapse patients.

Several particular observations are noted. First, although cell specific expression by BPH epithelium is readily apparent (Example 1), no significant gene expression changes in BPH were resolved when comparing relapsed status. This is consistent with the general observation that BPH is not a precursor lesion or factor in progression (Chung, L., Isaacs, W., and Simons, J. Prostate Cancer, Biology, Genetics, and the New Therapeutics. 2001, Human Press, New York). Second, most changes are associated with a negative γ indicating decreased gene expression with aggression, which correlates with dedifferentiation with progression (Chung et al. 2001). Third, many of the most significant gene expression changes are associated with stromal cells. The large number of differential changes in stroma may correlate with growing indications that stroma is an integral part of Prostate Cancer Progression through paracrine interactions.

The identification of genes specific to stroma and early relapse predicts that analysis of stroma alone as in negative clinical prostate biopsies may be predictive of the presence of cancer and whether indolent or aggressive disease is present. This hypothesis is readily testable both experimentally by validation studies and analytically by, for example, application of classifiers to independent data sets. A stroma classifier is developed in section 7.

When the original distribution of modified t-statistics for a particular cell-type X (e.g. stroma cell) is compared with the appropriate null-distribution, an increased frequency of modified t-statistics is apparent for (modified t-statistic)/(standard deviation) <˜−1. FDR is determined as the as the ratio of areas of interest of the null distribution to the original distribution of modified t-statistics.

7. Development of Candidate Classifier of Aggressive Prostate Cancer by use of genes differentially expressed in early relapse Prostate Cancer: the 43-gene classifier.

We sought to develop a classification rule based on known samples that could be applied to the classification of unknown samples. The modified t-statistics calculated in Section 5 (U133A samples) were used as the basis for building the classifying rule. We selected 1024 genes contributing the best 1024 modified t-statistics for all cell types. Some genes contributed more that one modified t-statistic owing to the presence of multiple probe sets for that gene on the U133A GeneChip. We built a restricted model of the type of Eqn (5) by setting a gamma=0 except for the 1024 genes with the best modified t-statistics. The model was fitted by employing a version of diagonal linear discriminant analysis. The generalization error and standard deviation was estimated by repeated 10-fold cross validation by serially leaving out the gene with the lowest modified t-statistic. A set of 43 genes was selected that had generalization errors less than one standard deviation from the minimum generalization error, as provided in Table 11.

The results of the classifier when applied to various data sets are in Table 7.

These results are likely underestimates since the nonrelapse data of this interim analysis necessarily contains gene signatures of cases that will relapse within 5 years (˜20% of all radical prostatectomy patients relapse; ˜40% relapse within 2 years of surgery, ˜49% relapse within 3 years; Chung et al 2001).

It should be noted that the classifier does not directly account for cell-specific gene expression.

8. Development of a nontumor-based Stromal classifier for aggressive Prostate Cancer.

Samples from tumor-bearing prostate glands that were confirmed by serial frozen sections to be free of tumor cells were used to predict genes associated with relapse in stroma, and BPH. The top 144 down-regulated genes in the permutation analysis are listed in Table 12. In addition, the top 100 up-regulated genes are also listed in Table 13.

The 144 genes were all tested as the starting set for a Support Vector Machine (SVM) application. This method seeks a subset of genes that discriminate two or more data sets in a manner that is independent of cell composition. Thus, a classifier derived in this was may be applied to independent data sets of unknown cell composition.

The result for the application of the 144 gene classifier to our nontumor samples was the correct classification of relapse status in 79.1% of the samples. The classifier has been tested on an entirely independent data set composed of known relapsed and nonrelapsed cases of Febbo et al. (Febbo P G, Sellers W R. Use of expression analysis to predict outcome after radical prostatectomy. J Urol. December 2003; 170(6 Pt 2):S11-9; discussion S19-20) with a result of 76%. However, the Febbo at al. 2003 are tumor samples only, with high percentage of tumor. These results far exceed random expectation. As before, these performance results are likely underestimates owing to the use of nonrelapse data in this interim analysis, which almost certainly contains late relapsing cases.

A number of embodiments are been described herein. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the methods, compositions and kits. Accordingly, since modifications will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims. TABLE 1 Genes and Sequences of real-time quantitative RT-PCR primers of measured gene transcripts Accession Llength HUGO Name No. UniGene Fwd Primer (5′-3′) Rev Primer (5′-3′) (bp)            G glyceraldehyde-3- NM_002046 Hs.169476 GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC 226 phosphate dehydrogenase kallikrein 3, (pros- NM_001648 Hs.171995 TGGTGCTGCACCCCTCAT CCAGGGTTGGGAATGCTTCT 70 tate specific antigen) tropomyosin 1 (alpha) NM_000366 Hs.77899 GAAGATGCCGACCGCAAAT CGTTCCAGGTCGCTCTCAAT 68 actin, alpha 2, NM_001613 Hs.195851 TGGTCATCCTCCCTTGAGAAGA CGTTCATTTCCGATGGTGATC 68 smooth muscle, aorta collagen, type I, NM_000088 Hs.172928 GGCTTCCCTGGTCCTCTTG GGGACCACGTTCACCACTTG 78 alpha 1 hepsin (transmembrane NM_002151 Hs.823 TTTGTGTGTGAGGACAGCATCTC GCCCCAACTCACAATGCC 66 protease, serine 1) MARCKS-like protein NM_023009 Hs.75061 GCGCTGAGCAGAATGAGTAGCT ACCTCACAAGGACAGCACAGTTT 79 LIM NM_006457 Hs.154103 CCTGGAAGCTCTGGGCTACAC TTCCAAACTTTCACAACACACTGA 70 thymosin, beta 4, Y NM_004202 Hs.159201 GCGACCTGGGCTCCATTT AGCCACTTCCGCGTTCAAG 63 chromosome kallikrein 2, pros- NM_005551 Hs.181350 CGTGCCCCTCATCCAGTCT GCCAGGGTTGGGAATGCT 65 tatic acid phosphatase, NM_001099 Hs.1852 TTTCTCAGGGCAGATGATGCT AAGCCCATTTTCCTCAAAGCT 71 prostate keratin 15 NM_002275 Hs.80342 CTCCAGTCCCTGCCTTCAGA GCATGCAAAGCCCTGAAATAA 66 keratin 5 (epider- NM_000424 Hs.433845 CACAGAGATGAACCGGATGATC TTGGCGCACTGTTTCTTGAC 69 molysis bullosa simplex, Dowling- Meara/Kobner/Weber- Cockayne types) prostaglandin D2 NM_000954 Hs.8272 GGGCTTCACAGAGGATACCATT AGTCCTATTGTTCCGTCATGCA 68 synthase (21 kD, brain) CD44 antigen (homing NM_000610 Hs.169610 CCTCTGCAAGGCTTTCAATAGC CGATGCTCAGAGCTTTCTCCAT 65 function and Indian blood group system) tropomyosin 2 (beta) NM_003289 Hs.300772 CGAGAGCCGAGCCAGACA CTCTGAGGCCATCAGGGACTT 76 Desmin NM_001927 Hs.279604 CCAGTCCTACACCTGCGAGATT CCTCCAATTCCCGCATCTG 77 Transforming growth NM_000660 Hs.1103 CTCTCCGACCTGCCACAGA AACCTAGATGGGCGCGATCT 72 factor, beta 1 (Camurati- Engelmann disease) filamin A, alpha NM_001456 Hs.195464 CAGGCTTGGTGTCTGCTTACG TCCCGCATTGCTCGTGTT 89 (actin binding protein 280) myosin, light poly- NM_006097 Hs.9615 TTAAGGAGGCTTTCAACATGATTG GTCGTGCAGGTCCTCCTTGT 68 peptide 9, regulatory myosin, heavy NM_002474 Hs.78344 ACGGGAGAGCTGGAAAAGC TTTTGGCGTTGCCGAAAG 67 polypeptide 11, smooth muscle Synaptogyrin 1 NM_004711 Hs.6139 CCAAAGGACAGCAGTGATGGA CCGGATTGGAAAATGAAGTCA 79 eukaryotic transla- NM_001402 Hs.181165 CTGAACCATCCAGGCCAAAT GCCGTGTGGCAATCCAAT 59 tion elongation factor 1 alpha 1 single-minded homolog NM_005069.2 Hs.27311 TTTAGGACCGTGGGTCATGC ATAGCTGAGTGCGTGGAGAGG 77 2 (Drosophila) alpha-methylacyl-CoA NM_014324.2 Hs.128749 GTGAAACAGAGTGATTGGTTGCA GAATGTGCTTAGAGGGAGATCATGA 70 racemase UDP-N-acteylglucosa- NM_003115.2 Hs.21293 CTCTCCTCTTATCTCCTATGCTGGA CGATGATTAGAGGTGCATGGAA 80 mine pyrophosphor- ylase 1 RAB4A, member RAS NM_004578.2 Hs.119007 GAGACAGCTGAGGTCACCGC ATTGTGTCCCAAATGCCACTG 104 oncogene family CD38 antigen (p45) NM_001775.1 Hs.66052 CACCATAAAAGAGCTGGAATCGA GTGCAAGATGAATCCTCAGGATTT 120 GTAGTGGAATATGTCTTCTGTATAA homeo box A9 NM_002142.3 CTAGGCT CATCCCCGAGAACACTTAAAATTT 108 tubulin, alpha 1 (testis specific) NM_006000.1 Hs.75318 TCTGTTTGCTGTTCATGACCCT AAGAACCCCTTTGCAGGTCTC 65 Arachidonate 15- NM_001141.1 Hs.111256 CATGCGAGGGCTTCATAGC GATGCCCCTCGAGATCTGG 197 lipoxygenase, second type

TABLE 3 Summary of Agreement Analysis Among Four Pathologists 126 Sample Slides 363 Ratings Average Pearson Correlation Coefficients: Tumor epithelial cells 0.92 BPH epithelial cells 0.73 Stroma-all cells 0.77 Dilated Cystic Glands 0.49 epithelial cells

TABLE 4 Summary of Prostate Carcinoma Cases with known Cell Composition and Clinical Follow-up Analyzed by Affymetrix GeneChips. RNA Non Non Extracts Tumor- Tumor- Relapse relapse Patients Analyzed Micro Bearing Bearing Tumor Tumor Analyzed on on both Set Patients Chips Samples Samples Samples Samples both U95/U133 U95/U133 U95Av2 88 38 50 34 54 Example 1 30 Recent 64 Unique to 110 U95Av2 118 50 68 13 35 Also run on U133A² TOTAL U133A 57 146 74 52 28 46 Also run on 93 U95² 91 146 TOTAL ¹As of July 2004; refers to relapse tumor samples and nonrelapse tumor samples. ²For the comparison of cell-specific genes derived following the methods of Example 1 using U95Av2 GeneChips, 110 patients analyzed on the U95Av2 platform were compared to 93 independent patients analyzed on the U133A platform. T-statistics for the four cell types were determined and compared as described in Section 5.

TABLE 5 Agreement Analysis of Cell-type Specific Gene Expression as determined using U95A GeneChip expression data (Example 1) and additional samples and by U113A GeneChip Expression data Pearson Correlation Coefficient for U95 vs. U133 with probability No t- statistic Cell Type t-statistic >2.4 cutoff TUMOR EPITHELIAL CELLS 0.827 0.51  p < 2.23e**−16 p < 2.2e**−16 BPH EPITHELIAL CELLS 0.723 0.366 p < 2.2e**−16 p < 2.2e**−16 STROMA CELLS 0.937 0.734 p < 2.2e**−16 p < 2.2e**−16 DILATED CYSTIC GLAND 0.750 0.323 EIPTHELIAL CELLS p < 7.4e**−13 p < 2.2e**−16

TABLE 6 Identification of 1098 probe sets that are significantly differentially expressed in early relapse Prostate Cancer by Cell- type based on analysis of 146 U133A GeneChips. False discovery rates are in parentheses. SAMPLES Relapsed within 2 years 28 NonRelapsed tumors (2-3 years) 46 Control: tissue from relapsed cases 46 Control: tissue from nonrelapsed cases 26 TOTAL 146 RESULTS Tumor cells of relapse tumor vs. nonrelapsed tumor 394 significant differences in gene expression 110 (0.22) increased in expression 284 (0.19) decreased in expression Stromal cells of relapse tumor vs. nonrelapsed tumor 704 significant differences  78 (0.22) increased in expression 626 (0.06) decreased in expression BPH cells - no significant differences

TABLE 7 Data Set Classification success % 146 U133A 67.75% of relapse and nonrelapse Arrays cases correct   80% of relapse cases correct Probe Sets 69.89% Common to U133A & U95

TABLE 9 Top genes identified as up- and down-regulated in prostate tumor cells of relapse patients, calculated by linear regression, including all samples with prostate cancer. (negative numbers for down-regulated. −1 is best) Affymetrix Large ProbeID T statistic Rank differences 218509_at 5.44 1 D 220587_s_at 5.22 2 208579_x_at 4.83 3 208490_x_at 4.56 4 209806_at 4.55 5 208527_x_at 4.55 6 208676_s_at 4.51 7 D 218186_at 4.26 8 209873_s_at 4.23 9 202148_s_at 4.23 10 D 201618_x_at 4.13 11 209391_at 4.07 12 200003_s_at 3.95 13 212445_s_at 3.94 14 64899_at 3.91 15 220584_at 3.87 16 202041_s_at 3.86 17 211982_x_at 3.86 18 D 215690_x_at 3.86 19 218275_at 3.84 20 202871_at 3.8 21 222067_x_at 3.79 22 210243_s_at 3.71 23 32837_at 3.62 24 211716_x_at 3.61 25 D 208629_s_at 3.6 26 213843_x_at 3.6 27 211899_s_at 3.59 28 203103_s_at 3.56 29 219798_s_at 3.55 30 215812_s_at 3.54 31 211060_x_at 3.52 32 208684_at 3.51 33 D 206491_s_at 3.5 34 218261_at 3.5 35 203720_s_at 3.46 36 201115_at 3.45 37 201388_at 3.45 38 220189_s_at 3.44 39 208308_s_at 3.44 40 D 210983_s_at 3.43 41 D 219360_s_at 3.41 42 201378_s_at 3.37 43 D 202779_s_at 3.37 44 D 203287_at 3.36 45 201168_x_at 3.35 46 202525_at 3.35 47 210854_x_at 3.35 48 208613_s_at 3.34 49 209696_at 3.31 50 217294_s_at 3.31 51 D 214784_x_at 3.31 52 219223_at 3.31 53 200852_x_at 3.31 54 209844_at 3.3 55 208546_x_at 3.29 56 204934_s_at 3.27 57 202676_x_at 3.25 58 212125_at 3.25 59 201771_at 3.24 60 202247_s_at 3.21 61 D 200997_at 3.21 62 207722_s_at 3.21 63 201709_s_at 3.2 64 203228_at 3.19 65 204109_s_at 3.19 66 M33197_5_at 3.19 67 208824_x_at 3.17 68 212282_at 3.17 69 209878_s_at 3.15 70 210761_s_at 3.15 71 208751_at 3.15 72 202758_s_at 3.14 73 218164_at 3.14 74 201548_s_at 3.14 75 209231_s_at 3.14 76 214501_s_at 3.13 77 58696_at 3.13 78 212081_x_at 3.12 79 210470_x_at 3.11 80 D 212563_at 3.1 81 202790_at 3.1 82 214336_s_at 3.09 83 65517_at 3.09 84 208523_x_at 3.09 85 D 208856_x_at 3.09 86 200895_s_at 3.09 87 208698_s_at 3.08 88 208621_s_at 3.08 89 202545_at 3.07 90 203952_at 3.06 91 201946_s_at 3.06 92 212772_s_at 3.05 93 217791_s_at 3.05 94 217784_at 3.05 95 201526_at 3.04 96 220707_s_at 3.04 97 200950_at 3.03 98 D 212002_at 3.03 99 218893_at 3.03 100 201587_s_at 3.03 101 208693_s_at 3.03 102 209516_at 3.03 103 217754_at 3.02 104 209592_s_at 3.02 105 202290_at 3.02 106 218695_at 3.01 107 220964_s_at 3.01 108 213059_at 3 109 204480_s_at 3 110 212845_at −3 −284 212535_at −3.01 −283 212150_at −3.01 −282 202000_at −3.01 −281 202133_at −3.01 −280 201153_s_at −3.01 −279 200673_at −3.02 −278 204655_at −3.02 −277 209658_at −3.02 −276 213044_at −3.02 −275 209656_s_at −3.03 −274 221788_at −3.03 −273 D 209465_x_at −3.03 −272 212956_at −3.04 −271 220617_s_at −3.04 −270 D 204345_at −3.04 −269 203017_s_at −3.05 −268 203636_at −3.06 −267 201865_x_at −3.06 −266 202269_x_at −3.07 −265 213338_at −3.07 −264 200762_at −3.07 −263 D 208131_s_at −3.08 −262 204753_s_at −3.09 −261 213158_at −3.1 −260 211577_s_at −3.1 −259 211562_s_at −3.1 −258 D 212226_s_at −3.1 −257 213005_s_at −3.1 −256 205348_s_at −3.11 −255 823_at −3.11 −254 212713_at −3.11 −253 D 200696_s_at −3.11 −252 204359_at −3.11 −251 209747_at −3.11 −250 207876_s_at −3.11 −249 213878_at −3.12 −248 211126_s_at −3.12 −247 211813_x_at −3.12 −246 D 208030_s_at −3.13 −245 218082_s_at −3.13 −244 210764_s_at −3.13 −243 D 200985_s_at −3.14 −242 209075_s_at −3.14 −241 209473_at −3.14 −240 212557_at −3.14 −239 D 212149_at −3.14 −238 206070_s_at −3.15 −237 221523_s_at −3.15 −236 D 209297_at −3.15 −235 212288_at −3.15 −234 213306_at −3.15 −233 202074_s_at −3.16 −232 203156_at −3.16 −231 215016_x_at −3.16 −230 201200_at −3.17 −229 207738_s_at −3.17 −228 202037_s_at −3.17 −227 D 209129_at −3.18 −226 217437_s_at −3.18 −225 202026_at −3.18 −224 217362_x_at −3.18 −223 219747_at −3.18 −222 209466_x_at −3.19 −221 200791_s_at −3.19 −220 202522_at −3.19 −219 213110_s_at −3.2 −218 202266_at −3.2 −217 D 209542_x_at −3.2 −216 201603_at −3.21 −215 202440_s_at −3.21 −214 212423_at −3.22 −213 204963_at −3.22 −212 209568_s_at −3.22 −211 211984_at −3.22 −210 213411_at −3.23 −209 201150_s_at −3.23 −208 201336_at −3.23 −207 201021_s_at −3.23 −206 214752_x_at −3.23 −205 209550_at −3.23 −204 221760_at −3.24 −203 200899_s_at −3.24 −202 206332_s_at −3.24 −201 211737_x_at −3.24 −200 208747_s_at −3.24 −199 204412_s_at −3.24 −198 209770_at −3.25 −197 206481_s_at −3.25 −196 212549_at −3.25 −195 211986_at −3.26 −194 203687_at −3.26 −193 212551_at −3.26 −192 201152_s_at −3.26 −191 211962_s_at −3.26 −190 203632_s_at −3.27 −189 208944_at −3.27 −188 212558_at −3.27 −187 201185_at −3.27 −186 219055_at −3.27 −185 219647_at −3.28 −184 203705_s_at −3.28 −183 205383_s_at −3.28 −182 204462_s_at −3.29 −181 213203_at −3.29 −180 219685_at −3.3 −179 202646_s_at −3.3 −178 205564_at −3.3 −177 203339_at −3.31 −176 204939_s_at −3.31 −175 202506_at −3.31 −174 218718_at −3.32 −173 D 203065_s_at −3.33 −172 206938_at −3.33 −171 205051_s_at −3.33 −170 212063_at −3.34 −169 216215_s_at −3.34 −168 213675_at −3.34 −167 35776_at −3.36 −166 212690_at −3.38 −165 204400_at −3.38 −164 202157_s_at −3.39 −163 209090_s_at −3.39 −162 204135_at −3.39 −161 201409_s_at −3.4 −160 208158_s_at −3.4 −159 220911_s_at −3.42 −158 201957_at −3.42 −157 209616_s_at −3.42 −156 D 220751_s_at −3.42 −155 209291_at −3.42 −154 200986_at −3.44 −153 206874_s_at −3.45 −152 209210_s_at −3.45 −151 204069_at −3.46 −150 214937_x_at −3.46 −149 201667_at −3.46 −148 202362_at −3.46 −147 201368_at −3.47 −146 207977_s_at −3.48 −145 201536_at −3.48 −144 212829_at −3.48 −143 210299_s_at −3.49 −142 D 212230_at −3.49 −141 219167_at −3.49 −140 209379_s_at −3.49 −139 208791_at −3.49 −138 D 212233_at −3.5 −137 D 204820_s_at −3.51 −136 202995_s_at −3.51 −135 200931_s_at −3.51 −134 203566_s_at −3.52 −133 D 221816_s_at −3.53 −132 203680_at −3.53 −131 212865_s_at −3.54 −130 218217_at −3.55 −129 218824_at −3.56 −128 212111_at −3.56 −127 212148_at −3.57 −126 217766_s_at −3.57 −125 203903_s_at −3.58 −124 215000_s_at −3.59 −123 208792_s_at −3.59 −122 206580_s_at −3.59 −121 213068_at −3.6 −120 209337_at −3.61 −119 208667_s_at −3.61 −118 213924_at −3.61 −117 204931_at −3.62 −116 217792_at −3.62 −115 202501_at −3.63 −114 201300_s_at −3.63 −113 204570_at −3.65 −112 202946_s_at −3.65 −111 212097_at −3.66 −110 200953_s_at −3.68 −109 D 209540_at −3.7 −108 204754_at −3.71 −107 D 203420_at −3.72 −106 200816_s_at −3.72 −105 202172_at −3.74 −104 212120_at −3.74 −103 205480_s_at −3.75 −102 204083_s_at −3.75 −101 204464_s_at −3.77 −100 221748_s_at −3.77 −99 212419_at −3.79 −98 203037_s_at −3.79 −97 203640_at −3.79 −96 212586_at −3.79 −95 202073_at −3.8 −94 209496_at −3.82 −93 212764_at −3.82 −92 D 212043_at −3.82 −91 D 201289_at −3.83 −90 200621_at −3.83 −89 D 207016_s_at −3.83 −88 205624_at −3.84 −87 207547_s_at −3.84 −86 201893_x_at −3.85 −85 201787_at −3.86 −84 211323_s_at −3.87 −83 D 202401_s_at −3.88 −82 207761_s_at −3.88 −81 201121_s_at −3.89 −80 D 207071_s_at −3.89 −79 204793_at −3.9 −78 218162_at −3.9 −77 212914_at −3.9 −76 218730_s_at −3.91 −75 D 201012_at −3.91 −74 D 209541_at −3.91 −73 200911_s_at −3.91 −72 201560_at −3.93 −71 204041_at −3.93 −70 218698_at −3.94 −69 201272_at −3.95 −68 210297_s_at −3.95 −67 204393_s_at −3.96 −66 D 207961_x_at −3.98 −65 221584_s_at −3.99 −64 212509_s_at −4.02 −63 212730_at −4.02 −62 218421_at −4.03 −61 209487_at −4.03 −60 213071_at −4.03 −59 D 209118_s_at −4.04 −58 218298_s_at −4.05 −57 203404_at −4.06 −56 D 203706_s_at −4.06 −55 213093_at −4.06 −54 202992_at −4.09 −53 D 201408_at −4.09 −52 217922_at −4.1 −51 218087_s_at −4.1 −50 D 218047_at −4.14 −49 200982_s_at −4.14 −48 200907_s_at −4.15 −47 202594_at −4.15 −46 205364_at −4.16 −45 212724_at −4.18 −44 208848_at −4.2 −43 202565_s_at −4.25 −42 212757_s_at −4.25 −41 208789_at −4.28 −40 D 203710_at −4.31 −39 212195_at −4.35 −38 203766_s_at −4.35 −37 201061_s_at −4.36 −36 213293_s_at −4.36 −35 209651_at −4.38 −34 212813_at −4.41 −33 209687_at −4.43 −32 202350_s_at −4.44 −31 210987_x_at −4.49 −30 202555_s_at −4.55 −29 209286_at −4.58 −28 205011_at −4.58 −27 212077_at −4.6 −26 218418_s_at −4.64 −25 209948_at −4.64 −24 D 202228_s_at −4.66 −23 217897_at −4.66 −22 D 209763_at −4.67 −21 202994_s_at −4.67 −20 207480_s_at −4.67 −19 207430_s_at −4.67 −18 D 201540_at −4.72 −17 216231_s_at −4.72 −16 203951_at −4.72 −15 209288_s_at −4.75 −14 221958_s_at −4.76 −13 201431_s_at −4.8 −12 200974_at −4.82 −11 221667_s_at −4.99 −10 202432_at −5.02 −9 200897_s_at −5.15 −8 209074_s_at −5.16 −7 D 201891_s_at −5.19 −6 201497_x_at −5.23 −5 202274_at −5.72 −4 200795_at −5.89 −3 201022_s_at −5.93 −2 210986_s_at −6.14 −1

TABLE 10 Top genes identified as up- and down-regulated in prostate stroma of relapse patients, calculated by linear regression, including all samples with prostate cancer. (negative numbers for down-regulated. −1 is best) Affymetrix number T statistic Rank Probe Set Name Probe Set D Name 204436_at 4.19 1 212076_at 3.94 2 202401_s_at 3.93 3 211323_s_at 3.85 4 D 211991_s_at 3.81 5 212713_at 3.77 6 D 207547_s_at 3.73 7 209473_at 3.68 8 200953_s_at 3.61 9 D 202501_at 3.61 10 205988_at 3.59 11 212151_at 3.57 12 203735_x_at 3.55 13 205456_at 3.51 14 218525_s_at 3.5 15 208789_at 3.49 16 D 204882_at 3.48 17 201148_s_at 3.47 18 207691_x_at 3.47 19 200610_s_at 3.46 20 215826_x_at 3.46 21 209582_s_at 3.45 22 D 209071_s_at 3.4 23 0 201080_at 3.39 24 210105_s_at 3.39 25 200621_at 3.38 26 D 218581_at 3.37 27 209070_s_at 3.35 28 221958_s_at 3.35 29 211203_s_at 3.35 30 201893_x_at 3.34 31 205011_at 3.34 32 203853_s_at 3.34 33 221447_s_at 3.34 34 212972_x_at 3.33 35 214760_at 3.3 36 202048_s_at 3.28 37 217187_at 3.27 38 204754_at 3.26 39 D 217362_x_at 3.25 40 210976_s_at 3.25 41 209057_x_at 3.2 42 D 205405_at 3.19 43 200974_at 3.19 44 213958_at 3.18 45 204795_at 3.17 46 219035_s_at 3.16 47 217580_x_at 3.16 48 D 209947_at 3.15 49 212822_at 3.15 50 217925_s_at 3.15 51 211697_x_at 3.15 52 D 38521_at 3.14 53 204341_at 3.14 54 D 216033_s_at 3.14 55 209646_x_at 3.14 56 208306_x_at 3.13 57 210444_at 3.13 58 209297_at 3.13 59 214738_s_at 3.1 60 202074_s_at 3.1 61 205482_x_at 3.09 62 201320_at 3.09 63 214694_at 3.08 64 212344_at 3.08 65 206868_at 3.08 66 211504_x_at 3.08 67 206057_x_at 3.07 68 219093_at 3.07 69 203950_s_at 3.06 70 200795_at 3.06 71 212239_at 3.05 72 211296_x_at 3.05 73 210288_at 3.04 74 205151_s_at 3.03 75 38149_at 3.02 76 211123_at 3.02 77 218338_at 3.01 78 217782_s_at −2.5 −626 211972_x_at −2.5 −625 220477_s_at −2.5 −624 201485_s_at −2.5 −623 203201_at −2.51 −622 217950_at −2.51 −621 209917_s_at −2.51 −620 203164_at −2.51 −619 218186_at −2.51 −618 218617_at −2.51 −617 203573_s_at −2.51 −616 203721_s_at −2.51 −615 201568_at −2.51 −614 209110_s_at −2.51 −613 209471_s_at −2.51 −612 208721_s_at −2.51 −611 208649_s_at −2.52 −610 212168_at −2.52 −609 209377_s_at −2.52 −608 217870_s_at −2.52 −607 218557_at −2.52 −606 209177_at −2.52 −605 202868_s_at −2.52 −604 209472_at −2.52 −603 214243_s_at −2.52 −602 218681_s_at −2.52 −601 217755_at −2.53 −600 221587_s_at −2.53 −599 220945_x_at −2.53 −598 211070_x_at −2.53 −597 216958_s_at −2.53 −596 213399_x_at −2.53 −595 209228_x_at −2.53 −594 201077_s_at −2.53 −593 218434_s_at −2.53 −592 218795_at −2.54 −591 202769_at −2.54 −590 201219_at −2.54 −589 200925_at −2.54 −588 211596_s_at −2.54 −587 208650_s_at −2.54 −586 221570_s_at −2.54 −585 202343_x_at −2.54 −584 202758_s_at −2.54 −583 212508_at −2.54 −582 204246_s_at −2.54 −581 217973_at −2.55 −580 216532_x_at −2.55 −579 201705_at −2.55 −578 221939_at −2.55 −577 222075_s_at −2.55 −576 219203_at −2.55 −575 215091_s_at −2.56 −574 209696_at −2.56 −573 217875_s_at −2.56 −572 217976_s_at −2.56 −571 212449_s_at −2.56 −570 201003_x_at −2.56 −569 200078_s_at −2.57 −568 202166_s_at −2.57 −567 203007_x_at −2.57 −566 202697_at −2.57 −565 221434_s_at −2.57 −564 215947_s_at −2.57 −563 200819_s_at −2.57 −562 209364_at −2.57 −561 218685_s_at −2.57 −560 204168_at −2.58 −559 203041_s_at −2.58 −558 209389_x_at −2.58 −557 208930_s_at −2.58 −556 203351_s_at −2.58 −555 209171_at −2.58 −554 201698_s_at −2.58 −553 206066_s_at −2.58 −552 213828_x_at −2.59 −551 214522_x_at −2.59 −550 203360_s_at −2.59 −549 206491_s_at −2.59 −548 219176_at −2.59 −547 212833_at −2.59 −546 201625_s_at −2.59 −545 204922_at −2.59 −544 207088_s_at −2.59 −543 207707_s_at −2.59 −542 209625_at −2.59 −541 202121_s_at −2.59 −540 221041_s_at −2.6 −539 210387_at −2.6 −538 218095_s_at −2.6 −537 D 215726_s_at −2.6 −536 204170_s_at −2.6 −535 201624_at −2.6 −534 213716_s_at −2.6 −533 206469_x_at −2.6 −532 205542_at −2.6 −531 217800_s_at −2.6 −530 208932_at −2.6 −529 200777_s_at −2.6 −528 201273_s_at −2.61 −527 203646_at −2.61 −526 208788_at −2.61 −525 41047_at −2.61 −524 220547_s_at −2.61 −523 201900_s_at −2.61 −522 212204_at −2.61 −521 212006_at −2.61 −520 217752_s_at −2.61 −519 221637_s_at −2.61 −518 210927_x_at −2.61 −517 209014_at −2.61 −516 217850_at −2.61 −515 202545_at −2.61 −514 209407_s_at −2.61 −513 203030_s_at −2.61 −512 214765_s_at −2.62 −511 204427_s_at −2.62 −510 204050_s_at −2.62 −509 214542_x_at −2.62 −508 203511_s_at −2.63 −507 209694_at −2.63 −506 209482_at −2.63 −505 217770_at −2.63 −504 205597_at −2.63 −503 200790_at −2.63 −502 220334_at −2.63 −501 201095_at −2.64 −500 208651_x_at −2.64 −499 D 205449_at −2.64 −498 209100_at −2.64 −497 216088_s_at −2.64 −496 201114_x_at −2.64 −495 210541_s_at −2.65 −494 213892_s_at −2.65 −493 202737_s_at −2.65 −492 218341_at −2.65 −491 D 210024_s_at −2.65 −490 201177_s_at −2.65 −489 220587_s_at −2.65 −488 213971_s_at −2.65 −487 213738_s_at −2.66 −486 212246_at −2.66 −485 216230_x_at −2.66 −484 203857_s_at −2.66 −483 212191_x_at −2.66 −482 202890_at −2.66 −481 209217_s_at −2.66 −480 202433_at −2.66 −479 201600_at −2.66 −478 209340_at −2.67 −477 208024_s_at −2.67 −476 202993_at −2.67 −475 200852_x_at −2.67 −474 204212_at −2.67 −473 203667_at −2.67 −472 213175_s_at −2.68 −471 211423_s_at −2.68 −470 213735_s_at −2.68 −469 209808_x_at −2.68 −468 218283_at −2.68 −467 203272_s_at −2.68 −466 202139_at −2.69 −465 220192_x_at −2.69 −464 217861_s_at −2.69 −463 217868_s_at −2.69 −462 200960_x_at −2.69 −461 202927_at −2.69 −460 219075_at −2.69 −459 203791_at −2.69 −458 218074_at −2.69 −457 218320_s_at −2.69 −456 200903_s_at −2.7 −455 222256_s_at −2.7 −454 200710_at −2.7 −453 201019_s_at −2.71 −452 218548_x_at −2.71 −451 217942_at −2.71 −450 209911_x_at −2.71 −449 1729_at −2.71 −448 213726_x_at −2.71 −447 203478_at −2.71 −446 212767_at −2.72 −445 217898_at −2.72 −444 213133_s_at −2.72 −443 218789_s_at −2.72 −442 221566_s_at −2.72 −441 202122_s_at −2.72 −440 207063_at −2.72 −439 203954_x_at −2.72 −438 209080_x_at −2.72 −437 202942_at −2.72 −436 209797_at −2.73 −435 212255_s_at −2.73 −434 213581_at −2.73 −433 212680_x_at −2.73 −432 216905_s_at −2.73 −431 218732_at −2.73 −430 209478_at −2.73 −429 218216_x_at −2.74 −428 202457_s_at −2.74 −427 205780_at −2.74 −426 203034_s_at −2.74 −425 209063_x_at −2.74 −424 217761_at −2.74 −423 D 208864_s_at −2.74 −422 201963_at −2.75 −421 201543_s_at −2.75 −420 201619_at −2.75 −419 209076_s_at −2.75 −418 202308_at −2.75 −417 211404_s_at −2.75 −416 204340_at −2.75 −415 220980_s_at −2.76 −414 215952_s_at −2.76 −413 201791_s_at −2.76 −412 216308_x_at −2.76 −411 204231_s_at −2.76 −410 213061_s_at −2.76 −409 218652_s_at −2.76 −408 206656_s_at −2.76 −407 213190_at −2.76 −406 201923_at −2.76 −405 209605_at −2.76 −404 218192_at −2.76 −403 218872_at −2.76 −402 209114_at −2.76 −401 D 218447_at −2.77 −400 202839_s_at −2.77 −399 207431_s_at −2.77 −398 214274_s_at −2.77 −397 215631_s_at −2.77 −396 204608_at −2.77 −395 216483_s_at −2.77 −394 218533_s_at −2.77 −393 221437_s_at −2.77 −392 208653_s_at −2.78 −391 217956_s_at −2.78 −390 211558_s_at −2.78 −389 204084_s_at −2.78 −388 D 209825_s_at −2.78 −387 209130_at −2.78 −386 204160_s_at −2.78 −385 204017_at −2.78 −384 217930_s_at −2.78 −383 207168_s_at −2.78 −382 202525_at −2.78 −381 204985_s_at −2.78 −380 214112_s_at −2.79 −379 215779_s_at −2.79 −378 D 218086_at −2.79 −377 214882_s_at −2.79 −376 214092_x_at −2.79 −375 219117_s_at −2.79 −374 202406_s_at −2.79 −373 203373_at −2.79 −372 217720_at −2.79 −371 210825_s_at −2.79 −370 218203_at −2.79 −369 D 202477_s_at −2.8 −368 221512_at −2.8 −367 201338_x_at −2.8 −366 212116_at −2.8 −365 206352_s_at −2.8 −364 201066_at −2.8 −363 206302_s_at −2.81 −362 201740_at −2.81 −361 201284_s_at −2.81 −360 200805_at −2.81 −359 204387_x_at −2.81 −358 202130_at −2.81 −357 204295_at −2.82 −356 202708_s_at −2.82 −355 202428_x_at −2.82 −354 214107_x_at −2.82 −353 217803_at −2.82 −352 205329_s_at −2.82 −351 204616_at −2.82 −350 207721_x_at −2.83 −349 200598_s_at −2.83 −348 202429_s_at −2.83 −347 211052_s_at −2.83 −346 214214_s_at −2.83 −345 D 209132_s_at −2.83 −344 213246_at −2.84 −343 219920_s_at −2.84 −342 203931_s_at −2.84 −341 204934_s_at −2.84 −340 209213_at −2.84 −339 D 221567_at −2.84 −338 200620_at −2.85 −337 201033_x_at −2.85 −336 208826_x_at −2.85 −335 204386_s_at −2.85 −334 219061_s_at −2.85 −333 203042_at −2.85 −332 214455_at −2.85 −331 D 201745_at −2.85 −330 212032_s_at −2.85 −329 74694_s_at −2.85 −328 201411_s_at −2.86 −327 213152_s_at −2.86 −326 209222_s_at −2.86 −325 205353_s_at −2.86 −324 213026_at −2.86 −323 205164_at −2.87 −322 212773_s_at −2.87 −321 214875_x_at −2.87 −320 204078_at −2.87 −319 203192_at −2.87 −318 210638_s_at −2.87 −317 214257_s_at −2.87 −316 211177_s_at −2.87 −315 200969_at −2.87 −314 222191_s_at −2.88 −313 201612_at −2.88 −312 218897_at −2.88 −311 210059_s_at −2.88 −310 210187_at −2.88 −309 208405_s_at −2.89 −308 218132_s_at −2.89 −307 202138_x_at −2.89 −306 207508_at −2.9 −305 219929_s_at −2.9 −304 218671_s_at −2.9 −303 207275_s_at −2.9 −302 220607_x_at −2.9 −301 202836_s_at −2.9 −300 205498_at −2.9 −299 D 213379_at −2.91 −298 201714_at −2.91 −297 218555_at −2.91 −296 218327_s_at −2.91 −295 203031_s_at −2.92 −294 203892_at −2.92 −293 221972_s_at −2.92 −292 218101_s_at −2.92 −291 221582_at −2.92 −290 208918_s_at −2.92 −289 209113_s_at −2.92 −288 200740_s_at −2.92 −287 211475_s_at −2.93 −286 208941_s_at −2.93 −285 205241_at −2.93 −284 210633_x_at −2.93 −283 218636_s_at −2.93 −282 212790_x_at −2.93 −281 59625_at −2.93 −280 218996_at −2.93 −279 218150_at −2.93 −278 200863_s_at −2.93 −277 205133_s_at −2.93 −276 203437_at −2.94 −275 209844_at −2.94 −274 210041_s_at −2.94 −273 219575_s_at −2.94 −272 203524_s_at −2.94 −271 213129_s_at −2.94 −270 203219_s_at −2.94 −269 215090_x_at −2.94 −268 208817_at −2.95 −267 217835_x_at −2.95 −266 218220_at −2.95 −265 202550_s_at −2.95 −264 210097_s_at −2.96 −263 201135_at −2.96 −262 219807_x_at −2.96 −261 213287_s_at −2.96 −260 218046_s_at −2.96 −259 58696_at −2.96 −258 219119_at −2.96 −257 40225_at −2.96 −256 217824_at −2.96 −255 221610_s_at −2.96 −254 211730_s_at −2.96 −253 222138_s_at −2.96 −252 219806_s_at −2.96 −251 201913_s_at −2.97 −250 208818_s_at −2.97 −249 217080_s_at −2.97 −248 209759_s_at −2.97 −247 49679_s_at −2.97 −246 202632_at −2.97 −245 219065_s_at −2.97 −244 213423_x_at −2.97 −243 219283_at −2.97 −242 36936_at −2.98 −241 203686_at −2.98 −240 221847_at −2.98 −239 D 205489_at −2.98 −238 202857_at −2.98 −237 201955_at −2.98 −236 218272_at −2.98 −235 65884_at −2.99 −234 204599_s_at −2.99 −233 220597_s_at −3 −232 202424_at −3 −231 221688_s_at −3 −230 202077_at −3.01 −229 208658_at −3.01 −228 218328_at −3.01 −227 205110_s_at −3.02 −226 219862_s_at −3.02 −225 222125_s_at −3.02 −224 218647_s_at −3.02 −223 203594_at −3.02 −222 206055_s_at −3.02 −221 201903_at −3.02 −220 218582_at −3.02 −219 208722_s_at −3.03 −218 201128_s_at −3.03 −217 217772_s_at −3.04 −216 204238_s_at −3.04 −215 211940_x_at −3.04 −214 209796_s_at −3.04 −213 218206_x_at −3.04 −212 220526_s_at −3.04 −211 201588_at −3.05 −210 218436_at −3.05 −209 220161_s_at −3.05 −208 203397_s_at −3.05 −207 203228_at −3.05 −206 201490_s_at −3.05 −205 219015_s_at −3.06 −204 202838_at −3.06 −203 51200_at −3.06 −202 202718_at −3.07 −201 215111_s_at −3.07 −200 203606_at −3.07 −199 209309_at −3.08 −198 203189_s_at −3.08 −197 217014_s_at −3.08 −196 202154_x_at −3.09 −195 201016_at −3.09 −194 203190_at −3.09 −193 218123_at −3.09 −192 220966_x_at −3.09 −191 209398_at −3.1 −190 212411_at −3.1 −189 202096_s_at −3.1 −188 209104_s_at −3.1 −187 212085_at −3.1 −186 208837_at −3.1 −185 217812_at −3.1 −184 208929_x_at −3.1 −183 204360_s_at −3.11 −182 208856_x_at −3.11 −181 213902_at −3.11 −180 208654_s_at −3.11 −179 211936_at −3.12 −178 221255_s_at −3.12 −177 212347_x_at −3.12 −176 209391_at −3.13 −175 203136_at −3.13 −174 208821_at −3.13 −173 216338_s_at −3.13 −172 218188_s_at −3.13 −171 221844_x_at −3.14 −170 201192_s_at −3.14 −169 208910_s_at −3.14 −168 206303_s_at −3.14 −167 213062_at −3.14 −166 200970_s_at −3.15 −165 216449_x_at −3.15 −164 208783_s_at −3.15 −163 202655_at −3.15 −162 218358_at −3.16 −161 221827_at −3.16 −160 200700_s_at −3.17 −159 210312_s_at −3.17 −158 213041_s_at −3.17 −157 218531_at −3.18 −156 213285_at −3.18 −155 215071_s_at −3.19 −154 202286_s_at −3.19 −153 214469_at −3.2 −152 220757_s_at −3.2 −151 218258_at −3.2 −150 220934_s_at −3.2 −149 218961_s_at −3.21 −148 209161_at −3.22 −147 202168_at −3.22 −146 208546_x_at −3.22 −145 208415_x_at −3.22 −144 208977_x_at −3.22 −143 201825_s_at −3.22 −142 218194_at −3.22 −141 201358_s_at −3.23 −140 210010_s_at −3.23 −139 200098_s_at −3.23 −138 217927_at −3.24 −137 220741_s_at −3.24 −136 201119_s_at −3.24 −135 218552_at −3.24 −134 208750_s_at −3.24 −133 208583_x_at −3.24 −132 218112_at −3.25 −131 219762_s_at −3.25 −130 218962_s_at −3.25 −129 210719_s_at −3.25 −128 219118_at −3.25 −127 203133_at −3.26 −126 202812_at −3.26 −125 209302_at −3.26 −124 202740_at −3.26 −123 214531_s_at −3.27 −122 205470_s_at −3.28 −121 D 212685_s_at −3.28 −120 200654_at −3.28 −119 219049_at −3.28 −118 221732_at −3.29 −117 203517_at −3.29 −116 201096_s_at −3.29 −115 213931_at −3.29 −114 D 208751_at −3.3 −113 203647_s_at −3.3 −112 202788_at −3.31 −111 208923_at −3.31 −110 218921_at −3.33 −109 218580_x_at −3.33 −108 209665_at −3.34 −107 205347_s_at −3.34 −106 200022_at −3.34 −105 217979_at −3.35 −104 202109_at −3.36 −103 218313_s_at −3.37 −102 208909_at −3.37 −101 201268_at −3.38 −100 213988_s_at −3.38 −99 D 207157_s_at −3.38 −98 204331_s_at −3.39 −97 209404_s_at −3.39 −96 209806_at −3.39 −95 204175_at −3.4 −94 201359_at −3.4 −93 220094_s_at −3.41 −92 213315_x_at −3.41 −91 218070_s_at −3.41 −90 210386_s_at −3.42 −89 208726_s_at −3.43 −88 202941_at −3.43 −87 213897_s_at −3.45 −86 204862_s_at −3.45 −85 200093_s_at −3.45 −84 D 209123_at −3.45 −83 202427_s_at −3.46 −82 D 203582_s_at −3.46 −81 204088_at −3.46 −80 220495_s_at −3.46 −79 210592_s_at −3.48 −78 208734_x_at −3.49 −77 46323_at −3.49 −76 D 211574_s_at −3.49 −75 210667_s_at −3.49 −74 217940_s_at −3.49 −73 200044_at −3.5 −72 201704_at −3.5 −71 204034_at −3.51 −70 212527_at −3.51 −69 208490_x_at −3.51 −68 203415_at −3.51 −67 202297_s_at −3.52 −66 200820_at −3.52 −65 52940_at −3.52 −64 201758_at −3.53 −63 209420_s_at −3.53 −62 201944_at −3.53 −61 212739_s_at −3.53 −60 201489_at −3.53 −59 218387_s_at −3.54 −58 222209_s_at −3.55 −57 200670_at −3.56 −56 203372_s_at −3.57 −55 202418_at −3.59 −54 36554_at −3.59 −53 210434_x_at −3.59 −52 202996_at −3.6 −51 212961_x_at −3.66 −50 218898_at −3.66 −49 218388_at −3.68 −48 207805_s_at −3.68 −47 202120_x_at −3.69 −46 217995_at −3.7 −45 D 208579_x_at −3.7 −44 208074_s_at −3.7 −43 200681_at −3.73 −42 201849_at −3.73 −41 D 200656_s_at −3.73 −40 D 209149_s_at −3.74 −39 202475_at −3.76 −38 208527_x_at −3.77 −37 204319_s_at −3.78 −36 D 205593_s_at −3.78 −35 219188_s_at −3.78 −34 203430_at −3.78 −33 200075_s_at −3.78 −32 D 207023_x_at −3.79 −31 216295_s_at −3.81 −30 204392_at −3.82 −29 222067_x_at −3.82 −28 200048_s_at −3.84 −27 D 200971_s_at −3.87 −26 217744_s_at −3.89 −25 200065_s_at −3.9 −24 211047_x_at −3.92 −23 201410_at −3.93 −22 201201_at −3.95 −21 218280_x_at −3.95 −20 214290_s_at −3.97 −19 D 201848_s_at −4 −18 207549_x_at −4.02 −17 D 201264_at −4.05 −16 D 202929_s_at −4.07 −15 D 200846_s_at −4.09 −14 D 201953_at −4.09 −13 212280_x_at −4.09 −12 202041_s_at −4.1 −11 218592_s_at −4.2 −10 201079_at 4.24 −9 D 213166_x_at −4.25 −8 202671_s_at −4.28 −7 204903_x_at −4.43 −6 203663_s_at −4.49 −5 D 212995_x_at −4.67 −4 D 217871_s_at −4.97 −3 D 201106_at −5.02 −2 202296_s_at −5.11 −1 D

TABLE 11 43 gene classifier for relapse of prostate cancer Affymetrix number 210986_s_at 201022_s_at 200795_at 202274_at 218509_at D 201497_x_at 220587_s_at 201891_s_at 209074_s_at D 200897_s_at 202296_s_at D 202432_at 201106_at 221667_s_at 217871_s_at D 208579_x_at 200974_at 201431_s_at 221958_s_at 209288_s_at 203951_at 216231_s_at 201540_at 207430_s_at D 207480_s_at 202994_s_at 212995_x_at D 209763_at 217897_at D 202228_s_at 209948_at D 218418_s_at 212077_at 205011_at 209286_at 208490_x_at 209806_at 208527_x_at 202555_s_at 208676_s_at D 210987_x_at 203663_s_at D 202350_s_at

TABLE 12 Top 144 genes identified as down- regulated in prostate stroma cells of relapse patients, calculated by linear regression, including only samples from regions of the prostate that did not have detectable tumor cells Affymetrix number T statistic Rank 211047_x_at −5.79 1 201106_at −5.18 2 208074_s_at −5.05 3 202120_x_at −4.82 4 212280_x_at −4.68 5 202296_s_at −4.45 6 D 211404_s_at −4.37 7 201201_at −4.34 8 208923_at −4.26 9 204903_x_at −4.21 10 210010_s_at −4.08 11 208929_x_at −3.96 12 52940_at −3.93 13 202041_s_at −3.9 14 210719_s_at −3.89 15 212995_x_at −3.87 16 D 202671_s_at −3.85 17 218552_at −3.83 18 217930_s_at −3.8 19 203663_s_at −3.79 20 D 200075_s_at −3.76 21 D 217744_s_at −3.73 22 207023_x_at −3.72 23 201848_s_at −3.69 24 208726_s_at −3.69 25 218388_at −3.68 26 212961_x_at −3.67 27 200656_s_at −3.66 28 D 217871_s_at −3.66 29 D 220757_s_at −3.63 30 213624_at −3.61 31 202096_s_at −3.6 32 209113_s_at −3.6 33 221972_s_at −3.59 34 221566_s_at −3.59 35 202929_s_at −3.59 36 D 208702_x_at −3.59 37 201953_at −3.57 38 201119_s_at −3.57 39 202996_at −3.57 40 201520_s_at −3.57 41 219929_s_at −3.54 42 214875_x_at −3.54 43 209420_s_at −3.53 44 201587_s_at −3.5 45 201489_at −3.49 46 213897_s_at −3.47 47 208751_at −3.45 48 203517_at −3.45 49 204360_s_at −3.43 50 201490_s_at −3.42 51 201264_at −3.42 52 D 214882_s_at −3.41 53 208669_s_at −3.4 54 213931_at −3.39 55 D 219119_at −3.37 56 36554_at −3.37 57 202424_at −3.36 58 218387_s_at −3.36 59 217716_s_at −3.35 60 221567_at −3.35 61 210097_s_at −3.33 62 59625_at −3.33 63 207805_s_at −3.33 64 213166_x_at −3.31 65 212085_at −3.3 66 215952_s_at −3.3 67 218592_s_at −3.3 68 216308_x_at −3.29 69 213061_s_at −3.29 70 209472_at −3.28 71 202308_at −3.28 72 208909_at −3.27 73 208787_at −3.27 74 204238_s_at −3.27 75 207157_s_at −3.27 76 204981_at −3.26 77 209407_s_at −3.26 78 218921_at −3.25 79 208734_x_at −3.25 80 208928_at −3.25 81 40225_at −3.24 82 210386_s_at −3.24 83 220607_x_at −3.23 84 212347_x_at −3.23 85 217940_s_at −3.23 86 210667_s_at −3.22 87 200637_s_at −3.22 88 41047_at −3.22 89 201705_at −3.21 90 200022_at −3.2 91 209222_s_at −3.2 92 218070_s_at −3.19 93 212191_x_at −3.19 94 222191_s_at −3.18 95 203647_s_at −3.18 96 203571_s_at −3.18 97 200065_s_at −3.17 98 208750_s_at −3.16 99 201192_s_at −3.16 100 208024_s_at −3.15 101 204608_at −3.15 102 204034_at −3.15 103 209149_s_at −3.14 104 218150_at −3.13 105 201849_at −3.13 106 D 218132_s_at −3.13 107 1729_at −3.13 108 203372_s_at −3.11 109 220597_s_at −3.1 110 209217_s_at −3.1 111 214274_s_at −3.09 112 218289_s_at −3.09 113 210130_s_at −3.09 114 209076_s_at −3.09 115 202812_at −3.08 116 202736_s_at −3.08 117 204392_at −3.08 118 203582_s_at −3.07 119 217912_at −3.07 120 201079_at −3.07 121 D 201095_at −3.07 122 218652_s_at −3.07 123 208918_s_at −3.06 124 219188_s_at −3.06 125 51200_at −3.06 126 200710_at −3.05 127 213062_at −3.05 128 200846_s_at −3.04 129 D 218188_s_at −3.04 130 213287_s_at −3.04 131 202737_s_at −3.03 132 212782_x_at −3.03 133 214494_s_at −3.03 134 221850_x_at −3.03 135 203430_at −3.02 136 204862_s_at −3.02 137 200654_at −3.02 138 200852_x_at −3.02 139 201704_at −3.02 140 217014_s_at −3.01 141 206469_x_at −3 142 202139_at −3 143 216862_s_at −3 144

TABLE 13 Top 100 genes identified as up- regulated in prostate stroma from patients that had relapsed, including only samples from regions of the prostate that did not have detectable tumor cells Affymetrix number T statistic Rank 204951_at 4.73 1 204795_at 4.64 2 51774_s_at 4.54 3 205456_at 4.52 4 211323_s_at 4.51 5 D 201320_at 4.28 6 204436_at 4.05 7 205988_at 3.98 8 212076_at 3.97 9 218525_s_at 3.94 10 209671_x_at 3.89 11 211991_s_at 3.73 12 205405_at 3.69 13 58900_at 3.66 14 210038_at 3.65 15 211599_x_at 3.59 16 207834_at 3.55 17 204901_at 3.53 18 209616_s_at 3.49 19 D 217187_at 3.48 20 219812_at 3.47 21 211123_at 3.44 22 209582_s_at 3.42 23 D 211902_x_at 3.42 24 221486_at 3.41 25 219035_s_at 3.39 26 210972_x_at 3.38 27 201080_at 3.38 28 219877_at 3.37 29 208598_s_at 3.35 30 209670_at 3.35 31 218581_at 3.34 32 210072_at 3.33 33 D 215826_x_at 3.33 34 213193_x_at 3.3 35 202501_at 3.3 36 207648_at 3.29 37 204562_at 3.29 38 207691_x_at 3.24 39 64064_at 3.23 40 211203_s_at 3.23 41 214760_at 3.22 42 204341_at 3.21 43 D 206053_at 3.21 44 202401_s_at 3.21 45 204852_s_at 3.21 46 200610_s_at 3.21 47 202964_s_at 3.2 48 205011_at 3.19 49 202809_s_at 3.18 50 38521_at 3.18 51 209062_x_at 3.16 52 211504_x_at 3.16 53 208306_x_at 3.15 54 217362_x_at 3.15 55 212151_at 3.15 56 212100_s_at 3.14 57 214738_s_at 3.14 58 202578_s_at 3.14 59 204882_at 3.14 60 204563_at 3.13 61 D 213386_at 3.13 62 206105_at 3.13 63 211796_s_at 3.13 64 212713_at 3.13 65 D 217418_x_at 3.12 66 204116_at 3.11 67 211710_x_at 3.1 68 204640_s_at 3.1 69 213370_s_at 3.09 70 214694_at 3.08 71 210444_at 3.08 72 218338_at 3.08 73 206767_at 3.08 74 209473_at 3.08 75 203157_s_at 3.07 76 200064_at 3.07 77 212972_x_at 3.07 78 215592_at 3.06 79 210915_x_at 3.06 80 205821_at 3.05 81 213831_at 3.04 82 214928_at 3.04 83 209057_x_at 3.03 84 D 208459_s_at 3.03 85 213958_at 3.02 86 207547_s_at 3 87 215946_x_at 2.99 88 210356_x_at 2.99 89 214450_at 2.99 90 204229_at 2.98 91 200621_at 2.98 92 D 208227_x_at 2.97 93 215762_at 2.96 94 38149_at 2.96 95 217925_s_at 2.95 96 215379_x_at 2.95 97 71933_at 2.94 98 211269_s_at 2.93 99 206180_x_at 2.91 100

TABLE 14 List of 35 (nonunique) genes associated with differential expression in aggressive prostate cancer found among the statistically differentially expressed genes of early relapse prostate cancer (cf. Tables 9 and 10). Set Name 148_rs_btsg_regcoeff_tstats_nam_Name 211323_s_at inositol 1,4,5-triphosphate receptor, type 1 208579_x_at histone 1, H2bk 208490_x_at histone 1, H2bf 209806_at histone 1, H2bk 209844_at homeo box B13 222067_x_at histone 1, H2bd 201893_x_at decorin 202401_s_at serum response factor (c-fos serum response element-binding transcription factor) 202525_at protease, serine, 8 (prostasin) 204934_s_at hepsin (transmembrane protease, serine 1) 207547_s_at TU3A protein 208527_x_at histone 1, H2be 218186_at RAB25, member RAS oncogene family 200621_at cysteine and glycine-rich protein 1 208789_at polymerase I and transcript release factor 212713_at microfibrillar-associated protein 4 205011_at loss of heterozygosity, 11, chromosomal region 2, gene A 208546_x_at histone 1, H2bh 209473_at ectonucleoside triphosphate diphosphohydrolase 1 209696_at fructose-1,6-bisphosphatase 1 221958_s_at hypothetical protein FLJ23091 200953_s_at cyclin D2 200852_x_at guanine nucleotide binding protein (G protein), beta polypeptide 2 202074_s_at optineurin 206491_s_at N-ethylmaleimide-sensitive factor attachment protein, alpha 208751_at N-ethylmaleimide-sensitive factor attachment protein, alpha 204754_at hepatic leukemia factor 200795_at SPARC-like 1 (mast9, hevin) 200974_at actin, alpha 2, smooth muscle, aorta 202041_s_at fibroblast growth factor (acidic) intracellular binding protein 202501_at microtubule-associated protein, RP/EB family, member 2 202545_at protein kinase C, delta 209297_at intersectin 1 (SH3 domain protein) 202758_s_at regulatory factor X-associated ankyrin-containing protein

TABLE 17 probeID U133 probeID U95A AFFX-HUMGAPDH/M33197_M_at 35905_s_at AFFX-HUMGAPDH/M33197_5_at 35905_s_at AFFX-HUMGAPDH/M33197_3_at 35905_s_at AFFX-HSAC07/X00351_M_at 32318_s_at AFFX-HSAC07/X00351_M_at AFFX-HSAC07/X00351_3_at AFFX-HSAC07/X00351_M_at AFFX-HSAC07/X00351_3_st AFFX-HSAC07/X00351_M_at AFFX-HSAC07/X00351_5_at AFFX-HSAC07/X00351_M_at AFFX-HSAC07/X00351_5_st AFFX-HSAC07/X00351_M_at AFFX-HSAC07/X00351_M_at AFFX-HSAC07/X00351_5_at 32318_s_at AFFX-HSAC07/X00351_5_at AFFX-HSAC07/X00351_3_at AFFX-HSAC07/X00351_5_at AFFX-HSAC07/X00351_3_st AFFX-HSAC07/X00351_5_at AFFX-HSAC07/X00351_5_at AFFX-HSAC07/X00351_5_at AFFX-HSAC07/X00351_5_st AFFX-HSAC07/X00351_5_at AFFX-HSAC07/X00351_M_at AFFX-HSAC07/X00351_3_at 32318_s_at AFFX-HSAC07/X00351_3_at AFFX-HSAC07/X00351_3_at AFFX-HSAC07/X00351_3_at AFFX-HSAC07/X00351_3_st AFFX-HSAC07/X00351_3_at AFFX-HSAC07/X00351_5_at AFFX-HSAC07/X00351_3_at AFFX-HSAC07/X00351_5_st AFFX-HSAC07/X00351_3_at AFFX-HSAC07/X00351_M_at 39817_s_at 39817_s_at 39817_s_at 39818_at 38671_at 38671_at 37996_s_at 37996_s_at 37950_at 37950_at 37408_at 37408_at 37384_at 37384_at 37117_at 37117_at 37022_at 37022_at 37005_at 37005_at 35846_at 35846_at 33850_at 242_at 33850_at 243_g_at 33850_at 32226_at 33767_at 33767_at 33323_r_at 33322_i_at 33323_r_at 33323_r_at 33322_i_at 33322_i_at 33322_i_at 33323_r_at 32094_at 32094_at 243_g_at 242_at 243_g_at 243_g_at 243_g_at 32226_at 222221_x_at 40098_at 222067_x_at 38576_at 222043_at 36780_at 221922_at 33185_at 221881_s_at 33891_at 221872_at 1042_at 221730_at 38420_at 221729_at 38420_at 221586_s_at 1044_s_at 221586_s_at 1639_s_at 221584_s_at 40737_at 221564_at 39348_at 221475_s_at 32432_f_at 219514_at 37573_at 219140_s_at 32552_at 218924_s_at 37855_at 218831_s_at 31431_at 218831_s_at 31432_g_at 218820_at 41837_at 218215_s_at 518_at 217871_s_at 895_at 217826_s_at 39039_s_at 217826_s_at 39040_at 217764_s_at 33371_s_at 217764_s_at 33372_at 217763_s_at 33371_s_at 217763_s_at 33372_at 217762_s_at 33371_s_at 217762_s_at 33372_at 217741_s_at 41542_at 217691_x_at 33143_s_at 217487_x_at 1739_at 217487_x_at 1740_g_at 217437_s_at 40841_at 217398_x_at 35905_s_at 217066_s_at 37996_s_at 217014_s_at 35834_at 216944_s_at 32778_at 216944_s_at 32779_s_at 216944_s_at 755_at 216905_s_at 35309_at 216899_s_at 36091_at 216887_s_at 34870_at 216866_s_at 34388_at 216840_s_at 36917_at 216733_s_at 36595_s_at 216733_s_at 36596_r_at 216689_x_at 39700_at 216689_x_at 552_at 216689_x_at 553_g_at 216623_x_at 37426_at 216602_s_at 34291_at 216594_x_at 32805_at 216483_s_at 38969_at 216474_x_at 32905_s_at 216442_x_at 311_s_at 216442_x_at 31719_at 216442_x_at 31720_s_at 216438_s_at 33421_s_at 216397_s_at 35615_at 216331_at 36892_at 216251_s_at 37648_at 216236_s_at 36979_at 216235_s_at 1507_s_at 216230_x_at 32574_at 216230_x_at 37371_at 216215_s_at 40260_g_at 216205_s_at 34369_at 216111_x_at 41258_at 216100_s_at 40832_s_at 216100_s_at 40833_r_at 216074_x_at 34213_at 216033_s_at 2039_s_at 216033_s_at 40480_s_at 215990_s_at 40091_at 215779_s_at 32819_at 215711_s_at 36909_at 215707_s_at 36159_s_at 215706_x_at 36958_at 215606_s_at 37869_at 215537_x_at 36131_at 215537_x_at 38621_at 215493_x_at 32673_at 215485_s_at 32640_at 215471_s_at 39732_at 215464_s_at 39416_at 215438_x_at 33932_at 215382_x_at 32905_s_at 215333_x_at 39054_at 215300_s_at 37874_at 215222_x_at 38704_at 215193_x_at 41723_s_at 215108_x_at 37426_at 215051_x_at 33641_g_at 215016_x_at 40304_at 215000_s_at 38651_at 214909_s_at 36131_at 214909_s_at 38621_at 214894_x_at 38704_at 214889_at 34423_at 214875_x_at 33944_at 214789_x_at 32038_s_at 214774_x_at 37426_at 214771_x_at 38730_at 214761_at 34950_at 214752_x_at 32749_s_at 214752_x_at 32750_r_at 214726_x_at 32145_at 214643_x_at 459_s_at 214598_at 33611_g_at 214582_at 35872_at 214582_at 746_at 214577_at 41373_s_at 214543_x_at 39759_at 214543_x_at 39760_at 214508_x_at 32065_at 214508_x_at 32066_g_at 214508_x_at 32067_at 214505_s_at 32542_at 214501_s_at 36576_at 214500_at 36576_at 214463_x_at 34027_f_at 214455_at 32980_f_at 214449_s_at 1818_at 214449_s_at 40555_at 214439_x_at 459_s_at 214308_s_at 31844_at 214307_at 31844_at 214271_x_at 33668_at 214266_s_at 39530_at 214265_at 41005_at 214212_x_at 36577_at 214170_x_at 32546_at 214167_s_at 31538_at 214117_s_at 37274_at 214077_x_at 37486_f_at 214040_s_at 32612_at 214039_s_at 41188_at 214027_x_at 40776_at 213994_s_at 35277_at 213993_at 35277_at 213992_at 39939_at 213982_s_at 34445_at 213982_s_at 34446_at 213974_at 38856_at 213947_s_at 41812_s_at 213901_x_at 40260_g_at 213892_s_at 34310_at 213867_x_at 32318_s_at 213867_x_at AFFX-HSAC07/X00351_3_at 213867_x_at AFFX-HSAC07/X00351_3_st 213867_x_at AFFX-HSAC07/X00351_5_at 213867_x_at AFFX-HSAC07/X00351_5_st 213867_x_at AFFX-HSAC07/X00351_M_at 213804_at 33290_at 213800_at 32250_at 213798_s_at 935_at 213791_at 38291_at 213787_s_at 32536_at 213746_s_at 32749_s_at 213746_s_at 32750_r_at 213702_x_at 36938_at 213702_x_at 461_at 213688_at 41143_at 213688_at 41144_g_at 213675_at 39750_at 213620_s_at 38454_g_at 213600_at 37831_at 213572_s_at 33305_at 213541_s_at 36383_at 213541_s_at 914_g_at 213524_s_at 38326_at 213519_s_at 36917_at 213506_at 36345_g_at 213506_at 38247_at 213492_at 37605_at 213492_at 598_at 213485_s_at 36732_at 213476_x_at 471_f_at 213455_at 38643_at 213453_x_at 35905_s_at 213446_s_at 1825_at 213428_s_at 38722_at 213422_s_at 35219_at 213400_s_at 32554_s_at 213400_s_at 32555_at 213395_at 36897_at 213371_at 34870_at 213338_at 35692_at 213325_at 34202_at 213307_at 37806_at 213293_s_at 36825_at 213275_x_at 32372_at 213189_at 34662_at 213176_s_at 33137_at 213154_s_at 40879_at 213152_s_at 32038_s_at 213151_s_at 32175_at 213138_at 38278_at 213134_x_at 37218_at 213107_at 32680_at 213102_at 35271_at 213071_at 38059_g_at 213068_at 38059_g_at 213041_s_at 37992_s_at 213041_s_at 37993_at 213005_s_at 37225_at 213004_at 37573_at 213001_at 37573_at 212998_x_at 36773_f_at 212977_at 34288_at 212937_s_at 38722_at 212914_at 39788_at 212886_at 34183_at 212878_s_at 39057_at 212865_s_at 34388_at 212845_at 40855_at 212843_at 1566_at 212843_at 41289_at 212838_at 34712_at 212826_s_at 40435_at 212826_s_at 40436_g_at 212817_at 38632_at 212793_at 41098_at 212792_at 39021_at 212765_at 34688_at 212764_at 33440_at 212758_s_at 33440_at 212757_s_at 32104_i_at 212757_s_at 32105_f_at 212747_at 40971_at 212744_at 33175_at 212730_at 39544_at 212724_at 35803_at 212713_at 39066_at 212694_s_at 36561_at 212670_at 31621_s_at 212670_at 39098_at 212669_at 32104_i_at 212669_at 32105_f_at 212667_at 671_at 212658_at 37542_at 212652_s_at 40605_at 212651_at 39771_at 212647_at 1879_at 212647_at 38338_at 212646_at 32593_at 212624_s_at 40512_at 212610_at 38443_at 212609_s_at 40781_at 212590_at 32827_at 212581_x_at 35905_s_at 212573_at 40455_at 212572_at 32182_at 212567_s_at 242_at 212567_s_at 243_g_at 212567_s_at 32226_at 212566_at 242_at 212566_at 243_g_at 212566_at 32226_at 212565_at 32182_at 212563_at 35615_at 212561_at 33924_at 212554_at 33404_at 212554_at 33405_at 212554_at 693_g_at 212551_at 33404_at 212551_at 33405_at 212551_at 693_g_at 212535_at 41747_s_at 212526_at 39852_at 212510_at 38394_at 212504_at 33407_at 212504_at 33408_at 212503_s_at 33407_at 212503_s_at 33408_at 212494_at 35358_at 212470_at 39419_at 212457_at 34669_at 212449_s_at 39396_at 212445_s_at 39356_at 212430_at 38661_at 212409_s_at 40832_s_at 212409_s_at 40833_r_at 212408_at 40832_s_at 212408_at 40833_r_at 212358_at 36095_at 212354_at 35832_at 212344_at 35832_at 212330_at 37758_s_at 212325_at 32812_at 212316_at 41812_s_at 212314_at 41585_at 212280_x_at 37041_at 212276_at 38098_at 212274_at 38098_at 212272_at 38098_at 212254_s_at 40304_at 212253_x_at 40304_at 212252_at 38716_at 212240_s_at 1269_at 212236_x_at 34301_r_at 212235_at 38671_at 212230_at 33862_at 212227_x_at 33850_at 212203_x_at 41745_at 212197_x_at 38730_at 212169_at 38761_s_at 212157_at 39757_at 212154_at 39757_at 212130_x_at 33850_at 212127_at 32151_at 212120_at 1818_at 212120_at 40555_at 212119_at 1818_at 212119_at 40555_at 212118_at 40176_at 212117_at 1818_at 212117_at 40555_at 212116_at 40176_at 212104_s_at 40260_g_at 212097_at 36119_at 212091_s_at 38722_at 212088_at 36602_at 212085_at 40435_at 212085_at 40436_g_at 212082_s_at 33994_g_at 212071_s_at 39556_at 212067_s_at 39409_at 212041_at 38686_at 212008_at 37336_at 211991_s_at 38833_at 211990_at 38833_at 211981_at 39333_at 211980_at 39333_at 211978_x_at 33667_at 211966_at 36659_at 211964_at 36659_at 211954_s_at 39028_at 211949_s_at 36597_at 211945_s_at 32808_at 211892_s_at 36533_at 211871_x_at 38176_at 211864_s_at 34678_at 211778_s_at 36761_at 211765_x_at 33667_at 211762_s_at 40407_at 211749_s_at 35783_at 211719_x_at 311_s_at 211719_x_at 31719_at 211719_x_at 31720_s_at 211678_s_at 38670_at 211678_s_at 41698_at 211658_at 39729_at 211654_x_at 36773_f_at 211651_s_at 581_at 211596_s_at 34800_at 211576_s_at 33135_at 211574_s_at 38441_s_at 211573_x_at 231_at 211573_x_at 38404_at 211562_s_at 37765_at 211559_s_at 1913_at 211559_s_at 37723_at 211558_s_at 37722_s_at 211538_s_at 36925_at 211538_s_at 645_at 211537_x_at 36905_at 211536_x_at 36905_at 211535_s_at 2056_at 211535_s_at 2057_g_at 211535_s_at 424_s_at 211473_s_at 39939_at 211423_s_at 33421_s_at 211404_s_at 33944_at 211378_x_at 33667_at 211323_s_at 32778_at 211323_s_at 32779_s_at 211323_s_at 755_at 211296_x_at 1366_i_at 211296_x_at 32335_r_at 211256_x_at 32673_at 211203_s_at 31809_at 211203_s_at 31810_g_at 211160_x_at 39329_at 211160_x_at 39330_s_at 211144_x_at 41468_at 211126_s_at 41401_at 211071_s_at 36941_at 211070_x_at 37692_at 211043_s_at 32522_f_at 211031_s_at 41396_at 211026_s_at 35792_at 211003_x_at 231_at 211003_x_at 38404_at 210990_s_at 37671_at 210986_s_at 36790_at 210986_s_at 36791_g_at 210986_s_at 36792_at 210982_s_at 37039_at 210976_s_at 36196_at 210973_s_at 2056_at 210973_s_at 2057_g_at 210973_s_at 424_s_at 210935_s_at 38736_at 210907_s_at 35218_at 210840_s_at 1825_at 210829_s_at 32668_at 210794_s_at 39026_r_at 210787_s_at 38716_at 210764_s_at 38772_at 210762_s_at 37951_at 210738_s_at 35285_at 210738_s_at 35871_s_at 210736_x_at 36467_g_at 210736_x_at 36469_at 210736_x_at 36470_s_at 210702_s_at 36533_at 210648_x_at 39360_at 210628_x_at 33137_at 210627_s_at 38464_at 210592_s_at 1173_g_at 210592_s_at 34304_s_at 210588_x_at 40836_s_at 210582_s_at 38618_at 210570_x_at 1238_at 210570_x_at 38431_at 210547_x_at 32634_s_at 210544_s_at 40409_at 210541_s_at 40176_at 210517_s_at 37680_at 210495_x_at 311_s_at 210495_x_at 31719_at 210495_x_at 31720_s_at 210471_s_at 32709_at 210470_x_at 38527_at 210338_s_at 1180_g_at 210337_s_at 40881_at 210317_s_at 1011_s_at 210299_s_at 32542_at 210298_x_at 32542_at 210243_s_at 39445_at 210237_at 35899_at 210202_s_at 459_s_at 210201_x_at 459_s_at 210186_s_at 151_s_at 210156_s_at 37737_at 210139_s_at 38653_at 210110_x_at 40836_s_at 210105_s_at 2039_s_at 210105_s_at 40480_s_at 210101_x_at 39691_at 210089_s_at 37671_at 210084_x_at 32905_s_at 210079_x_at 32709_at 210036_s_at 38225_at 210036_s_at 38858_at 210027_s_at 2025_s_at 210026_s_at 41817_g_at 210026_s_at 41818_at 210024_s_at 34850_at 209967_s_at 32065_at 209967_s_at 32066_g_at 209967_s_at 32067_at 209948_at 38298_at 209897_s_at 39634_at 209896_s_at 38443_at 209895_at 38443_at 209872_s_at 41359_at 209868_s_at 31671_at 209868_s_at 31672_g_at 209868_s_at 333_s_at 209868_s_at 33867_s_at 209863_s_at 31791_at 209834_at 32094_at 209823_x_at 36773_f_at 209818_s_at 32970_f_at 209786_at 35737_at 209786_at 35738_at 209772_s_at 266_s_at 209747_at 1767_s_at 209708_at 36834_at 209702_at 37242_at 209696_at 36495_at 209695_at 36008_at 209687_at 32666_at 209687_at 33834_at 209685_s_at 1217_g_at 209685_s_at 1336_s_at 209685_s_at 160029_at 209665_at 39752_at 209663_s_at 36892_at 209656_s_at 37958_at 209655_s_at 37958_at 209651_at 35146_at 209646_x_at 38503_at 209645_s_at 38503_at 209625_at 40629_at 209624_s_at 36432_at 209623_at 36432_at 209621_s_at 39690_at 209608_s_at 34790_at 209583_s_at 37716_at 209582_s_at 37716_at 209576_at 33809_at 209568_s_at 37539_at 209563_x_at 41143_at 209563_x_at 41144_g_at 209550_at 36073_at 209539_at 37543_at 209516_at 36462_at 209505_at 1147_at 209496_at 34407_at 209488_s_at 1276_g_at 209488_s_at 34162_at 209488_s_at 34163_g_at 209488_s_at 38047_at 209488_s_at 38049_g_at 209487_at 1276_g_at 209487_at 34162_at 209487_at 34163_g_at 209487_at 38047_at 209487_at 38049_g_at 209482_at 32213_at 209470_s_at 36939_at 209469_at 36939_at 209440_at 36489_at 209437_s_at 35277_at 209436_at 35277_at 209433_s_at 34341_at 209427_at 31830_s_at 209427_at 31831_at 209426_s_at 41706_at 209425_at 41706_at 209424_s_at 41706_at 209406_at 35291_at 209402_s_at 38625_g_at 209402_s_at 39521_at 209401_s_at 38625_g_at 209401_s_at 39521_at 209398_at 37018_at 209391_at 38726_at 209389_x_at 37692_at 209379_s_at 37617_at 209368_at 41473_at 209367_at 38259_at 209366_x_at 38458_at 209366_x_at 38459_g_at 209363_s_at 34356_at 209363_s_at 34357_g_at 209360_s_at 1882_g_at 209360_s_at 2026_at 209356_x_at 35347_at 209355_s_at 33862_at 209340_at 41242_at 209337_at 39243_s_at 209323_at 41141_at 209318_x_at 36943_r_at 209312_x_at 41723_s_at 209309_at 35834_at 209302_at 35631_at 209292_at 41536_at 209291_at 41536_at 209288_s_at 33362_at 209287_s_at 33362_at 209265_s_at 32245_at 209265_s_at 32246_g_at 209242_at 39701_at 209210_s_at 36577_at 209209_s_at 36577_at 209203_s_at 40879_at 209200_at 37710_at 209199_s_at 37710_at 209198_s_at 36144_at 209197_at 36144_at 209194_at 38410_at 209170_s_at 37251_s_at 209167_at 37251_s_at 209154_at 39416_at 209147_s_at 34797_at 209142_s_at 1423_at 209129_at 39341_at 209118_s_at 40567_at 209114_at 34775_at 209113_s_at 41526_at 209104_s_at 41322_s_at 209101_at 36638_at 209091_s_at 39691_at 209090_s_at 39691_at 209074_s_at 38044_at 209047_at 36156_at 209039_x_at 40098_at 209009_at 38375_at 208985_s_at 40616_at 208980_s_at 1366_i_at 208980_s_at 32335_r_at 208978_at 35828_at 208966_x_at 1456_s_at 208964_s_at 39372_at 208964_s_at 39373_at 208964_s_at 41719_i_at 208964_s_at 41720_r_at 208962_s_at 39372_at 208962_s_at 39373_at 208962_s_at 41719_i_at 208962_s_at 41720_r_at 208944_at 1814_at 208944_at 1815_g_at 208941_s_at 39387_at 208910_s_at 37668_at 208905_at 35818_at 208904_s_at 39798_at 208899_x_at 33854_at 208894_at 37039_at 208881_x_at 36985_at 208868_s_at 35785_at 208853_s_at 40125_at 208852_s_at 40125_at 208848_at 37707_i_at 208848_at 37708_r_at 208843_s_at 35806_at 208842_s_at 35806_at 208837_at 41163_at 208801_at 33837_at 208800_at 33837_at 208792_s_at 36780_at 208791_at 36780_at 208787_at 37726_at 208786_s_at 39370_at 208781_x_at 39360_at 208778_s_at 34791_at 208770_s_at 35263_at 208767_s_at 41188_at 208763_s_at 36629_at 208763_s_at 36630_at 208756_at 1644_at 208756_at 32230_at 208747_s_at 40496_at 208737_at 38814_at 208702_x_at 33944_at 208700_s_at 38789_at 208699_x_at 38789_at 208698_s_at 38527_at 208687_x_at 1180_g_at 208682_s_at 34859_at 208679_s_at 1718_at 208675_s_at 38791_at 208650_s_at 266_s_at 208637_x_at 39329_at 208637_x_at 39330_s_at 208636_at 39329_at 208636_at 39330_s_at 208633_s_at 38704_at 208632_at 34883_at 208628_s_at 36140_at 208627_s_at 36140_at 208591_s_at 35872_at 208591_s_at 746_at 208527_x_at 31523_f_at 208523_x_at 31524_f_at 208490_x_at 31522_f_at 208456_s_at 32827_at 208454_s_at 32765_f_at 208447_s_at 36489_at 208430_s_at 36467_g_at 208430_s_at 36469_at 208430_s_at 36470_s_at 208370_s_at 32168_s_at 208308_s_at 39122_at 208306_x_at 32035_at 208264_s_at 40616_at 208146_s_at 38323_at 208131_s_at 36533_at 208112_x_at 40098_at 208029_s_at 41188_at 207984_s_at 34656_at 207977_s_at 38059_g_at 207961_x_at 32582_at 207961_x_at 37407_s_at 207961_x_at 767_at 207961_x_at 773_at 207961_x_at 774_g_at 207957_s_at 1217_g_at 207957_s_at 1336_s_at 207957_s_at 160029_at 207949_s_at 32634_s_at 207936_x_at 31941_s_at 207876_s_at 35330_at 207843_x_at 38458_at 207843_x_at 38459_g_at 207842_s_at 38437_at 207836_s_at 1276_g_at 207836_s_at 34162_at 207836_s_at 34163_g_at 207836_s_at 38047_at 207836_s_at 38049_g_at 207824_s_at 32553_at 207821_s_at 36117_at 207802_at 36464_at 207761_s_at 38717_at 207741_x_at 32905_s_at 207714_s_at 39167_r_at 207630_s_at 32065_at 207630_s_at 32066_g_at 207630_s_at 32067_at 207629_s_at 40099_at 207563_s_at 38614_s_at 207549_x_at 38441_s_at 207547_s_at 38044_at 207542_s_at 36156_at 207507_s_at 34811_at 207453_s_at 38632_at 207390_s_at 31830_s_at 207390_s_at 31831_at 207348_s_at 1188_g_at 207317_s_at 36505_at 207266_x_at 31671_at 207266_x_at 31672_g_at 207266_x_at 333_s_at 207266_x_at 33867_s_at 207260_at 31685_at 207172_s_at 2087_s_at 207172_s_at 36976_at 207124_s_at 38176_at 207121_s_at 36926_at 207071_s_at 40077_at 207001_x_at 36629_at 207001_x_at 36630_at 206938_at 565_at 206932_at 32363_at 206868_at 34034_at 206858_s_at 40674_s_at 206842_at 40021_at 206813_at 36252_at 206701_x_at 1198_at 206666_at 36280_at 206649_s_at 34669_at 206631_at 828_at 206580_s_at 35347_at 206558_at 39608_at 206558_at 39609_at 206459_s_at 33684_at 206458_s_at 33684_at 206434_at 33596_at 206433_s_at 33596_at 206429_at 36345_g_at 206429_at 38247_at 206385_s_at 36965_at 206382_s_at 1088_at 206382_s_at 40023_at 206377_at 36319_at 206375_s_at 528_at 206352_s_at 41281_s_at 206352_s_at 41282_s_at 206351_s_at 41281_s_at 206351_s_at 41282_s_at 206332_s_at 1456_s_at 206284_x_at 32522_f_at 206117_at 36790_at 206117_at 36791_g_at 206117_at 36792_at 206116_s_at 36790_at 206116_s_at 36791_g_at 206116_s_at 36792_at 206106_at 983_at 206076_at 39447_f_at 206070_s_at 1234_at 206065_s_at 41422_at 206030_at 39654_at 206009_at 1508_at 205980_s_at 37117_at 205963_s_at 36541_at 205961_s_at 39243_s_at 205942_s_at 33278_at 205942_s_at 41149_at 205942_s_at 33279_s_at 205937_at 470_at 205935_at 38183_at 205934_at 1182_at 205895_s_at 36597_at 205882_x_at 33102_at 205882_x_at 33103_s_at 205827_at 37572_at 205805_s_at 213_at 205803_s_at 39123_s_at 205803_s_at 39125_at 205782_at 1380_at 205782_at 1466_s_at 205780_at 2011_s_at 205780_at 36891_at 205776_at 37874_at 205743_at 40024_at 205741_s_at 36467_g_at 205741_s_at 36469_at 205741_s_at 36470_s_at 205730_s_at 39597_at 205709_s_at 40217_s_at 205709_s_at 40218_at 205683_x_at 33321_r_at 205645_at 40663_at 205620_at 39979_at 205611_at 39588_at 205608_s_at 1929_at 205608_s_at 39315_at 205575_at 39920_r_at 205573_s_at 37808_at 205548_s_at 37218_at 205547_s_at 36931_at 205505_at 38218_at 205480_s_at 37373_at 205475_at 35837_at 205438_at 40524_at 205433_at 37841_at 205431_s_at 1831_at 205430_at 1831_at 205407_at 35234_at 205404_at 35702_at 205384_at 32109_at 205382_s_at 40282_s_at 205348_s_at 40318_at 205329_s_at 40605_at 205325_at 37191_at 205304_s_at 34428_at 205303_at 34428_at 205294_at 37760_at 205294_at 37761_at 205262_at 38225_at 205262_at 38858_at 205249_at 37863_at 205225_at 1681_at 205221_at 31844_at 205219_s_at 37825_at 205200_at 36569_at 205168_at 1319_at 205160_at 39648_at 205158_at 32664_at 205157_s_at 34301_r_at 205155_s_at 33630_s_at 205132_at 39063_at 205120_s_at 37223_at 205116_at 36917_at 205110_s_at 36232_at 205110_s_at 468_at 205047_s_at 36671_at 205018_s_at 33318_at 205011_at 38151_at 205001_s_at 38355_at 204993_at 38279_at 204979_s_at 36040_at 204964_s_at 33302_at 204964_s_at 33303_at 204963_at 33302_at 204963_at 33303_at 204939_s_at 38734_at 204938_s_at 38734_at 204934_s_at 37639_at 204931_at 37247_at 204929_s_at 32533_s_at 204929_s_at 32534_f_at 204903_x_at 37041_at 204894_s_at 33756_at 204875_s_at 35071_s_at 204872_at 38364_at 204834_at 39591_s_at 204834_at 39592_r_at 204803_s_at 1776_at 204802_at 1776_at 204790_at 1857_at 204780_s_at 37643_at 204777_s_at 38051_at 204755_x_at 401_s_at 204754_at 401_s_at 204753_s_at 401_s_at 204751_x_at 39302_at 204749_at 743_at 204744_s_at 40827_at 204734_at 37582_at 204731_at 1897_at 204730_at 37265_at 204714_s_at 35245_at 204713_s_at 35245_at 204688_at 41449_at 204615_x_at 36985_at 204610_s_at 41851_at 204608_at 36528_at 204607_at 35345_at 204595_s_at 41354_at 204570_at 39031_at 204556_s_at 36521_at 204518_s_at 37422_at 204517_at 37422_at 204491_at 38526_at 204484_at 41715_at 204472_at 37279_at 204464_s_at 1507_s_at 204463_s_at 1507_s_at 204442_x_at 33137_at 204436_at 36856_at 204430_s_at 34362_at 204429_s_at 34362_at 204427_s_at 36972_at 204426_at 36972_at 204424_s_at 38028_at 204422_s_at 1593_at 204422_s_at 41806_at 204421_s_at 1593_at 204421_s_at 41806_at 204412_s_at 33767_at 204396_s_at 1135_at 204395_s_at 1135_at 204394_at 33708_at 204393_s_at 32200_at 204392_at 251_at 204352_at 35238_at 204345_at 35168_f_at 204345_at 35169_at 204344_s_at 39099_at 204341_at 38881_i_at 204341_at 38882_r_at 204331_s_at 33214_at 204319_s_at 33121_g_at 204312_x_at 877_at 204273_at 1198_at 204271_s_at 1198_at 204223_at 37022_at 204163_at 35740_at 204151_x_at 32805_at 204147_s_at 37758_s_at 204141_at 296_at 204141_at 39331_at 204141_at 297_g_at 204140_at 32718_at 204135_at 31897_at 204134_at 31904_at 204133_at 31882_at 204123_at 1188_g_at 204122_at 38363_at 204117_at 37950_at 204114_at 753_at 204100_at 35846_at 204099_at 32565_at 204083_s_at 32312_at 204083_s_at 32313_at 204083_s_at 32314_g_at 204069_at 40763_at 204059_s_at 33644_at 204059_s_at 837_s_at 204058_at 33644_at 204058_at 837_s_at 204045_at 38317_at 204042_at 1058_at 204038_s_at 40387_at 204037_at 40387_at 204031_s_at 35745_f_at 204031_s_at 35746_r_at 204030_s_at 36536_at 204005_s_at 40621_at 204000_at 38176_at 203973_s_at 1052_s_at 203966_s_at 36501_at 203966_s_at 857_at 203953_s_at 33904_at 203951_at 34203_at 203944_x_at 32673_at 203931_s_at 39812_at 203926_x_at 37992_s_at 203926_x_at 37993_at 203911_at 1251_g_at 203909_at 36542_at 203908_at 35285_at 203908_at 35871_s_at 203903_s_at 35644_at 203886_s_at 32783_at 203851_at 1736_at 203811_s_at 158_at 203811_s_at 33533_at 203810_at 158_at 203810_at 33533_at 203787_at 32668_at 203766_s_at 37765_at 203752_s_at 1612_s_at 203752_s_at 41483_s_at 203748_x_at 31671_at 203748_x_at 31672_g_at 203748_x_at 333_s_at 203748_x_at 33867_s_at 203739_at 32034_at 203733_at 41637_at 203729_at 39182_at 203725_at 1911_s_at 203722_at 37331_g_at 203710_at 32778_at 203710_at 32779_s_at 203710_at 755_at 203698_s_at 40230_at 203688_at 38120_at 203680_at 37221_at 203666_at 32666_at 203666_at 33834_at 203663_s_at 41223_at 203649_s_at 37017_at 203649_s_at 614_at 203641_s_at 41755_at 203638_s_at 1143_s_at 203638_s_at 1363_at 203638_s_at 1145_g_at 203620_s_at 32224_at 203592_s_at 33900_at 203586_s_at 41774_at 203585_at 32139_at 203582_s_at 39244_at 203582_s_at 621_at 203576_at 41111_at 203562_at 37743_at 203557_s_at 34352_at 203542_s_at 40202_at 203524_s_at 36124_at 203498_at 32076_at 203456_at 34318_at 203455_s_at 1173_g_at 203455_s_at 34304_s_at 203453_at 35207_at 203449_s_at 1329_s_at 203449_s_at 32255_i_at 203449_s_at 32256_r_at 203435_s_at 1389_at 203434_s_at 1389_at 203430_at 41454_at 203423_at 38634_at 203415_at 37569_at 203414_at 37565_at 203413_at 32598_at 203411_s_at 37378_r_at 203397_s_at 36483_at 203397_s_at 36484_at 203370_s_at 39530_at 203369_x_at 39530_at 203324_s_at 339_at 203324_s_at 40168_at 203320_at 39428_at 203311_s_at 33152_at 203304_at 37678_at 203303_at 36921_at 203300_x_at 41549_s_at 203296_s_at 34377_at 203243_s_at 40060_r_at 203242_s_at 40060_r_at 203241_at 39429_at 203233_at 404_at 203219_s_at 34310_at 203218_at 1238_at 203218_at 38431_at 203197_s_at 39743_at 203196_at 1931_at 203196_at 34955_at 203186_s_at 38087_s_at 203180_at 36686_at 203174_s_at 35765_at 203167_at 1375_s_at 203167_at 34722_at 203151_at 35917_at 203140_at 40091_at 203139_at 40049_at 203138_at 41855_at 203099_s_at 32111_at 203088_at 39038_at 203068_at 35190_at 203066_at 35350_at 203065_s_at 36119_at 203063_at 37384_at 203043_at 39168_at 203041_s_at 38402_at 203041_s_at 38403_at 203033_x_at 32546_at 203007_x_at 39396_at 202995_s_at 38026_at 202995_s_at 38027_at 202994_s_at 38026_at 202994_s_at 38027_at 202992_at 37394_at 202978_s_at 41495_at 202949_s_at 38422_s_at 202946_s_at 37755_at 202941_at 34893_at 202936_s_at 33436_at 202935_s_at 33436_at 202931_x_at 459_s_at 202929_s_at 33689_s_at 202929_s_at 41180_i_at 202921_s_at 39850_at 202916_s_at 35318_at 202915_s_at 35318_at 202908_at 35164_at 202898_at 32092_at 202890_at 39732_at 202889_x_at 39732_at 202886_s_at 41429_at 202884_s_at 41429_at 202836_s_at 33631_at 202836_s_at 33632_g_at 202828_s_at 34747_at 202812_at 31816_at 202802_at 37722_s_at 202796_at 33719_at 202796_at 36452_at 202795_x_at 34046_at 202787_s_at 1637_at 202786_at 40966_at 202784_s_at 41722_at 202779_s_at 893_at 202770_s_at 1913_at 202770_s_at 37723_at 202769_at 1913_at 202769_at 37723_at 202766_s_at 32535_at 202765_s_at 32535_at 202760_s_at 35985_at 202759_s_at 35985_at 202748_at 32700_at 202740_at 37713_at 202738_s_at 37392_at 202736_s_at 32559_s_at 202736_s_at 32560_s_at 202734_at 36116_at 202732_at 34376_at 202729_s_at 1495_at 202728_s_at 1495_at 202722_s_at 32626_at 202721_s_at 32626_at 202719_s_at 32134_at 202688_at 1715_at 202686_s_at 38433_at 202685_s_at 38433_at 202655_at 36615_at 202637_s_at 32640_at 202609_at 1467_at 202606_s_at 32219_at 202605_at 33308_at 202599_s_at 40088_at 202598_at 39712_at 202583_s_at 39547_at 202579_x_at 35737_at 202579_x_at 35738_at 202566_s_at 40069_at 202565_s_at 40069_at 202555_s_at 32847_at 202554_s_at 1121_g_at 202554_s_at 32798_at 202548_s_at 40828_at 202542_s_at 39734_at 202534_x_at 37913_at 202522_at 353_at 202506_at 38409_at 202504_at 1898_at 202499_s_at 36979_at 202497_x_at 36979_at 202465_at 31609_s_at 202450_s_at 128_at 202450_s_at 129_g_at 202440_s_at 37745_s_at 202440_s_at 37746_r_at 202428_x_at 37692_at 202427_s_at 37000_at 202410_x_at 1664_at 202407_s_at 40904_at 202404_s_at 32305_at 202404_s_at 32306_g_at 202404_s_at 32307_s_at 202403_s_at 32305_at 202403_s_at 32306_g_at 202403_s_at 32307_s_at 202401_s_at 40109_at 202395_at 38719_at 202388_at 37701_at 202371_at 32251_at 202362_at 1848_at 202350_s_at 32239_at 202296_s_at 41551_at 202296_s_at 41552_g_at 202291_s_at 41287_s_at 202286_s_at 291_s_at 202286_s_at 41286_at 202283_at 40856_at 202274_at 1197_at 202273_at 1771_s_at 202269_x_at 35735_at 202266_at 34825_at 202262_x_at 36131_at 202262_x_at 38621_at 202254_at 40805_at 202242_at 38408_at 202228_s_at 35747_at 202222_s_at 40776_at 202202_s_at 37671_at 202201_at 37002_at 202193_at 38618_at 202180_s_at 38064_at 202161_at 175_s_at 202159_at 34291_at 202148_s_at 37741_at 202138_x_at 41250_at 202133_at 33876_at 202132_at 33876_at 202123_s_at 1635_at 202123_s_at 32974_at 202123_s_at 39730_at 202123_s_at 1636_g_at 202123_s_at 32975_g_at 202117_at 39700_at 202117_at 552_at 202117_at 553_g_at 202105_at 34391_at 202092_s_at 33198_at 202089_s_at 1798_at 202081_at 36097_at 202075_s_at 40081_at 202074_s_at 41742_s_at 202074_s_at 41744_at 202073_at 41742_s_at 202073_at 41744_at 202069_s_at 36195_at 202023_at 40425_at 202021_x_at 33850_at 202005_at 35309_at 201995_at 222_at 201993_x_at 32393_s_at 201980_s_at 32544_s_at 201977_s_at 35744_at 201968_s_at 32210_at 201958_s_at 34925_at 201958_s_at 41137_at 201957_at 34925_at 201957_at 41137_at 201955_at 1923_at 201955_at 39251_at 201947_s_at 35759_at 201946_s_at 35759_at 201934_at 32248_at 201931_at 40509_at 201923_at 38435_at 201912_s_at 33932_at 201909_at 41214_at 201900_s_at 38780_at 201892_s_at 36624_at 201869_s_at 32554_s_at 201869_s_at 32555_at 201868_s_at 32554_s_at 201868_s_at 32555_at 201867_s_at 32554_s_at 201867_s_at 32555_at 201858_s_at 32227_at 201852_x_at 32488_at 201848_s_at 38010_at 201843_s_at 32551_at 201842_s_at 32551_at 201841_s_at 36785_at 201839_s_at 575_s_at 201828_x_at 33856_at 201805_at 34346_at 201792_at 39069_at 201787_at 38026_at 201787_at 38027_at 201785_at 37402_at 201761_at 40074_at 201760_s_at 40167_s_at 201758_at 147_at 201744_s_at 38038_at 201743_at 36661_s_at 201742_x_at 36098_at 201738_at 33351_at 201735_s_at 40880_r_at 201723_s_at 38041_at 201719_s_at 32585_at 201718_s_at 32585_at 201694_s_at 789_at 201689_s_at 33840_at 201688_s_at 33840_at 201667_at 32531_at 201662_s_at 33880_at 201662_s_at 33881_at 201660_at 33880_at 201660_at 33881_at 201655_s_at 32845_at 201650_at 40899_at 201647_s_at 33823_at 201641_at 39061_at 201627_s_at 35303_at 201625_s_at 35303_at 201621_at 37005_at 201617_x_at 41738_at 201617_x_at 41739_s_at 201616_s_at 41738_at 201616_s_at 41739_s_at 201615_x_at 41738_at 201615_x_at 41739_s_at 201609_x_at 41775_at 201604_s_at 40438_at 201596_x_at 35766_at 201583_s_at 40851_r_at 201582_at 40851_r_at 201577_at 1521_at 201577_at 39073_at 201568_at 34400_at 201560_at 33891_at 201559_s_at 33891_at 201543_s_at 41451_s_at 201540_at 32542_at 201539_s_at 32542_at 201538_s_at 41225_at 201538_s_at 41226_at 201537_s_at 41225_at 201537_s_at 41226_at 201536_at 41225_at 201536_at 41226_at 201524_x_at 1660_at 201524_x_at 36604_at 201523_x_at 1660_at 201523_x_at 36604_at 201522_x_at 34842_at 201521_s_at 32789_at 201516_at 241_g_at 201505_at 581_at 201497_x_at 32582_at 201497_x_at 37407_s_at 201497_x_at 767_at 201497_x_at 773_at 201497_x_at 774_g_at 201496_x_at 32582_at 201496_x_at 37407_s_at 201496_x_at 767_at 201496_x_at 773_at 201496_x_at 774_g_at 201495_x_at 32582_at 201495_x_at 37407_s_at 201495_x_at 767_at 201495_x_at 773_at 201495_x_at 774_g_at 201482_at 1257_s_at 201475_x_at 39342_at 201460_at 36179_at 201460_at 36180_s_at 201459_at 35758_at 201457_x_at 34783_s_at 201457_x_at 41547_at 201446_s_at 33852_at 201438_at 38077_at 201431_s_at 36149_at 201430_s_at 36149_at 201421_s_at 38987_at 201420_s_at 38987_at 201416_at 33131_at 201403_s_at 39018_at 201397_at 34367_at 201391_at 1468_at 201387_s_at 36990_at 201386_s_at 35306_at 201380_at 40119_at 201375_s_at 924_s_at 201361_at 39693_at 201361_at 39694_at 201347_x_at 40133_s_at 201339_s_at 36688_at 201337_s_at 35783_at 201327_s_at 38416_at 201312_s_at 39714_at 201311_s_at 39714_at 201301_s_at 37374_at 201300_s_at 36159_s_at 201293_x_at 33667_at 201289_at 38772_at 201284_s_at 37401_g_at 201272_at 36589_at 201268_at 1980_s_at 201268_at 33415_at 201266_at 39425_at 201264_at 38647_at 201263_at 38473_at 201240_s_at 37359_at 201234_at 35365_at 201221_s_at 40875_s_at 201215_at 34793_s_at 201193_at 39023_at 201185_at 719_g_at 201161_s_at 39839_at 201155_s_at 34369_at 201153_s_at 34306_at 201152_s_at 34306_at 201151_s_at 34306_at 201150_s_at 1034_at 201150_s_at 1035_g_at 201149_s_at 1034_at 201149_s_at 1035_g_at 201148_s_at 1034_at 201148_s_at 1035_g_at 201147_s_at 1034_at 201147_s_at 1035_g_at 201146_at 853_at 201144_s_at 1154_at 201144_s_at 39784_at 201142_at 1154_at 201142_at 39784_at 201137_s_at 38095_i_at 201130_s_at 977_s_at 201127_s_at 40881_at 201120_s_at 38802_at 201115_at 1470_at 201108_s_at 115_at 201105_at 33412_at 201098_at 36677_at 201091_s_at 38084_at 201091_s_at 38085_at 201079_at 34885_at 201069_at 39007_at 201061_s_at 40419_at 201060_x_at 40419_at 201058_s_at 39145_at 201042_at 231_at 201042_at 38404_at 201040_at 37307_at 201037_at 39175_at 201022_s_at 38385_at 201021_s_at 38385_at 201020_at 1424_s_at 201014_s_at 39056_at 201013_s_at 39056_at 201005_at 39389_at 201001_s_at 36959_at 200996_at 35271_at 200986_at 39775_at 200985_s_at 39351_at 200982_s_at 39082_at 200974_at 32755_at 200971_s_at 37035_at 200970_s_at 37035_at 200968_s_at 35823_at 200931_s_at 36601_at 200930_s_at 36601_at 200923_at 37754_at 200911_s_at 40841_at 200910_at 40774_at 200907_s_at 41191_at 200906_s_at 41191_at 200904_at 32321_at 200903_s_at 40821_at 200897_s_at 41191_at 200894_s_at 38729_at 200889_s_at 34648_at 200886_s_at 41221_at 200884_at 40862_i_at 200884_at 40863_r_at 200863_s_at 36660_at 200859_x_at 32749_s_at 200859_x_at 32750_r_at 200836_s_at 242_at 200836_s_at 243_g_at 200836_s_at 32226_at 200835_s_at 242_at 200835_s_at 243_g_at 200835_s_at 32226_at 200823_x_at 33674_at 200820_at 1312_at 200820_at 32584_at 200813_s_at 32569_at 200808_s_at 36958_at 200807_s_at 37720_at 200806_s_at 37720_at 200803_s_at 33988_at 200803_s_at 33989_f_at 200801_x_at 32318_s_at 200801_x_at AFFX-HSAC07/X00351_3_at 200801_x_at AFFX-HSAC07/X00351_3_st 200801_x_at AFFX-HSAC07/X00351_5_at 200801_x_at AFFX-HSAC07/X00351_5_st 200801_x_at AFFX-HSAC07/X00351_M_at 200795_at 36627_at 200790_at 1081_at 200790_at 36203_at 200788_s_at 32260_at 200778_s_at 40281_at 200762_at 40607_at 200750_s_at 1839_at 200750_s_at 38708_at 200750_s_at 1840_g_at 200715_x_at 35119_at 200700_s_at 39080_at 200698_at 39080_at 200696_s_at 32612_at 200693_at 409_at 200672_x_at 39556_at 200671_s_at 39556_at 200670_at 39755_at 200670_at 39756_g_at 200669_s_at 504_at 200665_s_at 671_at 200657_at 37740_r_at 200652_at 36147_at 200644_at 36174_at 200625_s_at 935_at 200622_x_at 955_at 200621_at 38700_at 200620_at 39033_at 200611_s_at 38736_at 200609_s_at 38736_at 200604_s_at 227_g_at 200604_s_at 41768_at 200082_s_at 34646_at 200074_s_at 31907_at 200068_s_at 40125_at 200066_at 218_at 200059_s_at 1394_at 200059_s_at 37309_at 200055_at 868_at 200052_s_at 36189_at 200024_at 32437_at 200015_s_at 40281_at 200008_s_at 35307_at 

1. A method of determining gene expression levels in one or more cell types in heterogeneous cell samples, comprising the steps of: (a) determining the relative content of each cell type in two or more related heterogeneous cell samples, wherein at least two of the samples do not contain the same relative content of each cell type; (b) measuring overall levels of one or more gene expression analytes in each sample; (c) determining the regression relationship between the relative content of each cell type and the measured overall levels; and (d) calculating the level of each of the one or more analytes in each cell type according to the regression relationship determined in step (c), wherein gene expression levels correspond to the calculated levels of analytes.
 2. The method of claim 1, further comprising a step of identifying genes differentially expressed in at least one cell type relative to at least one other cell type.
 3. The method of claim 1 wherein the analyte is selected from the group consisting of a nucleic acid molecule and a protein.
 4. A method of identifying genes differentially expressed in malignant cells relative to non-malignant cells, comprising the steps of: (a) determining the relative content of each cell type in two or more cell samples of the same tissue or organ, wherein the two or more cell samples include at least a first sample containing malignant cells and a second sample that does not contain the same relative content of each cell type as the first sample; (b) measuring overall expression levels of one or more genes in each sample; (c) determining the regression relationship between the relative content of each cell type and the measured overall levels; (d) calculating the level of each of the one or more genes in each cell type according to the regression relationship determined in step (c); and (e) identifying genes differentially expressed in malignant cells relative to non-malignant cells.
 5. A method of characterizing one or more cell types in a subject, comprising the steps of: (a) measuring expression levels of one or more genes in a heterogeneous cell sample from a subject; (b) comparing the measured levels to a plurality of reference expression levels of the one or more genes, wherein the plurality of reference levels are indicative of two or more cell types; and (c) if the measured levels match reference levels indicative of a specific cell type in the sample, identifying a subject as having the specific cell type.
 6. A method of characterizing one or more cell types in a subject, comprising the steps of: (a) measuring expression levels of one or more genes in a cell sample from a subject; (b) comparing the measured levels to reference expression levels of the one or more genes, wherein the reference expression levels are determined according to the method of claim 1; and (c) if the measured levels match reference levels indicative of a specific cell type in the sample, identifying a subject as having the specific cell type.
 7. The method of claim 1, wherein the specific cell type is selected from the group consisting of malignant cell and non-malignant cell adjacent to a malignant cell in a subject.
 8. A method of identifying a subject as having malignant cells, comprising the steps of: (a) measuring expression levels of one or more genes in a heterogeneous cell sample from a subject; (b) comparing the measured levels to a plurality of reference expression levels of the one or more genes, wherein the plurality of reference levels are indicative of two or more cell types; and (c) if the measured levels match reference levels indicative of in malignant cells in the sample or of non-malignant cells in the sample that had been adjacent to malignant cells in the subject, identifying a subject as having malignant cells.
 9. A method of identifying a subject as having malignant cells, comprising the steps of: (a) measuring expression levels of one or more genes in a cell sample from a subject; (b) comparing the measured levels to reference expression levels of the one or more genes, wherein the reference expression levels are determined according to the method of claim 1; and (c) if the measured levels match reference levels indicative of in malignant cells in the sample or of non-malignant cells in the sample that had been adjacent to malignant cells in the subject, identifying a subject as having malignant cells.
 10. A method of identifying a subject as having malignant cells, comprising the steps of: (a) assaying a cell sample from a subject for non-malignant cells in the sample that had been adjacent to malignant cells in the subject; and (b) if the malignant-cell-adjacent non-malignant cells are present in the sample, identifying a subject as having malignant cells.
 11. The method of claim 7, wherein the malignant-cell-adjacent non-malignant cells are stromal cells.
 12. A method of determining gene expression levels in one or more cell types corresponding to two or more phenotypes comprising the steps of: (a) determining the relative content of each cell type in two or more related heterogeneous cell samples, wherein at least two of the samples do not contain the same relative content of each cell type, and wherein at least two of the samples correspond to different phenotypes; (b) measuring overall levels of one or more gene expression analytes in each sample; (c) determining the regression relationship between the relative content of each cell type for each phenotype and the measured overall levels; and (d) calculating the level of each of the one or more analytes in each cell type for each phenotype according to the regression relationship determined in step (c), wherein gene expression levels in each cell type for each phenotype correspond to the calculated levels of analytes.
 13. A method of identifying a phenotype of a subject, comprising the steps of (a) measuring expression levels of one or more genes in a cell sample from a subject; (b) comparing the measured levels to reference expression levels of the one or more genes, wherein the reference expression levels are determined according to the method of claim 12; and (c) if the measured levels match reference levels indicative of a specific phenotype, identifying a subject as having the specific phenotype.
 14. The method of claim 12, wherein the phenotype is indicative of a prognosis of a disease or disorder.
 15. A method of determining gene expression levels in one or more cell types indicative of a disease or disorder comprising the steps of: (a) determining the relative content of each cell type in two or more related heterogeneous cell samples, wherein at least two of the samples do not contain the same relative content of each cell type, and wherein at least one sample is from a subject with a disease or disorder and at least one sample is from a subject without a disease or disorder; (b) measuring overall levels of one or more gene expression analytes in each sample; (c) determining the regression relationship between the relative content of each cell type for both disease and non-disease and the measured overall levels; and (d) calculating the level of each of the one or more analytes in each cell type for both disease and non-disease according to the regression relationship determined in step (c), wherein gene expression levels in each cell type for both disease and non-disease correspond to the calculated levels of analytes.
 16. A method of identifying a disease or disorder in a subject, comprising the steps of (a) measuring expression levels of one or more genes in a cell sample from a subject; (b) comparing the measured levels to reference expression levels of the one or more genes, wherein the reference expression levels are determined according to the method of claim 15; and (c) if the measured levels match reference levels indicative of a specific disease or disorder, identifying a subject as having the specific disease or disorder.
 17. The method of claim 14, wherein the disease prognosis is selected from the group consisting of tumor relapse, aggressiveness of tumor, indolence of tumor, subject survival, and likelihood of successful treatment of tumor.
 18. The method of claim 14, wherein the sample has been clinically classified as negative of a tumor, and presence in the sample of non-malignant cells adjacent to malignant cells is indicative of tumor, tumor relapse, aggressiveness of tumor, or likelihood of successful treatment of tumor.
 19. A method of identifying environment-dependent changes in gene expression of a cell type, comprising the steps of: (a) determining the relative content of each cell type in two or more related heterogeneous cell samples, wherein at least two of the samples do not contain the same relative content of each cell type, and wherein cells of the same type that are in different cell environments are separately classified; (b) measuring overall levels of one or more gene expression analytes in each sample; (c) determining the regression relationship between the relative content of each cell classification and the measured overall levels; (d) calculating the level of each of the one or more analytes in each cell classification according to the regression relationship determined in step (c); and (e) identifying genes differentially expressed in separately classified cells of the same type, thereby identifying environment-dependent changes in gene expression of a cell type.
 20. A method of identifying tumor-dependent changes in gene expression of a cell type, comprising the steps of: (a) determining the relative content of each cell type in two or more related heterogeneous cell samples, wherein at least two of the samples do not contain the same relative content of each cell type, and wherein cells associated with tumor are classified separately from cells of the same type that are not associated with tumor; (b) measuring overall levels of one or more gene expression analytes in each sample; (c) determining the regression relationship between the relative content of each cell classification and the measured overall levels; (d) calculating the level of each of the one or more analytes in each cell classification according to the regression relationship determined in step (c); and (e) identifying genes differentially expressed in cells associated with tumor relative to cells of the same type that are not associated with tumor.
 21. A method of identifying a phenotype of a subject, comprising the steps of (a) measuring expression levels of one or more genes in a heterogeneous cell sample from a subject; (b) comparing the measured levels to reference expression levels of the one or more genes, wherein the plurality of reference levels are indicative of two or more phenotypes; and (c) if the measured levels match reference levels indicative of a specific phenotype, identifying a subject as having the specific phenotype.
 22. The method of claim 1 wherein all steps are performed without physically separating the cells in the sample.
 23. The method of claim 1, wherein the step of determining the regression relationship further comprises determining the regression of overall levels of each analyte on the cell proportions.
 24. A method for classifying a cell sample as indicative of prostate cancer or not indicative of prostate cancer, comprising detecting the expression levels of one or more genes relative to a reference, the genes comprising at least one indicating gene, wherein each indicating gene comprises either: (a) a nucleotide sequence at least 90% identical to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof or (b) a nucleotide sequence that hybridizes under high stringency to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof.
 25. Use of a combination for classifying a sample as indicative of prostate cancer or not indicative of prostate cancer, wherein the combination detects the expression levels of one or more genes relative to a reference, the genes comprising at least indicating gene, wherein each indicating gene comprises either: (a) a nucleotide sequence at least 90% identical to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof or (b) a nucleotide sequence that hybridizes under high stringency to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof.
 26. The method of claim 24, wherein the combination detects the expression levels of genes relative to a reference, the genes comprising at least 2, 3, 4, 5, 7, 10, 15, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500, 750, 1,000, 1,250, 1,500, 1,750, 2,000, 2,250, 2,500, or 2750 indicating genes.
 27. A microarray wherein at least 50%, 70%, 80%, 90%, 95%, 97%, 98%.or 99% of the loci of the array specifically detect the expression level of the 2 or more indicating genes of claim
 24. 28. A method of treating prostate cancer comprising modulating the activity of a gene product selected from the group consisting of: (a) a product of a gene comprising a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof; and (b) a product of a gene comprising a nucleotide sequence that hybridizes under high stringency to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof.
 29. Use of a compound for the preparation of a composition for inhibiting prostate cancer, wherein the compound modulates the activity of a gene product selected from the group consisting of: (a) a product of a gene comprising a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof; and (b) a product of a gene comprising a nucleotide sequence that hybridizes under high stringency to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof.
 30. The use of claim 29, wherein the compound is selected from the group consisting of an antibody, an antisense compound, a ribozyme, a DNAzyme, an RNA interference compound, a small molecule, a heterologous nucleic acid molecule encoding the gene, the gene product, and any combination thereof.
 31. The method of claim 28, wherein the modulating step further comprises administering to a subject with prostate cancer a compound that inhibits the activity of the gene product selected from the group consisting of an antibody, an antisense compound, a ribozyme, a DNAzyme, an RNA interference compound, a small molecule, an any combination thereof.
 32. The method of claim 31, wherein the modulating compound specifically binds to mRNA encoding the gene or the protein gene product.
 33. The method of claim 28, wherein the modulating step further comprises administering to a subject with prostate cancer a compound that increases the activity of the gene product selected from the selected from the group consisting of heterologous nucleic acid molecule encoding the gene, the gene product, and a combination thereof.
 34. The method of claim 33, wherein the heterologous nucleic acid molecule is an expression vector.
 35. A screening method comprising contacting with a test compound a cell expressing a gene selected from the group consisting of: (a) a gene comprising a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof; and (b) a gene comprising a nucleotide sequence that hybridizes under high stringency to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof, and measuring expression levels of the gene, wherein a change in expression levels relative to a reference identifies the compound as a compound that modulates a expression of the gene.
 36. A screening method comprising contacting with a test compound a gene product selected from the group consisting of: (a) a product of a gene comprising a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof; and (b) a product of a gene comprising a nucleotide sequence that hybridizes under high stringency to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof, and either: (i) identifying a test compound that specifically binds to the gene product, or (ii) identifying a test compound that inhibits binding of a compound known to bind-the gene product.
 37. A method for classifying a cell sample as indicative of a prostate cancer prognosis, comprising detecting the expression levels of one or more genes relative to a reference, the genes comprising at least one indicating gene, wherein each indicating gene comprises either: (a) a nucleotide sequence at least 90% identical to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof or (b) a nucleotide sequence that hybridizes under high stringency to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof.
 38. Use of a combination for classifying a sample as indicative of a prostate cancer prognosis, wherein the combination detects the expression levels of one or more genes relative to a reference, the genes comprising at least one indicating gene, wherein each indicating gene comprises either: (a) a nucleotide sequence at least 90% identical to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof or (b) a nucleotide sequence that hybridizes under high stringency to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof.
 39. The method of claim 37, wherein the combination detects the expression levels of genes relative to a reference, the genes comprising at least 2, 3, 4, 5, 7, 10, 15, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500, 750, 1,000, 1,250, 1,500, 1,750, 2,000, 2,250, 2,500, or 2750 indicating genes.
 40. A microarray wherein at least 50%, 70%, 80%, 90%, 95%, 97%, 98% or 99% of the loci of the array specifically detect the expression level of the 2 or more indicating genes of claim
 37. 41. The method of claim 37, wherein the prostate cancer prognosis is selected from the group consisting of tumor relapse, aggressiveness of tumor, indolence of tumor, subject survival, and likelihood of successful treatment of tumor.
 42. The method of claim 24, wherein at least one of the gene products corresponds to a Probe or Identifer/LocusLink with a modified t statistic in tumor >2.5 or ≦−2.5.
 43. The method of claim 24, wherein at least one of the gene products corresponds to a Probe or Identifer/LocusLink with a modified t statistic in benign prostatic hypertrophy (BPH) >2.5 or ≦−2.5.
 44. The method of claim 24, wherein at least one of the gene products corresponds to a Probe or Identifer/LocusLink with a modified t statistic in stroma >2.5 or ≦−2.5.
 45. The method of claim 24, wherein the gene product is selected from the group consisting of: (a) a product of a gene comprising a nucleotide sequence at least 90% identical to the nucleotide sequence of a Probe identified in Table 9 as having a modified t statistic in tumor ≧2.5 or ≦−2.5; (b) a product of a gene comprising a nucleotide sequence at least 90% identical to the nucleotide sequence of a gene encoded by an Identifier and LocusLink identified in Table 9 as having a modified t statistic in tumor ≧2.5 or ≦−2.5; (c) a product of a gene comprising a nucleotide sequence at least 90% identical to the nucleotide sequence of a Probe identified in Table 10 as having a modified t statistic in stroma ≧2.5 or ≦−2.5; and (d) a product of a gene comprising a nucleotide sequence at least 90% identical to the nucleotide sequence of a gene encoded by an Identifier and LocusLink identified in Table 10 as having a modified t statistic in stroma ≧2.5 or ≦−2.5.
 46. The method of claim 42, wherein the modified t statistic is ≧3 or ≦−3.
 47. The method of claim 42, wherein the modified t statistic is ≧3.5 or ≦−3.5.
 48. The method of claim 42, wherein the modified t statistic is ≧4 or ≦−4.
 49. The method of claim 42, wherein the modified t statistic is ≧4.5 or ≦−4.5.
 50. The method of claim 42, wherein the modified t statistic is ≧5 or ≦−5.
 51. The method of claim 1, wherein the one or more gene expression analytes comprise two or more gene expression analytes, or wherein the two or more genes comprise two or more genes.
 52. The method of claim 1, wherein the one or more genes does not include a gene provided in Table
 14. 53. A compound that modulates the activity of a gene product selected from the group consisting of: (a) a product of a gene comprising a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof; and (b) a product of a gene comprising a nucleotide sequence that hybridizes under high stringency to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof.
 54. The compound of claim 53, wherein the compound is selected from the group consisting of an antibody, an antisense compound, a ribozyme, a DNAzyme, an RNA interference compound, a small molecule, a heterologous nucleic acid molecule encoding the gene, the gene product, and any combination thereof.
 55. The compound of claim 53 in pharmaceutically acceptable form.
 56. A compound that indicates the presence of a gene product selected from the group consisting of: (a) a product of a gene comprising a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof; and (b) a product of a gene comprising a nucleotide sequence that hybridizes under high stringency to a nucleotide sequence selected from SEQ ID NO:1-38,826 or a complement thereof.
 57. The compound of claim 56, wherein the compound is selected from the group consisting of a nucleic acid molecule that specifically binds at least 10 nucleotides in the gene or a complement thereof or a fragment thereof, an antibody that specifically binds the gene or a complement thereof, and an antibody that specifically binds the gene product or a fragment thereof.
 58. A combination, comprising two or more compounds of claim
 53. 59. The combination, comprising at least at least 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20 compounds or more compounds of claim
 53. 60. The method of claim 24, wherein expression levels of genes are detected by detecting products of the genes.
 61. The method, compound or combination of claim 28, wherein the product of the gene is selected from the group consisting of RNA transcribed from the gene and protein translated from mRNA transcribed from the gene.
 62. Diagnostic markers for prostate cancer as set forth in SEQ ID NO:1-10,000.
 63. A kit comprising nucleic acids, polypeptides and/or antibodies useful in detecting the markers set forth in SEQ ID NO:1-38,826 for detecting prostate cancer.
 64. A method of treating or preventing prostate cancer comprising suppressing gene expression or inhibiting or neutralizing the product of the genes that are listed as tumor markers and that are up-regulated in SEQ ID NO:1-38,826.
 65. The method of claim 64, wherein the method uses antibodies, antisense, ribozyme, a DNAzyme, RNA interference, and/or small molecule therapy to neutralize the gene or gene products.
 66. Prognostic markers for early relapse in prostate cancer as set forth in SEQ ID NO:1-38,826.
 67. A kit comprising nucleic acids, polypeptides and/or antibodies useful in detecting the markers set forth in SEQ ID NO:1-38,826 for detecting early relapse of prostate cancer.
 68. A method of treating or preventing prostate cancer comprising suppressing gene expression or inhibiting or neutralizing the gene product of genes that are up-regulated in the tumor epithelial cells of early relapsed prostate cancer samples, wherein such genes have a T>3 for RS:T (column G in Table 8).
 69. The method of claim 61, wherein the method uses antibodies, antisense, ribozyme, a DNAzyme, RNA interference, and/or small molecule therapy to neutralize the gene or gene products.
 70. A method as described herein.
 71. A computer implemented method as described herein.
 72. The use of claim 25, wherein the combination comprises a combination selected from the group consisting of two or more nucleotide probes, a nucleotide probe array, two or more antibodies, an antibody array, and two or more PCR primer pairs. 